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 ANOVA — analysis of variance
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 ns — not significant 
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 PKA — cAMP-dependent protein kinase
 PKG — cGMP-dependent protein kinase
 p.o. — per os
 sGC — soluble guanylyl cyclase
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General Introduction
The memory system represents one of the most fundamental but also one of the most 
complex systems in the brain. Nearly all living organisms, from Drosophila to primates, ex-
hibit some kind of learning and memory. Evolution has favored those organisms that learn 
from previous experience and found some way to store previous information for later use. 
The primitive mechanism of memory formation is believed to be comparable between spe-
cies with regard to the underlying cellular mechanisms. Therefore, fundamental research 
using animal models of cognition in vivo or in vitro can realize better comprehension of 
the human memory system. Furthermore, pathological situations in which memory func-
tioning is compromised provide valuable information about the memory system and its 
underlying mechanisms.
Memory impairment can occur as a result of normal aging or pathological conditions. 
Because life expectancy is increasing and the middle-aged cohort is greater than previous 
decades, the absolute number of old people will increase substantially. As a consequence 
of this double aging, the age-associated problems will increase. One of the more serious 
problems older people are facing is a decline in cognitive functions (Mattson et al. 2002). 
Memory impairments have a strong negative impact on the daily activities and quality 
of life of aged people. The loss of cognitive functioning is even more serious in pathologi-
cal conditions such as Alzheimer’s disease or other dementia. But also in depressed and 
schizophrenic patients, prominent memory deficits are present (Blaney 1986; Frith 1996). 
So far, several preventive strategies have been described which could ameliorate or slow 
down the cognitive decline resulting from brain aging. Research has focused on avoiding 
genetic and environmental factors that cause neuronal dysfunction and death or by en-
hancement of the ability of neurons to adapt to the aging process (Mattson et al. 2002). 
Examples of avoiding genetic factors are genetic counseling or germ line gene therapy and 
examples of avoiding environmental factors are dietary restrictions or behavioral modifi-
cation. These strategies can induce successful ageing and can reduce the risk of cognitive 
decline and dementia (for a review see Mattson et al. 2002). Despite these strategies, there 
is a great need for drugs that counteract the processes involved in ageing and more specifi-
cally the decline of cognitive functions and memory.
For the enhancement of memory or reversal of cognitive deficits different drug targets 
have been suggested based on neurotransmitter systems. Serotonergic, cholinergic and do-
paminergic neurotransmitter systems have been shown to be involved in memory. Further-
more, cognitive performance, including memory, can be facilitated by numerous biological 
factors. Memory can be improved or impaired for example by neurotransmitters, neuro-
modulators, intracellular molecules, hormones, plant extracts and nutritional ingredients 
(Cahill et al. 1994; Davis and Squire 1984; DeZazzo and Tully 1995; Izquierdo et al. 1998; 
McGaugh 1989; Messier 2004).
A still relatively novel and promising field in memory research focuses on the involve-
ment of second messenger systems. Inhibition of phosphodiesterase (PDE) enzymes is a way 
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to enhance second messenger signaling and consequently influence the pathways involved 
in learning and memory. A more detailed description of the different PDEs is given later.
In this thesis the effects of PDE inhibition (PDE-I) on memory are investigated in dif-
ferent animal models of cognition. PDE-I in mice, rats and monkeys is studied as well as the 
temporal effects of PDE-I. Studies were conducted to asses the effects of PDE-I on intact 
memory as well as deficit memory models. In general, the effects of cyclic adenosine mono-
phosphate (cAMP) and cyclic guanosine monophosphate (cGMP) manipulations were stud-
ied on learning and memory by means of inhibition of specific PDEs. 
Memory systems
There are several ways of classifying memory, based on the duration of storage (temporal 
basis), the nature (structure), and the physical domain of  information to be stored. In Fig. 1 
a schematic representation of the temporal and structural basis of memory is presented.
Duration of storage
A basic and generally accepted classification of memory is based on the duration of memory 
retention. This classification identifies three distinct types of memory: sensory store, short-
term memory, and long-term memory. In the sensory store, all the incoming information 
from the sensory organs is accumulated and by the process of attention certain items can 
be transferred to working memory. Sensory memory is characterized by the duration of 
memory retention which ranges from milliseconds up to 3 s, whereas short-term memory 
can store information up to 15 s. These stores generally have limited capacity and duration. 
However, stored information can be retrieved in a period of time which ranges from days to 
years; this type of memory is called long-term memory. 
Short-term storage has also been referred to as working memory (Baddeley 2003). 
To store an item in long-term memory there is a transitional phase of consolidation. It is 
suggested that there are two stages for storing new information, i.e a early and a late con-
solidation (Ng et al. 1991; Prickaerts et al. 2004). It may be that short-term memory is sup-
ported by transient changes in neuronal communication, whereas long-term memories are 
maintained by more stable and permanent changes in neural structure that are dependent 
on protein synthesis.
Nature of information
Long-term memory can be divided into declarative (explicit) and procedural (implicit) mem-
ories (Squire et al. 1993; Zola-Morgan and Squire 1993). Declarative memory requires con-
scious recall, i.e. a conscious process to call back the information. It is sometimes called 
explicit memory, since it consists of information that is explicitly stored and retrieved. De-
clarative memory can be further sub-divided into semantic memory, which concerns facts 
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taken independent of context; and episodic memory, which concerns information specific 
to a particular context, such as a time and place. In contrast, procedural memory (or im-
plicit memory) is not based on the conscious recall of information, but on implicit learning 
(Schacter 1987). Procedural memory is primarily employed in learning motor skills and 
should be considered a subset of implicit memory. 
Physical domain of information
The information stored in the memory system can also be classified based on its represen-
tative domain. Some examples of these domains are the visual, auditory, tactile, olfactory 
or spatial domain. Memory for a spatial location or a spatial map is stored in different 
cortical areas then for example the memory of faces. Specific lesions of the cortex can lead 
to impairment in the capability to recognize faces, prosopagnosia, whereas other memory 
functions remain unaffected. 
Measuring memory in behavioral experiments.
In humans it is fairly easy to measure specific aspects of memory performance. Memory 
tests can be designed and subjects can be given specific instructions to perform optimally 
the test. To test memory performance in humans countless tests are available, and stan-
Figure 1: Schematic representation of the temporal features of memory and the nature of information.  Forgetting can occur in the STM/
WM due to not attending to the new information. Forgetting can also occur in the LTM. Information can be transferred from STM to LTM 
after rehearsal by the process of consolidation. The working memory, according to Baddeley (2003) is composed of two parallel systems 
which are supervised by the Central Executive. These systems are only defined for humans. The long-term memory can be divided in differ-
ent subsystems. The declarative memory system represents facts of a subject and the non-declarative system hold information about skills. 
The episodic memory is information that is unique for each individual subject whereas the semantic memory is information of general 
knowledge. STM: Short-term memory; WM: Working memory; LTM: Long-term memory.
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dardized batteries of memory tests are usually constructed so that all of the modalities 
of memory can be tested. Examples of these memory testing batteries are the Wechsler 
Memory Scale (WMS-I or WMS-II), Wechsler Memory Scale revised (WMS-R), Randt 
memory test or Guild Memory Test (for review see Lezak 1995).
In animal research testing memory function is not as straightforward, i.e. the pre-
dictive value of animal memory (i.e. does the outcome of the animal test predict the out-
come in humans) and construct validity (i.e. does the test measure what it is supposed 
to measure) is more difficult. In respect to face validity, when studying memory processes 
in nonhuman subjects no instructions can be given and behavioral tests should therefore 
be designed in such a way that the animal’s behavior directly reflects certain aspects of 
memory. In addition, several factors can be confounders in such tests, i.e. memory tests 
can be influenced among others by attention, motivation or anxiety-related behavior. 
Nevertheless several reliable memory tests, that investigate specific domains of memory, 
have been designed for memory assessment in nonhuman subjects. Box 1 gives an over-
view of the rodent memory tests used in the behavioral research described in this thesis. 
The examples of human and animal memory tests given above are not exhaustive and 
there are many more examples to be given. However it reaches beyond the scope of the 
present thesis to give a further detailed description of all these tests. 
To assess the effects of possible pro-cognitive compounds, drugs can be tested in 
various behavioral test paradigms. A compound can be evaluated in healthy animals, 
in age impaired animals but also in genetic or drug induced disease models. A well known 
model for memory impairment is the scopolamine model (Bartus et al. 1985; Ebert and 
Kirch 1998). The anticholinergic agent scopolamine has shown to impair memory in sev-
eral behavioral tests and is widely used to evaluate whether a novel compound is able to 
reverse the scopolamine deficit. In the present thesis we evaluated the effect of a PDE-I 
in the scopolamine model in the ORT. Another model that has shown to impair memory 
in both humans and rodents is acute tryptophan depletion (Lieben et al. 2005a; Lieben 
et al. 2004c; Park et al. 1994; Riedel et al. 1999; Sambeth et al. in press; Schmitt et al. 
2000). In this model subjects are administered a diet that contains all essential amino 
acids except for tryptophan, the precursor of serotonin. The resulting tryptophan deple-
tion in the blood causes a drop in brain tryptophan and consequently in central serotonin 
levels. These effects of acute tryptophan depletion are associated with impaired memory 
performance, especially consolidation of episodic memories. In this thesis we further in-
vestigated the acute tryptophan depletion model and tried to reverse its memory deficit 
with a PDE4-I. 
Genetic modified or transgenic rats and mice are also often used to study mecha-
nisms of pathology and basic brain functions. To evaluate the effects of the knockout of 
specific isoforms of the PDE4 gene we investigated two transgenic mouse strains. PDE4-
B and PDE4-D mice were tested in a fear conditioning paradigm and a spatial water maze 
test. All these experiments add to the better understanding of the role of PDEs in learn-
ing and memory.
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Box 1: Behavioral tests used in this thesis for measuring learning and memory in rodents
Object Recognition Test: (Ennaceur and Delacour 1988)
In the training trial an animal is allowed to explore two similar objects in an arena. After a delay, 
usually 1 to 48 h, the animal is re-exposed to the arena but this time with one familiar and one novel 
object. The times exploring the object are scored by an observer. When the animal remembers the 
familiar object it will spend more time exploring the novel object. This task is thought to be depen-
dent on the hippocampus and rhinal cortex.
Fear Conditioning Test: Contextual and cue 
Animals are placed in a testing chamber and allowed to acclimate for 2 min. In the training trial an 
animal is subjected to one or more pairings of cue (i.e. tones, lights, the conditioning stimulus, CS) 
for about 30 s  immediately followed by a noxious stimulus (i.e. a foot shock, the unconditioned 
stimulus, US). In the test session, usually 24 h later the animal is returned to the chamber for 
5 min and no conditioning stimuli are presented. During the context test trial freezing behavior 
is measured (no movement except for breathing) which implicates the learned association between 
the foot shocks and the testing chamber. In the cue test, the animal is placed in a different chamber 
and is allowed to acclimate for 2 min after which it is exposed to the CS again for 3 min. The differ-
ence in freezing behavior before and during the CS reflects the learned association of the CS (tone) 
and the foot shock. Both hippocampus and amygdala are involved in contextual fear conditioning, 
whereas cue conditioning is dependent on only the amygdala (LeDoux 2000).
Water Escape Test (Morris 1984)
Animals are exposed to a large (diameter about 2m for rats and 1m for mice) circular tank filled 
with water. Over several training sessions, animals learn the location of a submerged platform to 
escape the water. Based on external spatial cues the animals navigate the tank to find the platform 
that is placed at a fixed location. Swimming speed, escape latency and distance swum are calculated 
and are a measure for spatial learning. After (usually 24 h) the learning trials a retention test can be 
applied in which the platform is removed from the tank and the time spent in the quadrant of the 
tank were the platform used to be is a measure for spatial memory retrieval. This task is believed 
to be hippocampus dependent, although the amygdala might also have a relevant role in successful 
spatial learning. 
Phosphodiesterases:
Phosphodiesterases (PDEs) are enzymes that break down cyclic nucleotides, i.e. cAMP or 
cGMP. The family of PDEs is large and thus far eleven classes have been identified based on 
their substrate. PDEs can be selective for either cAMP or cGMP or both and these nucleo-
tides play an important role in intracellular signaling and in processes of neuroplasticity, 
such as long term potentiation (LTP) (Frey et al. 1993b; Son et al. 1998).  The difference be-
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tween PDE-Is as cognition enhancers and more conventional drugs is that most other drugs 
act on specific neurotransmitter systems whereas PDE-Is can modulate multiple biochemi-
cal systems through second messenger signaling. PDE-Is elevate concentrations of second 
messengers (cAMP and/or cGMP) which in turn trigger various intracellular mechanisms. 
As such, these second messengers are thought to be involved in processes of synaptic plas-
ticity through the mechanism of LTP (Frey et al. 1993b; Impey et al. 1996b). The next sec-
tion will focus on LTP and the role of PDEs in this process. 
Table 1: Overview and properties of known enzymes of the cyclic nucleotide phosphodiesterases. 
Type Number of Genes Localization Description Substrate
Selective
Inhibitors
PDE1 3 brain, heart, smooth muscle
Ca2+ -CaM 
stimulated cAMP/cGMP
calimidazolium, phenethiazines, 
vinpocetine, SCH51866
PDE2 1 brain, heart, adrenal cortex cGMP stimulated cAMP/cGMP EHNA, Bay 60-7550
PDE3 2
brain, heart, smooth 
muscle, adipose 
platelets
cGMP inhibited cAMP Amrinone, bucladesine, enoximone, cilostamide, milrinone, SK&F 95654 
PDE4 4 ubiquitous cAMP specific cAMP rolipram, rofluminast, Ariflo, MEM1018, MEM1091, HT0712
PDE5 1 brain, lung, platelets, smooth muscle cGMP specific cGMP
zaprinast, sildenafil, vardenafil, 
tadelafil, SK&F 96231
PDE6 4 rod and cones photo receptor Photoreceptor cGMP (sildenafil, vardenafil)
PDE7 2
brain, skeletal muscle, 
kidney, T-cells, liver, 
testis
cAMP high 
affinity cAMP ?
PDE8 2 brain, liver, testis, ovary
cAMP high 
affinity cAMP Dipyridamole
PDE9 1 brain, kidney cGMP high affinity cGMP BAY 73-6691
PDE10 1 brain, testis cAMP-inhibited cGMP ?
PDE11 1 skeletal muscle, kid-ney, liver, pituitary Dual substrate cAMP/cGMP (tadelafil)
Note that the list of tissues in the localization column is not exhaustive. 
Long term potentiation
Long term potentiation (LTP) is a process in the brain that can explain certain aspects 
of synaptic plasticity. LTP is the increase in the chemical strength of a synapse after 
a tetanus stimulation that lasts for over an hour. Experimentally, a series of short, 
high frequency electric stimulation to a nerve cell synapse can strengthen, or potenti-
ate, that synapse for minutes to hours. Hippocampal LTP has been proposed to be 
a neurophysiological correlate of memory (Bliss and Collingridge 1993). Studies that 
investigated the underlying molecular mechanisms of LTP have provided molecular 
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tools for improving LTP and consequently memory. Among the various molecules in-
volved in LTP, cAMP and cGMP play a prominent role (Bailey et al. 1996a; Chien et 
al. 2003; Son et al. 1998). 
In general, LTP is often divided into two phases, an early phase (E-LTP), which 
is short lasting and a late phase (L-LTP), that lasts longer and depends on gene tran-
scription and protein synthesis (Pang and Lu 2004; Voronin et al. 1995).
Early LTP
In general, E-LTP can be experimentally induced in the CA1 area of the hippocampus by 
applying a couple trains of tetanic stimulation to the synaptic connection between two neu-
rons. E-LTP is typically induced by one or two trains of 100 Hz, 1 s stimulation separated 
by 20 s (Lu and Hawkins 2002). This form of LTP lasts less than 3 h and requires no gene 
transcription or protein synthesis. Shortly, the induction process of E-LTP involves the acti-
vation of NMDA receptors, a subclass of glutamate receptors. Post-synaptic depolarization 
after short tetanus stimulation removes the voltage-dependent magnesium block of NMDA 
receptors. This results in an influx of Ca2+ through the NMDA receptor in the post-synaptic 
neuron (Pang and Lu 2004). Elevated intracellular Ca2+ levels trigger a cascade of reactions 
including the production of Nitric Oxide (NO) and activation of the Ca2+-calmodulin-de-
pendent protein kinase II (CaMKII). Initially, cGMP was thought to act mainly pre-synapti-
cally in the E-LTP as part of a NO/sGC/cGMP pathway. In this respect NO is regarded as 
a retrograde messenger. Elevation of cGMP could result in either more glutamate release via 
activation of pre-synaptic voltage-gated cGMP-dependent ion channels, or more glutamate 
synthesis via cGMP-dependent protein kinase (PKG). However, post-synaptic mechanisms 
of action are also suggested, via the insertion of post-synaptic AMPA receptors by activation 
of CaMKII (Lu and Hawkins 2002).
Late LTP 
In the CA1 area of the hippocampus, L-LTP can be experimentally induced by a series of 
three or more trains of tetanic stimulation spaced roughly 10 min apart. L-LTP is typically 
induced by three or four trains of stimulation separated by 5-10 min. In contrast to E-LTP, L-
LTP requires activation of cAMP-dependent protein kinase (PKA) and results in synthesis of 
RNA and proteins (Lu and Hawkins 2002). Therefore, L-LTP has been proposed as a possible 
molecular analogue of long-term memory. Several pathways might be involved in L-LTP. 
cAMP response element binding protein (CREB) is thought to be the primary transcription 
factor in the cascade of gene expression that leads to permanent structural changes at the 
level of the synapse (Impey et al. 1996b). 
Recently, it has been shown that a cGMP/PKG/CREB pathway is also involved in 
L-LTP (Lu and Hawkins 2002; Lu et al. 1999). Thus, cAMP and cGMP play an important 
role in intracellular signaling and in processes of neuroplasticity such as long term poten-
tiation (LTP) (see Fig 2).
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PDE inhibition and LTP
Two key players in LTP processes are the cyclic nucleotides cAMP and cGMP, because they 
play an important role in intracellular signaling (Bailey et al. 1996a; Chien et al. 2003; Son 
et al. 1998). Therefore the hypothesis that PDE inhibition could enhance memory through 
the process of LTP arose and several studies have been performed to investigate this pos-
sibility. A couple of very important studies provided the base for some of the behavioral 
experiments described in this thesis. These previous studies showed that intra-hippocampal 
infusion of 8Br-cAMP improved memory performance when injected 3 or 6 h after one-trial 
training, but not when injected directly after the training trial. In contrast, intra-hippocam-
pal injections with 8Br-cGMP only improved memory performance when injected directly 
after the learning trial and not when injected 3 h or 6 h later (Bernabeu et al. 1997b; Berna-
beu et al. 1996; Prickaerts et al. 2002a). The time dependent effects of cAMP and cGMP in 
memory performance may underlie different cellular mechanisms and we speculated that 
these mechanisms might be related to early and late consolidation processes. 
Figure 2: Simplified diagram of involvement of cGMP and cAMP in long-term potentiation (LTP). After the release of glutamate from the 
pre-synaptic neuron, it binds to AMPA and NMDA receptors. If the signal is strong enough, calcium (Ca2+) will enter the post-synaptic 
neuron through the NMDA receptor and activates calmodulin (CaM) which in turn stimulates adenylate cyclase (AC). Subsequently, cAMP 
is synthesized, which can lead to protein synthesis via activation of cAMP-response element binding protein (CREB). Besides activation of 
CaM, Ca2+ activates constitutive nitric oxide synthase (NOS). After activation of NOS the gaseous molecule nitric oxide (NO) is formed, 
and it can have a dual action. First, NO can diffuse back to the pre-synaptic region and activate soluble guanylate cyclase (sGC). cGC in-
creases cGMP levels which in turn can potentiate the release of glutamate. A second action of NO is the activation of sGC post-synaptically. 
This can also lead to protein synthesis (through the activation of CREB). These phenomena, including other molecular events, are generally 
assumed to underlie LTP. PDEs break down cGMP and cAMP. Selective PDE inhibitors can therefore increase cGMP levels pre-synaptically 
and/or increase cAMP and cGMP levels post-synaptically.
Ca2+
CaM
NOS
NO
cGMP
sGC
sGC cGMP
CREB
cAMP
Pre-synaptic Post-synaptic
: glutamate
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Effects of PDE-I on cognition
Many different classes of PDEs exists (See Table 1) and most of them are expressed in the brain 
(except for PDE6 and PDE11). By far, not all classes of PDEs have selective inhibitors and if 
they do then these cannot always cross the blood-brain barrier. For the scope of the present 
thesis three PDE-Is are of importance, namely PDE2-I, PDE4-I and PDE5-I. These inhibitors 
are widely available, can be administered peripherally and show central effects. The next sec-
tion will focus on these three PDE-I and their effects on cognition. Of note, to our knowledge 
these are the only PDE-Is to have ever been tested in learning and memory research.
Effects of PDE2-I on cognition
PDE2 hydrolyses both cAMP and cGMP. Thus far, only a few studies have been published 
that investigated the effects of PDE2 inhibition in behavioral models. To our knowledge, 
BAY 60-7550 is the only selective PDE2 inhibitor which has been tested in learning and 
memory models (Boess et al. 2004; Rutten et al. 2006c). In vitro experiments showed that 
this compound increases both cAMP and cGMP levels in cortical neurons and hippocampal 
fibers (Boess et al. 2004).
Recent findings
Different behavioral tests were used to characterize the effects of Bay 60-7550 on memory 
performance (Boess et al. 2004). At a dose of 3 mg/kg (p.o.) Bay 60-7550 fully antagonized 
the spatial WM deficit in a T-maze after treatment with the NMDA antagonist dizocilpine 
(MK-801, 0.04 mg/kg, i.p.).
When given immediately after training in tasks of object or social recognition, Bay 
60-7550 improved object recognition in both rats (1 and 3 mg/kg, p.o.) and mice (0.3 and 
1 mg/kg, p.o). Likewise, social recognition was improved in rats (1 and 3 mg/kg, p.o.) as well 
as mice (0.6, 2 and 6 mg/kg, p.o.). These effects of BAY 60-7550 on early consolidation 
processes may be mainly mediated by cGMP and not cAMP, since cGMP, but not cAMP, in-
jections into the hippocampus immediately after training improved LTM in tasks of object 
recognition and passive avoidance learning. In the present thesis the effect of BAY 60-7550 
(3 mg/kg, p.o.) on object recognition memory was further investigated, in particular the ef-
fect of time of treatment was studied (chapter 4). 
The effects of PDE4-I on cognition
Ample evidence supports a role for the cAMP/PKA/CREB pathway in learning and memory 
processes (Barco et al. 2003; Tully et al. 2003). PDE4 inhibitors specifically inhibit cAMP and 
the underlying mechanism for their cognitive-enhancing effects may involve modulation of 
activity within the cAMP/PKA/CREB pathway (Imanishi et al. 1997; Nagakura et al. 2002). 
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In the literature most studies use the prototypical PDE4 inhibitor, rolipram, to examine the 
effects of PDE4-I on memory (Table 2 for an overview). Furthermore, rolipram has good 
brain penetration and a relatively short half-life of 1–3 h(Krause and Kuhne 1988). Hippo-
campal slices treated with rolipram in vitro, showed that cAMP levels were increased (Barad 
et al. 1998; van Staveren et al. 2001). One of the perceived liabilities of rolipram is emesis 
(i.e. nausea), and second generation PDE4 inhibitors such as cilomilast (Ariflo®) and roflu-
milast are thought to be less emetic. But these newer PDE4 inhibitors have been developed 
for peripheral indications, such as respiratory disorders (COPD), and so far no data have 
been published regarding their activity in memory models. Four new PDE4 inhibitors have 
recently been reported in the literature or presented at meetings: MEM1018, MEM1091, 
MEM1414 and HT0712; (Bourtchouladze et al. 2003; Trippodi and Rose 2002; Zhang et 
al. 2005). The review by Blokland et al (2006) gives an extensive review of the literature on 
PDE4-I and memory. The following section will add the latest recent studies from the litera-
ture and some studies presented in this thesis that add to the growing literature on PDE4-I 
and cognitive enhancement. 
Recent findings
Apart from the studies of rolipram and HT0712 on short-term and long-term memory, 
a recent study by Zhang et al. (2005) showed memory enhancing effects of two novel 
PDE4 inhibitors MEM 1018, MEM 1091. In this study it was shown that these selec-
tive PDE4 inhibitors ameliorated the behavioral deficits caused by the NMDA receptor 
antagonist MK801 in the radial arm maze and the inhibitory avoidance test. These ef-
fects are likely to be caused by an enhancement of cAMP-mediated signaling in the brain 
(Zhang et al. 2005). 
Furthermore, a novel study by Monti et al. (2005) for the first time showed behavioral 
effects after chronic rolipram treatment. Rolipram was administered through osmotic mini-
pumps for 7 days and animals were tested in fear conditioning afterwards. Chronic rolipram 
treatment enhanced retention and slowed down extinction of conditioned fear. In addition 
hippocampal CREB and Arc were activated in slices after chronic rolipram treatment (Monti 
et al. 2006). These studies again show the involvement of cAMP, through PDE4 inhibition, 
in processes of synaptic plasticity and learning and memory. 
Reviewing the available literature on rolipram there seemed to be a lack of a systematic 
and profound evaluation of the effects of PDE4 inhibition on acquisition, consolidation and 
retrieval of LTM. In the present thesis several experiments were carried out to elucidate 
some issues on the effects of rolipram on short-term and long-term memory and the pro-
cesses of acquisition and consolidation in particular. Furthermore, we investigated the ef-
fects of PDE4-I in non-human primates. An overview of the available literature on the effects 
of PDE4-I on learning and memory is given in Table 2, which is an adapted and updated ver-
sion of the overview in Blokland et al (2006). Results of the studies presented in this thesis 
were left out of the Table.
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To our knowledge, the effects of PDE4-Is on learning and memory performance have not 
been tested in human studies yet. A possible explanation for this might be that the most 
used PDE4-I in behavioral studies, rolipram, produces severe emetic side effects in humans. 
Novel PDE4-Is are thought to produce less negative side effects, but thus far no human 
memory studies have been reported.
Table 2: Effects of PDE4 inhibitors on learning and memory processes 
Task
(memory process)
Model
(species) Treatment Results Reference
Morris water maze
(spatial, hippocampus-
dependent)
Microsphere embo-
lism-induced cerebral 
ischaemia
(rat)
rolipram 3 mg/kg, ip,  
10 days, after embolism
 Rolipram attenuates 
acquisition deficit mea-
sured at days 7–9 
(Nagakura et al. 
2002)
Radial arm water maze
(spatial, hippocampus-
dependent)
APP-PS1 Alzheimer 
(mouse)
rolipram 0.1 uM/kg  
for 3 weeks
Improvement wh en 
tested at 2 months after 
3–week treatment
(Gong et al. 2004)
Barnes circular maze
(spatial, hippocampus-
dependent)
Age-deficit
(18 months old mouse)
rolipram 0.016 mg/kg, ip, 
40 min before training
More mice acquire the 
task and number of er-
rors is reduced
(Bach et al. 1999)
Radial arm maze
(working & reference 
memory, hippocam-
pus-dependent)
Scopolamine 0.5/1.0mg/
kg, ip, 
30 min before test
(rat)
rolipram 0.01–1 mg/kg, 
ip, 45 min before test
MED: 0.1 (working 
memory) and >0.1 mg/
kg (reference memory)
(Zhang and 
O’Donnell 2000)
Scopolamine 0.5 mg/kg 
ip, 30 min before test
(rat)
(±)-rolipram  
0.01–1 mg/kg, po
 (-)-rolipram 0.005–1mg/
kg, po
 (+)-rolipram (0.1–50 
mg/kg, po)
MED (working memory):
(±)-rolipram 0.02–0.2 
mg/kg
(-)-rolipram 0.01–0.02 
and 0.2/0.5 mg/kg (bi 
phasic)
(+)-rolipram 20/50 mg/kg
(Egawa et al. 1997)
Glutamate antagonist 
dizocilpine 0.l mg/kg, ip, 
60 min before test
(rat)
rolipram 0.01–0.1 mg/kg, 
ip, 30 min before test
MED: 0.05 (working 
memory) and 0.1 mg/kg 
(reference memory)
(Zhang et al. 2000)
Rolipram 0.1 mg/kg, 
MEM 1018 and MEM 
1091 at 0.1–2.5 mg/kg, ip, 
45 min before test
MED: 0.1 mg/kg rolipram 
working memory, 
MED: 2.5 mg/kg MEM 
1018 working and refer-
ence memory
MED:2.5 mg/kg MEM 
1091 on reference 
memory. 
(Zhang et al. 2005)
MEK inhibitor UO126, 
8ug/rat into hippocam-
pus, given twice: 60 and 
30 min before test (rat)
Rolipram, 0.05, 0.1, mg/
kg, ip, 30 min before test
MED: 0.1 mg/kg (refer-
ence memory) (Zhang et al. 2004a)
Passive avoidance
(inhibitory avoidance 
learning, hippocam-
pus and amygdala 
dependent)
Scopolamine, 3 mg/kg ip, 
30 min before retention 
test
(rat)
Given 60 min before 
retention test.
(±)-rolipram 0.01–
0.1 mg/kg, po
 (-)-rolipram 0.005–0.02 
mg/kg, po
 (+)-rolipram 0.3–10 
mg/kg, po
MED:
(±)-rolipram 0.02–0.1 
mg/kg
(-)-rolipram 0.01–0.02 
mg/kg
(+)-rolipram 2 mg/kg; no 
effect at 10 mg/kg
(Egawa et al. 1997)
Scopolamine, 1.5 mg/kg, 
ip, immediately after 
training
(mouse)
Rolipram 10 and 30 
mg/kg, po, 30 min before 
training
MED: 30 mg/kg (Ghelardini et al. 2002)
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Task
(memory process)
Model
(species) Treatment Results Reference
Scopolamine, 1 mg/kg, ip 
30 min before acquisition
(mouse)
Rolipram, 1–30 mg/kg, ip, 
30 min before acquisition MED: 10 mg/kg
(Imanishi et al. 
1997)
Glutamate antagonist 
dizocilpine 0.l mg/kg, ip, 
60 min before test
(rat)
Rolipram 0.1 mg/kg, ip, 
30 min before test MED: ≤ 0.1 mg/kg
(Zhang and 
O’Donnell 2000)
Rolipram 0.1mg/kg, MEM 
1018 and MEM 1091 at 
0.1 – 2.5 mg/kg, ip, 45 
min before test
MED: Rolipram 0.1mg/kg, 
MEM1018 0.1–2.5mg/kg 
and MEM 1091 0.5–2.5 
mg/kg on reversal 
latency
(Zhang et al. 2005)
MEK inhibitor UO126, 
8ug/rat into hippocam-
pus, given twice: 60 and 
30 min before test
Rolipram, 0.1, mg/kg, ip, 
30 min before test or 30 
ug/rat into hippocampus, 
20 min before test
Reversal retention deficit 
48–h post training (Zhang et al. 2004a)
3–panel runway task
(working memory, hip-
pocampus- prefrontal 
cortex dependent)
Scopolamine, 0.56 
mg/kg, ip, 15 min before 
first trial
(rat)
Rolipram, 0.032, 0.1 
mg/kg, ip, 30 min before 
first trial
MED: 0.1 mg/kg for 
decrease errors
(Imanishi et al. 
1997)
Cerebral ischemia by 
four-vessel occlusion
(rat)
Rolipram, 0.032, 0.1 
mg/kg, ip, 30 min before 
first trial (immediately 
after reperfusion)
MED: 0.1 mg/kg for 
decrease errors
(Imanishi et al. 
1997)
ECS immediately after 
training
(rat)
Rolipram, 0.1 , 0.32 mg/
kg, ip, just before ECS
MED: 0.32 mg/kg for 
decrease errors
(Imanishi et al. 
1997)
Inhibitory avoidance
(hippocampus and 
amygdala dependent)
1. Protein synthesis 
inhibitor anisomycin, 150 
mg/kg, sc, 30 min before 
training
2. Low baseline
(mouse)
Rolipram 3, 10 mg/kg, 
ip, immediately after 
training  or 3 hours after 
training 
MED 10 mg/kg, given im-
mediately after training 
(1 + 2) (Randt et al. 1982)
Contextual fear-condi-
tioning
(hippocampus and 
amygdala dependent)
Unimpaired 
(mouse)
Rolipram 0.03 mg/kg, sc, 
30 min before training
Improved retention 24 h 
after training (Barad et al. 1998)
Unimpaired
(rat)
Rolipram 0.5 mg/kg per 
day for 7 days chronic 
delivery by osmotic mini-
pumps
Improved memory 
consolidation and slower 
extinction of conditioned 
fear
(Monti et al. 2006)
Impaired TG2576 
Alzheimer mice
(mouse)
Rolipram 30 min prior to 
training at 0.1 mg/kg ip
Improvement in mutants 
and wild type (Comery et al. 2005)
APP-PS Alzheimer mice
(mouse)
Rolipram 0.1 uM/kg for 
3 weeks
Improvement when 
tested 2 months follow-
ing 3–week treatment
(Gong et al. 2004)
Novel object 
recognition
(hippocampus and rhi-
nal cortex dependent)
Unimpaired young (rat)
MEM1414 given:
1. prior to training
2. immediately after 
training
3. immediately prior to 
testingrolipram
Improvement when 
given prior to or after 
training
(Trippodi and Rose 
2002)
Unimpaired young and 
aged
(rat)
MEM1018 at 0.05, 0.5, 5 
mg/kg, ip
MED: ≤ 0.05 mg/kg 
(young) and 0.5 mg/kg 
(aged)
(Trippodi and Rose 
2003)
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Task
(memory process)
Model
(species) Treatment Results Reference
Unimpaired young (rat)
Rolipram 0.01, 0.03 and 
0.1 mg/kg ip given:
1. 30 min before training
2. directly after training
3. 3h after training.
-Results are presented in 
present thesis-
(Rutten et al. 2006b) 
& Chapter 3
Unimpaired young (rat)
Rolipram 0.03 mg/kg ip. 
Given:
1. directly after training
2. 1h after training
3. 3h after training
4. 6h after training
-Results are presented in 
present thesis-
(Rutten et al. 2006c) 
& Chapter 4
Scopolamine (0.1 
mg/kg, i.p. 30 min before 
training
(rat)
Rolipram 0.03, 0. and 0.3 
mg/kg, i.p. 30 min before 
training.
-Results are presented in 
present thesis-
(Rutten et al. 2006b) 
& Chapter 3
Acute Tryptophan Deple-
tion 3h before training 
(rat)
Rolipram 0.03, 0.1 and 
0.3 mg/kg ip 30 min 
before training
-Results are presented in 
present thesis-
(Rutten et al. in 
press) & Chapter 5
Heterozygous CBP 
mutants
(mouse)
Rolipram 0.1 mg/kg, 
ip; HT0712 0.001 – 0.5 
mg/kg, ip 20 min before 
training
MED: 0.1 mg/kg for both 
drugs. Improved object 
recognition at 24 hours
(Bourtchouladze  
et al. 2003)
Object location 
memory (hippocampal 
dependent, spatial 
memory)
Unimpaired young and 
aged-impaired
(rat)
MEM1018 at 0.05, 0.5, 5 
mg/kg, ip
MED: ≤ 0.05 mg/kg 
(young) and 0.5 mg/kg 
(aged)
(Trippodi  
and Rose 2003)
Delayed responding
(prefrontal cortex 
dependent, working 
memory)
Unimpaired young and 
aged-impaired
(rhesus monkey)
Rolipram 0.01–100 
ug/kg, im 1 hour before 
testing
At 0.1 ug/kg, trend for 
improvement in young 
Aged subjects impaired 
by 10 ug/kg.
(Ramos et al. 2003)
Object retrieval
(prefrontal cortex 
dependent, executive 
functioning, response 
inhibition)
Unimpaired 
(cynomolgus macaques)
Rolipram 0.003, 0,01 and 
0.03 mg/kg, im 30min 
before testing
-Results are presented in 
present thesis- Chapter 7
Abbreviations: ip: intra peritoneal;sc: sub cutane;  po: oral; im: intra muscular MED: mediation
PDE5 and cognition
PDE5 inhibitors
Prickaerts et al. (1997) for the first time described memory enhancing effects of PDE5 
inhibition. In that study zaprinast was used to investigate memory enhancing effects, 
however zaprinast is not selective for P DE5, i.e. it also inhibits PDE1, 9, 10, and 11. 
Since then, more highly selective PDE5 inhibitors have been developed, but for the phar-
macological treatment of erectile dysfunction. At the moment three PDE5 inhibitors are 
approved for use in several countries; sildenafil (Viagra), vardenafil (Levitra), and tadalafil 
(Cialis) (Blokland et al. 2006, in press). One review is available for a detailed discussion on 
the behavioral effects of PDE5-I (seePrickaerts et al. 2004). The next section will provide 
some of the more recent findings from the literature and from our own research, as pre-
23
General Introduction
sented in this thesis. A complete summary of the available literature at present on PDE5-I 
and memory is shown in Table 3. 
Thus far several studies have shown effects of selective PDE5 inhibitors on memory 
performance in the object recognition task in rats (Prickaerts et al. 2005; Prickaerts et al. 
1997; Prickaerts et al. 2002b). Studies described in the present thesis extend these findings 
and investigated the effects of PDE5-I in mice (chapters 2 and 4). 
Several studies have shown improvement in the elevated plus maze, a behavioral test 
that measures anxiety and spatial memory in rats and mice. Sildenafil and zaprinast im-
proved performance in this task in rats (Singh and Parle 2003) and mice (Patil et al. 2004b), 
however another study failed to show an effect of sildenafil in this test and in the open field 
test (Volke et al. 2003). A possible explanation for this contradiction is that in the previous 
studies sildenafil was administered immediately after the learning trial and in this study 
sildenafil was administered 30 min before the first trial. This further supports the role of 
cGMP in early consolidation instead of acquisition processes (See Prickaerts et al. 2005). 
Sildenafil treatment also ameliorated the deficits induced by two different models for diabe-
tes and electro convulsive shocks (Patil et al. 2006; Patil et al. 2004b). 
Previous studies showed no effects of PDE5-I on spatial tasks, i.e. the water escape task 
or the Y maze (Prickaerts et al. 2004). However, in hyperammonemia or portacaval shunt 
deficit models for liver failure, both sildenafil and zaprinast reversed spatial recognition defi-
cits in rats (Erceg et al. 2006; Erceg et al. 2005a; Erceg et al. 2005b). 
Previous work showed that zaprinast reversed the deficits induced by the NOS inhibi-
tor 7-nitroindazole in rats in the ORT (Prickaerts et al. 1997). Recent work adds to this in 
that sildenafil reversed the effects the NOS inhibitor L-NAME, in a complex maze learn-
ing paradigm (Devan et al. 2006). Furthermore, various studies investigated the effects of 
PDE5-I on active and passive avoidance learning in rats, mice and neonatal chicks. Memory 
impairments caused by scopolamine, a model for diabetes and electro convulsive shocks 
in rats were reversed by sildenafil treatment (Devan et al. 2004; Patil et al. 2006; Patil et 
al. 2004b). Although one study failed to show improvement in learning performance after 
sildenafil treatment in unimpaired and aged rats (Shafiei et al. 2006), others show improve-
ment of learning and memory after treatment with PDE5-I in unimpaired and aged mice 
and in neonatal chicks (Campbell and Edwards 2006; Patil et al. 2004a). Taken together, 
a growing amount of evidence shows pro-cognitive effects of PDE5-I in several behavioral 
memory models. Most research so far has focused on rodent models and it would be of great 
importance to extend these findings into non-human primates or human clinical studies. 
Since PDE5-I are clinically accepted for the treatment of male erectile dysfunction, these 
drugs can be easily tested in a clinical experimental setup. 
The effects of sildenafil (100 mg) on early information processing and memory process-
es in humans have only sporadically been studied. Thus far, no clear effects on the behavioral 
measures of attention and verbal recognition memory have been reported (Schultheiss et al. 
2001). However, there are some methodological considerations since only STM was mea-
sured at an already optimal performance allowing a minimal window for treatment effects. 
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Yet, in the same study, attention-related event-related brain potential (ERP) measures were 
enhanced by sildenafil. In addition, another study reported that the simple choice reaction 
time was faster in sildenafil-treated subjects (Schultheiss et al. 2001). Thus, early informa-
tion processing in humans can be influenced by PDE5 inhibition, but these processes as well 
as memory-related processes clearly need more investigation. A recent study by our group, 
presented in this thesis, investigated the effects of sildenafil on performance in a prefrontal 
task in non-human primates (chapter 7).
Taken together, animal studies indicate that PDE5 inhibitors have the potential to improve 
early consolidation processes of LTM, although this may be excluded for spatial informa-
tion. This memory improvement might be mediated by elevations in central cGMP levels. 
Sildenafil treatment in humans and primates suggests that information processing may be 
improved. Table 3 gives an overview of the available literature on the effects of PDE5-I on 
learning and memory. Recently obtained results by our group are described in the present 
thesis, but were left out of this table.
Table 3: Effects of PDE5 inhibitors on learning and memory processes
Task
(memory pro-
cess)
Model
(species) Treatment Results Reference
Object Recognition 
task 
(hippocampus-  
and rhinal cortex-
dependent)
Unimpaired (rat)
Sildenafil Citrate (1, 3, 10 mg/kg, po). 
30min before or immediately after first 
trial. (24h interval T1-T2)
Sildenafil (3mg/kg T0  
or 10mg/kg T1-30min) 
improves memory consoli-
dation 
(Prickaerts et al. 
2005)
Unimpaired (rat) Zaprinast (3 or 10mg/kg,ip) immedi-ately after first trial. (4h interval T1-T2)
Zaprinast (10mg/kg) 
improved memory consoli-
dation.
(Prickaerts et al. 
1997)
Unimpaired (rat)
Sildenafil (1, 3, 10mg/kg,po) im-
mediately after first trial. (24h interval 
T1-T2)
Sildenafil (3mg/kg) im-
proved memory consolida-
tion in ORT. 
(Prickaerts et al. 
2002b)
Unimpaired (rat)
Vardenafil (0.1, 0.3, 1, 3 mg/kg,po) im-
mediately after first trial. (24h interval 
T1-T2)
Vardenafil (0.3mg/kg) 
improved memory consoli-
dation in ORT.
(Prickaerts et al. 
2002b)
Unimpaired (rat)
Vardenafil (1mg/kg, po) immediately 
after, 1h, 3h or 6h after first trial. (24h 
interval T1-T2)
-Results are presented in 
present thesis-
(Rutten et al. 
2006c) 
& Chapter 4
Unimpaired (mouse)
Sildenafil (0.3, 1, 3 mg/kg, po) im-
mediately after first trial. (24h interval 
T1-T2)
-Results are presented in 
present thesis-
(Rutten et al. 
2005) 
& Chapter 2
Impaired by NOS 
inhibitor (rat)
7–nitroindazole (10 or 30mg/kg,ip)
Zaprinast (3 or 10mg/kg,ip) immedi-
ately after first trial. (1h interval T1-T2)
Zaprinast (10 mg/kg) 
reversed the NOS-I (10mg/
kg) deficit in ORT
(Prickaerts et al. 
1997)
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Task
(memory pro-
cess)
Model
(species) Treatment Results Reference
Elevated Plus-maze: 
anxiety and spatial 
memory. Unimpaired (rat)
Sildenafil (2, 4, 8 mg/kg, ip) 30min 
before or immediately after first trial.
Sildenafil (8mg/kg) before 
T1 marginally increased 
spatial memory acquisition.
Sildenafil (2, 4, 8mg/kg) 
imm. after T1 increased 
spatial memory retention. 
(Singh and Parle 
2003)
Unimpaired
(mouse)
Sildenafil (0.05–10 mg/kg, ip) 30min 
before test
No effects on plus maze 
performance. (Volke et al. 2003)
Unimpaired 
(mouse)
Age impaired
(mouse)
Sildenafil (0.25, 0.5, 1mg/kg, ip) im-
mediately after first trial. 
Sildenafil improved spatial 
memory performance in 
young (0.5 and 1.0mg/kg) 
and aged (0.25–1 mg/kg) 
animals.
(Patil et al. 2004a)
Unimpaired 
(mouse)
Age impaired
(mouse)
Zaprinast (0.5, 1, 2mg/kg,ip) immedi-
ately after first trial
Zaprinast improved spatial 
memory performance in 
young (1.0 and 2.0mg/kg) 
and aged (0.5–2 mg/kg) 
animals.
(Patil et al. 2004a)
Impaired by diabetes-
STZ (rat)
Streptozotocin (STZ) (60mg/kg,ip)
Sildenafil (0.25, 0.5, 1 mg/kg, ip) im-
mediately after training.
Sildenafil (all doses) re-
versed STZ spatial memory 
deficits.
(Patil et al. 2006)
Impaired by diabetes-
LPS 
(mouse)
Lipopolysaccharine (LPS: 50ug, ip) and 
sildenafil (0.25, 0.5, 1 mg/kg, ip)  or za-
prinast (0.5, 1, 2mg/kg,ip) immediately 
after training
Sildenafil (0.5 and 1 mg/kg) 
and Zaprinast (1 and 2 mg/
kg) reversed LPS spatial 
memory deficits. 
(Patil et al. 2004b)
Impaired by Electro 
convulsive shock (rat)
Shocks (0.2mA,0.2s/day for 15 days)
Sildenafil (0.5, 1, 2 mg/kg, ip) immedi-
ately after training.
Sildenafil (all doses) 
reversed  spatial memory 
deficits
(Patil et al. 2006)
Open Field Unimpaired(mouse)
Sildenafil (0.05–10 mg/kg,ip) 30min 
before test No effects on anxiety (Volke et al. 2003)
Y-maze: spatial rec-
ognition memory 
(hippocampus /
cerebellum- depen-
dent)
Unimpaired (rat) Vardenfil (3mg/kg, po) daily after last 
trial.
No effects on spatial 
recognition
(Prickaerts et al. 
2004)
Impaired by Hyperam-
monemia
(rat) 
Sildenafil (50mg/L) in drinking water 
two days before training.
Sildenafil (in drink water) 
reversed spatial recogni-
tion deficits.
(Erceg et al. 2006)
Impaired by Hyperam-
monemia
(rat)
Ammonium acetate containing diet 
(28 days before testing)
Zaprinast (50uM, 0.25 ul/h, 2 days 
before testing) in cerebral ventricle.
Zaprinast (through mini-
pump) reversed spatial 
recognition deficits.
(Erceg et al. 
2005a)
Impaired by Portacaval 
Shunts
(rat)
Portacaval shunt operation 28 days 
before test.
Sildenafil (50mg/L) in drinking water 
two days before training.
Sildenafil (in drink water) 
reversed spatial recogni-
tion deficits.
(Erceg et al. 
2005b)
Water Escape Task: 
spatial memory 
(hippocampus)
Unimpaired (rat) Zaprinast (10mg/kg, ip) daily after 
last trial.
No effects on acquisition 
or retention of spatial 
memory
(Prickaerts et al. 
2004)
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Task
(memory pro-
cess)
Model
(species) Treatment Results Reference
Complex Maze 
Learning (hippo-
campus)
Impaired by NOS 
inhibitor (rat)
L-NAME (60mg/kg,ip) 30min before 
training 
Sildenafil (1, 1.5, 3, or 4.5 mg/kg, ip) 
15min before training.
Sildenafil (1.5mg/kg) 
attenuated the L-NAME 
deficit in Maze learning.
(Devan et al. 
2006)
Active Avoidance 
learning (hippo-
campus)
Impaired by Scopol-
amine (rat)
Scop. (0.75mg/kg, i.p) 30min before 
training
Sildenafil (1.5, 3 or 4.5mg/kg,ip) 15min 
before training.
Sildenafil (3mg/kg) 
reversed the scopolamine 
deficit in active avoidance 
task.
(Devan et al. 
2004)
Unimpaired
(mouse)
Sildenafil (1, 3, 10 or 30 mg/kg, i.p.) 30 
min before training or immediately 
after training
Sildenafil (3mg/kg) im-
proved performance (both 
30min before and imm. 
after training) in active 
avoidance.
(Baratti and Boc-
cia 1999)
Passive Avoidance 
(hippocampus) Unimpaired (rat)
Sildenafil (1, 3, 10, 20 mg/kg, ip) im-
mediately after training in young and 
old rats. 
Sildenafil has no effect on 
retention performance in 
passive avoidance.
(Shafiei et al. 
2006)
Unimpaired
(neonate chick)
Zaprinast (0.1–750uM/side, ic) im-
mediately after training.
Zaprinast (>100uM) en-
hanced early consolidation. 
(Campbell and 
Edwards 2006)
Unimpaired 
(mouse)
Age impaired
(mouse)
Sildenafil (0.25, 0.5, 1mg/kg, ip) im-
mediately after first trial. 
Sildenafil improved 
consolidation in young (0.5 
and 1.0mg/kg) and aged 
(0.25–1 mg/kg) animals.
(Patil et al. 2004a)
Unimpaired 
(mouse)
Age impaired
(mouse)
Zaprinast (0.5, 1, 2mg/kg,ip) immedi-
ately after first trial
Zaprinast improved spatial 
memory performance in 
young (1.0 and 2.0mg/kg) 
and aged (0.5–2 mg/kg) 
animals.
(Patil et al. 2004a)
Impaired by Diabetes 
(rat)
STZ (60mg/kg,ip)
Sildenafil (0.25, 0.5, 1 mg/kg, ip) im-
mediately after training.
Sildenafil (all doses) re-
versed STZ memory deficit 
of diabetes.
(Patil et al. 2006)
Impaired by Electro 
convulsive shock (rat)
Shocks (0.2mA,0.2s/day for 15 days)
Sildenafil (0.5, 1, 2 mg/kg, ip) immedi-
ately after training.
Sildenafil (all doses) 
reversed memory deficit of 
diabetes.
(Patil et al. 2006)
Impaired by diabetes-
LPS 
(mouse)
Lipopolysaccharine (LPS: 50ug, ip) and 
sildenafil (0.25, 0.5, 1 mg/kg, ip)  or za-
prinast (0.5, 1, 2mg/kg,ip) immediately 
after training
Sildenafil (0.5 and 1 mg/kg) 
and Zaprinast (1 and 2 mg/
kg) reversed LPS induced 
memory deficits. 
(Patil et al. 2004b)
Object retrieval/
detour task (pre-
frontal)
Unimpaired
(cynomolgus macaque)
Sildenafil (0.3, 1, 3 mg/kg, im) 30 min 
before test.
-Results are presented in 
present thesis- Chapter 7
Verbal recognition 
memory  & ERP Unimpaired (human)
Sildenafil (100mg) capsule 1h before 
test.
ERP:Reduction of of nega-
tivity in 150–250ms range.
(Schultheiss et al. 
2001)
Auditory selective 
attention Unimpaired (human)
Sildenafil (100mg) capsule 1h before 
test.
ERP: indicative of enhanced 
ability to focus attention
(Schultheiss et al. 
2001)
Simple Choice reac-
tion test. Unimpaired (human)
Sildenfil (100mg) capsule 1h before 
test.
Sildenafil enhanced simple 
reaction times. (Grass et al. 2001)
Abbreviations: ip: intra peritoneal;sc: sub cutane;  po: oral; im: intra muscular; ERP: evoked response potential
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Aim and outline of the Thesis
Taken together the studies described above strongly indicate that PDE-Is can enhance the 
effects of cAMP and/or cGMP and may therefore improve learning and memory. The main 
question in this thesis was whether PDE-I enhances specific memory modalities and pro-
cesses in different animal models. 
As mentioned before the PDE5-I enhances memory in rats and mice. We investigated silde-
nafil in the object recognition task in Swiss mice and looked at the cGMP immunoreactivity 
(IR) in the hippocampus. Since the pre-synaptic mechanism of NO-cGMP is suggested in the 
early phase of LTP (see above) we tried to show a pre-synaptic co-localization of cGMP and 
a pre-synaptic marker (i.e. synaptophysin) (Chapter 2).
The effect of rolipram and the temporal effects on object memory were investigated in rats. 
Bernabeu et al. (1996) showed that intra-hippocampal injections of 8Br-cAMP were only ef-
fective 3h after learning. We hypothesized that the PDE4 inhibitor rolipram, that enhances 
cAMP levels, should therefore also be effective around 3h after learning. We investigated the 
administration time-dependent effects of rolipram on memory performance in the object 
recognition task. Furthermore we wanted to test the effects if rolipram in the scopolamine 
deficit model. (Chapter3). 
To further examine the administration time related effects of PDE-Is and the time-depen-
dent effects of cAMP and cGMP on object memory we examined the effects of three dif-
ferent PDE-Is, namely PDE-4, -5, and -2 inhibitors in rats. Compounds were administered 
at different time points after training. (Chapter 4)
To test the notion that PDE4-I can also enhance memory by interaction with different neu-
rotransmitter systems, for instance rolipram attenuated the scopolamine-induced memory 
deficit, we hypothesized that rolipram may also reverse the deficit caused by a different mod-
el for amnesia, namely acute trypthophan depletion. (Chapter 5)
To study the function of PDE4 in animal models, PDE4 knock-out (KO) mice have been 
generated (Jin et al. 2005).These KO mice have been generated for two different isoforms of 
PDE4, namely PDE4D and PDE4B that are widely distributed in the mouse, rat, monkey and 
human brain (Dlaboga et al. 2006; Perez-Torres et al. 2000). Based on the literature, it was 
hypothesized that PDE4D-KO animals have a pro-cognitive-antidepressive profile (Zhang 
et al. 2002). To see whether this hypothesis holds, we tested PDE4B and PDE4D KO mice 
in a fear conditioning paradigm. Animals were tested for LTM, STM and control experiments 
for locomotion and nociception (i.e pain perception) were conducted (Chapter 6). 
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To further extend the knowledge on the cognitive enhancing effects of PDE4-I and PDE5-I 
we decided to investigate the effects of these compounds in Cynomolgus macaques. The 
model of object retrieval focuses on prefrontal mediated responses. We hypothesized that 
PDE –I may also produce enhancing effects in other brain regions, such as the prefrontal 
cortex (Chapter 7).
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2 The Selective PDE5 inhibitor sildenafil improves object memory in Swiss mice  
and increase cGMP levels  
in hippocampal slices
K. Rutten, J. De Vente, A. Şik, M. Markerink–van Ittersum, 
J. Prickaerts And A. Blokland
Behavioral Brain Research (2005) 164: 1–16
Previous studies have shown memory enhancing effects of phosphodi-
esterase type 5 (PDE5) inhibitors in rats. However, differences in nitric 
oxide (NO)-mediated cyclic GMP (cGMP) signaling in the hippocampus 
have been described between rats and mice. In the present study we in-
vestigated the memory enhancing effects of the PDE5 inhibitor, sildenafil 
on memory performance in Swiss mice using the object recognition task. 
Sildenafil (0.3, 1 and 3 mg/kg) was administered orally directly after the 
first trial. The memory for the objects was retested 24-h later when mice 
show no memory for the familiar object. Sildenafil improved the object dis-
crimination performance of Swiss mice at a dose of 1 mg/kg. Hippocam-
pal slices of Swiss mice incubated with sildenafil (10 µM) increased cGMP 
levels in varicosities in the CA3 region of the hippocampus and a number 
of short, thin fibers. Addition of DEA/NO, an NO donor (10µM), in the 
presence of sildenafil (10 µM) strongly increased cGMP immunoreactiv-
ity of varicosities in the CA3 region. Double immunostaining of cGMP 
with the presynaptic marker synaptophysin did not reveal any co-local-
ization of these markers under any circumstance. Taken together, inhibi-
tion of PDE5 improves object recognition memory in mice. Furthermore, 
a postsynaptic role of cGMP could be involved in this respect. 
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Introduction
Recently, evidence has been accumulating that cyclic GMP (cGMP) plays a role in memory 
processes (e.g Bernabeu et al. 1996; Prickaerts et al. 2002a). Accordingly, inhibition of the 
cGMP hydrolysing phosphodiesterase type 5 (PDE5) may be an important tool to improve 
early consolidation of memory (see Prickaerts et al. 2004). 
In vitro experiments demonstrated that the selective PDE5 inhibitors zaprinast, vardenafil 
and sildenafil increase NO-mediated cGMP accumulation in the dorsal hippocampus of rats 
as assessed with radioimmunoassay and immunocytochemistry (de Vente et al. 1996; Prick-
aerts et al. 2002a; van Staveren et al. 2001).
All these experiments have been performed in rat tissues. Recently, we observed 
that in the mouse hippocampus slice preparation cGMP-immunoreactivity was already 
observed in astrocytes without stimulation of a NO donor (van Staveren et al. 2004). 
Under similar conditions, such a pattern of cGMP-immunoreactivity has never been ob-
served in the rat hippocampus. Thus, there are differences in the cellular localisation and 
activity of NO-mediated cGMP signalling between mouse and rat hippocampus. Never-
theless, the expression pattern of PDE 5 mRNA were not different between the species 
(van Staveren et al. 2004).
Considering the differences in NO mediated cGMP signalling mentioned above, the 
aim of the present study was to examine the memory-enhancing properties of PDE5 inhibi-
tors in mice. For the first time the object recognition task (ORT) was used to study the ef-
fects of PDE5 inhibition, i.e. sildenafil, on the delay-dependent forgetting in mice.
In addition to the behavioural study, we evaluated the effects of PDE5 inhibition on 
cGMP-immunoreactivity (cGMP-IR) in hippocampal slices using cGMP immunocytochem-
istry in a separate experiment. Since NO, as a retrograde messenger, is assumed to mediate 
a presynaptic effect (Arancio et al. 2001; Son et al. 1998), we also analyzed whether cGMP 
immunoreactivity co-localized with the presynaptic marker synaptophysin.
Materials and methods
Animals
All experimental procedures were approved by the local ethical committee of the Maastricht 
University for animal experiments and met governmental guidelines. Ten 6-month-old male 
Swiss mice (Charles River, NL) were used for behavioral testing and four mice were used for 
immunocytochemistry. The animals were housed individually in standard Makrolon cages 
on sawdust bedding in an air-conditioned room (about 20° C). The mice were not housed 
in the same room in which they were tested. A radio, which was playing softly, provided 
background noise in all rooms. All testing was done between 9.00 and maximally 16.00 h. 
The animals were kept under a reversed 12/12-hour light/dark cycle (lights on from 18.00 to 
6.00 h) and had free access to food and water.
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Object recognition memory
The object recognition test was performed as described elsewhere (Sik et al. 2003). The appa-
ratus consisted of a circular arena, 43 cm in diameter. Half of the 40 cm high wall was made 
of white polyvinyl chloride, the other half of transparent polyvinyl chloride. Fluorescent red 
tubes and a light bulb provided a constant illumination of about 20 lux on the floor of the 
apparatus. Two objects were placed symmetrically about 5 cm away from the white wall. 
Each object was available in triplicate. We used four different sets of objects. The different 
objects were: 1) a cone made of brass (maximal diameter 6 cm and total height 3.8 cm), 
2) a transparent glass bottle (diameter 2.7 cm, height 8.5 cm) filled with sand, 3) a massive 
metal cube (2.5 × 5 × 7.5 cm) with two holes (diameter 1.5 cm), and 4) a massive aluminum 
cube with a tapering top (4.5 × 4.5 × 8.5 cm). The objects could not be displaced by a mouse.
In the first week, the animals were handled daily and were adapted to the procedure in 
three days, i.e. they were allowed to explore the apparatus (without any objects) twice for 5 min 
each day. In the following two weeks, the mice were tested until they showed a good discrimina-
tion performance. A saline injection (0.4 ml) was always given after the first exploration period 
to adapt the mice to the p.o. administrations. The next week, testing of the drugs began.
A testing session comprised of two trials. The duration of each trial was 3 min. During 
the first trial (T1) the apparatus contained two identical objects (samples). A mouse was al-
ways placed in the apparatus facing the wall at the middle of the front (transparent) segment. 
After the first exploration period, the mouse was put back in its home cage. Subsequently, 
after a predetermined delay interval (24h), the mouse was put back in the apparatus for the 
second trial (T2), but now with two dissimilar objects, a familiar one (the sample) and a new 
one. The times spent exploring each object during T1 and T2 were recorded manually using 
a personal computer.
Exploration was defined as follows: directing the nose to the object at a distance of no more 
than 2 cm and/or touching the object with the nose. Sitting on the object was not considered 
as exploratory behavior. In order to avoid the presence of olfactory cues the objects were always 
thoroughly cleaned before each trial. All combinations and locations of objects were used in a bal-
anced manner to reduce potential biases due to preferences for particular locations or objects. 
Treatments
The effects of sildenafil treatment on object memory performance were tested at different 
doses (0.3, 1, and 3 mg/kg). Sildenafil was freshly suspended in 1% Tylose (methyl-cellulose) 
on every experimental day. Since we expected sildenafil to improve memory performance, 
a 24 h delay interval between T1 and T2 was chosen. Administrations were always given im-
mediately after the first trial (p.o.; in 5 ml/kg). Two testing sessions were given each week, 
one session comprising Monday and Tuesday and the other one comprising Thursday and 
Friday. The doses were tested in a random order. Each dose condition was tested twice and 
the scores per condition were pooled for each mouse.
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Tissue preparation
The mice were decapitated and their brains were immediately transferred into ice-cold Krebs-
Ringer bicarbonate buffer (Krebs buffer) of the following composition: 121.1 mM NaCl, 
1.87 mM KCl, 1.17 mM KH2PO4, 1.15 mM MgSO4, 26.2 mM NaHCO3, 2.0 mM CaCl2 and 
11.0 mM glucose, aerated with  95% O2 and 5% CO2 at pH 7.4. 
Hippocampal slices (300 µm) were cut using a Vibroslicer (Campden Instruments). 
Throughout the procedure, slices were kept under aeration with 95% O2 and 5% CO2. Af-
ter sectioning in ice-cold Krebs buffer, slices were brought to room temperature and then 
transferred to incubation wells and incubated for 30 minutes at 35.5° C in Krebs buffer in 
the presence or absence of 10µM sildenafil. Next, the slices were incubated for another 10 
minutes with or without 10µM diethylamino-NONOate (DEA/NO). Sildenafil was dissolved 
in DMSO and the controls contained the appropriate concentration of DMSO. 
Immunocytochemistry
After the incubation period, slices were fixed with ice-cold fixative solution of 4% freshly 
prepared depolymerised paraformaldehyde in 0.1 M phosphate buffer (pH 7.4) for 30 min-
utes at 4° C. Thereafter, slices were fixed for another 90 minutes with 4% paraformalde-
hyde containing 10% sucrose. After washing at 4° C in 0.1 M phosphate buffer (pH 7.4) 
containing 10% sucrose, slices were aligned in a plane and snap-frozen with CO2 in Tis-
sue-Tek O.C.T. compound. Cryostat sections (10 µm) were cut and thawed onto chrome-
alumn/gelatin coated slides and processed for immunocytochemistry. 
Frozen sections were dried for 20 minutes at room temperature, followed by three 
5 min. washes with Tris-buffered saline (TBS). Sections were incubated overnight at 4° C 
with primary antibodies diluted in TBS containing 0.3% Triton X-100 (TBS-T). cGMP was 
visualized with sheep anti-formaldehyde fixed cGMP (1:4000). The specificity of the cGMP 
antibody has been detailed elsewhere (De Vente et al. 1998). Sections were incubated with 
the anti-cGMP alone or in combination with anti-synaptophysin (1:500 in TBST). After 
incubation with primary antibodies, sections were washed with TBS-T, TBS and TBS-T; 
each step lasted at least 10 min. For the visualization of the primary antibodies, sections 
were incubated with Alexa fluor 488 donkey anti-sheep IgG conjugate (1:100) for sheep 
antibodies, whereas anti-synaptophysin antiserum was visualized with CY-3 conjugated 
donkey anti-rabbit antiserum (1:800). Incubations with the secondary antibodies lasted 
for 90 min in the dark at room temperature. Thereafter, sections were washed 2 times in 
TBS-T and 1 time in TBS, and mounted with TBS-glycerol. Sections were examined using 
an Olympus AX-70 microscope equipped with an F-view cooled CCD camera. Images were 
stored as 8-bit files using Analysis® software, assembled using Adobe Photoshop 7.0.1, 
adjusting contrast and brightness both at a level of +30.
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Statistical analysis
The basic measures were the times spent by mice exploring an object during T1 and T2. The 
time spent exploring the two identical samples will be represented by ‘a1’ and ‘a2’. The time 
spent in T2 exploring the sample and new object will be represented by ‘a’ and ‘b’, respec-
tively. Based on these exploration times different parameters were calculated (see Table 1) 
(Sik et al. 2003). 
Table 1. Measures involved in the object recognition test
Exploration Habituation Discrimination
e1 = a1 + a2 h1 = e1-e2 d2= b - a / e2
e2 = a + b
e1 is the measure of the time spent exploring both identical objects (a1 and a2) in the 
first trial, and e2 is the measure of the time spent exploring both the familiar (a) and new 
object (b) in the second trial; h1 is the measure of global habituation from trial 1 to trial 2; d1 
and d2 are the measures of discrimination between the new and familiar objects. In fact, d2 
is a relative measure of discrimination which corrects d1 for exploration activity (e2). Since 
the nature of the exploration and discrimination measures is different, they were analyzed 
differently. For e1, e2 and h1 the effects of the different dose conditions were analyzed with 
a within-subject repeated measures design (General Linear Model, GLM). Differences be-
tween dose conditions were calculated in more detail using a Bonferroni post-hoc test. 
When assessing the discrimination performance, we are only interested whether the 
dose conditions differ from the untreated vehicle condition. To evaluate the discrimination 
we compared the d2 values of the different doses with the vehicle group using independent 
sample t-tests. To control for multiple comparisons, the critical α was divided by the number 
of comparisons made. Since three comparisons were made between the vehicle group and 
the three dose groups, the critical α was 0.05/3 = 0.017. 
Results
Effects of Sildenafil treatment in the ORT
The results of treatment with sildenafil are summarized in Table 2. Additional analysis of 
measures of location preference (left or right side of arena) or object preference showed 
no differences between conditions (data not shown). In T1 there was no difference be-
tween treatment sessions on the total level of exploration (e1: F(3,27) = 2.92, n.s.). How-
ever, the total level of exploration 24 h after T1 was different between treatment conditions 
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(e2: F(3,27) = 5.51, P < 0.01). Post-hoc comparisons showed that the level of exploration in 
the highest dose condition (3 mg/kg) was higher than in the vehicle condition. The explora-
tion level in the other treatment conditions did not differ from the exploration level in the 
vehicle condition. The index measure of habituation of exploratory behavior h1 did not dif-
fer between treatment conditions (h1: F(3,27) = 2.14, n.s.). 
Table 2. Results of treatment with Sildenafil on the measures of the object recognition test. Swiss mice 
(n=10 per dose) received a p.o. injection of sildenafil at doses of 0, 0.3, 1 or 3 mg/kg directly after the first 
trial. The delay between the first and the second trial was 24 h.
VEHICLE 0.3 mg/kg 1 mg/kg 3 mg/kg
 Mean values (±S.E.M.) of total exploration time (s) during the first (e1) and second trial (e2)
e1 13.15 (1.98) 17.73 (2.39) 11.96 (1.55) 15.69 (1.71)
e2 9.43 (1.21) 16.88 (2.17) 15.60 (2.26) 21.82 (3.44) 
Mean values (± S.E.M) of the global index of habituation (h1) from the first to the second trial
h1 3.72 (2.26) 0.85 (3.11) -3.64 (3.01) -6.13 (3.29)
Figure 1: Effects of sildenafil treatment on the discrimination performance in an object recognition task in Swiss mice (means + S.E.M.). 
In the vehicle session, mice were treated with 0.1% Tylose solution. In the drug session, animals were treated with doses of 0.3, 1 and 3 
mg/kg sildenafil. Sildenafil improved the performance of the mice at the dose of 1 mg/kg. Differences from the vehicle group are depicted 
by asterisks (** d2 > vehicle group; P < 0.01).
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The effects of treatment with sildenafil on the d2 index are presented in figure 1. When com-
paring the d2 indices of the three dose conditions to the vehicle condition, only the d2 value 
of the medium dose (1 mg/kg) was higher than the vehicle group (t= -2.86; P < 0.01).
Immunocytochemistry 
Incubation of mouse hippocampal slices in vitro in the absence of PDE inhibitors resulted in 
cGMP-positive astrocytes mainly in the CA1 area (not shown, see van Staveren et al. 2004). 
However, when the slices were incubated in the presence of 10µM sildenafil, cGMP-IR was 
additionally visualized in varicosities in the CA3 region of the hippocampus (Fig. 2a) and 
a number of short, thin fibers (Fig. 2c). Addition of 10µM DEA/NO to the incubation me-
dium in the presence of 10µM sildenafil strongly increased the number of cGMP-IR varicosi-
ties in the CA3 region (Fig. 2e). Double immunostaining of cGMP-IR with synaptophysin did 
not reveal any co-localization of these markers under any circumstance (Fig. 2b, d and f).
Discussion
Behavioral studies
As shown in a previous study, mice can be tested in the ORT  and the relative discrimination 
index (d2) can be used as a measure of object memory in mice (Sik et al. 2003). The present 
study investigated the effect of the selective PDE5 inhibitor sildenafil on the object recogni-
tion task in mice. The levels of exploration did not differ between treatment conditions in 
the first trial. However, in the second trial the level of exploration for the vehicle condition 
was lower than for the highest dose condition (3 mg/kg). We do not have a clear explanation 
for the low exploration value for the vehicle group in the second trial, but levels of explora-
tion were sufficient for a reliable assessment of discrimination performance in all treatment 
conditions. The habituation index is a measure for the difference in exploration times be-
tween T1 and T2.  The measure of global habituation (h1) showed no differences between 
treatment conditions. Of note, the corrected discrimination index (d2) is regarded the key 
parameter for assessing discrimination performance.
This study shows that selective PDE5 inhibitors improve object memory performance 
in mice. In the vehicle treatment conditions the mice show no memory of the familiar ob-
ject after 24 hours. However, administration of sildenafil (p.o.) directly after the first trial, 
improved object memory at the dose of 1 mg/kg. Our findings corroborate previous data 
showing that sildenafil improves the performance in a passive avoidance task (Baratti and 
Boccia 1999). In addition, the present data extends the notion that inhibition of PDE5 can 
improve object memory in different species. 
The Effects of Phosphodiesterase Inhibition on Memory 
40
Figure 2: cGMP-IR in hippocampal slices of the CA3 area. a,c) Slices incubated with 10µM sildenafil. 2e) Slices incubated with 10 µM 
sildenafil and 10µM DEA/NO. b,d,f) Synaptophysin immunostaining of the same areas of the same sections as shown in a, c and e. Bars: 
50µm for a and b; 25 µm for c – f.
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Immunocytochemistry
As discussed earlier, using rat brain slices and a selective PDE5 inhibitor, a NO donor is nec-
essary for cGMP detection in the hippocampus (van Staveren et al. 2004). In the mouse hip-
pocampus cGMP levels are already detectable without NO administration and even without 
PDE inhibitors in astrocytes. After administration of 10µM sildenafil, cGMP-IR was visual-
ized in varicosities in the CA3 region of the hippocampus. Addition of a NO donor strongly 
increased cGMP-IR. In contrast to the differences in the levels of cGMP with or without 
stimulation with an NO donor in rats and mice, this effect of sildenafil appears to show 
a similarity between these two species. Accordingly, it can be suggested that the PDE5 inhi-
bition leads to enhanced cGMP levels in varicosities in the hippocampal region in rodents. 
At present it is unknown whether the expression of cGMP in varicosities after PDE5 inhibi-
tion occurs in the same type of neurons. 
Current concepts on the working mechanism of NO in strengthening synaptic contacts 
define a presynaptic effect of NO, in conjunction with the retrograde messenger role of NO 
(Garthwaite and Boulton 1995). The hippocampal slices incubated in the presence of 10µM 
sildenafil showed cGMP-IR within varicosities in the CA3 region of the hippocampus. Our 
present results do not demonstrate a colocalization of cGMP with synaptophysin in the CA3 
region of the mouse hippocampus. However, when using 1mM IBMX as a PDE inhibitor we 
observed an occasional presence of cGMP in presynaptic structures identified by synapto-
physin (van Staveren et al. 2004). Our results might indicate either that PDE5 is not present 
in presynaptic structures, or that cGMP cannot be detected in presynaptic structures un-
der the prevailing conditions. This latter possibility is reminiscent to the situation observed 
in cerebellar Purkinje cells, where NO-mediated cGMP synthesis has been demonstrated 
(Hartell et al. 2001), although cGMP-IR has never been convincingly demonstrated in these 
cells for unknown reasons. It has been stated that the sensitivity of the immunocytochemi-
cal method might be too low to detect low levels of cGMP in these cells (see de Vente and 
Steinbusch 1992 for a detailed discussion). Nevertheless, it has also been argued that the 
detection level of the method might be between 0.1 and 1.0 µM cGMP (Tanaka et al. 1997), 
which is within the range of cGMP levels observed after stimulation of sGC. Although no co-
localisation with synaptophysin and cGMP was found, the present findings do not rule out 
possible pre-synaptic cGMP activity. The presynaptic action of NO/sGC/cGMP is assumed 
to be part of the mechanism of E-LTP. Evidence has been presented that improvement of 
object recognition after sildenafil might in part be mediated by an effect on E-LTP (Ingram 
et al. 1996). The effects of sildenafil on memory we have observed are longer lasting, which 
implies that after induction of E-LTP its effects on memory outlast the period of E-LTP dura-
tion. It is possible that E-LTP is converted into L-LTP, as has been observed recently (Pang et 
al. 2004). Of note, the latter is associated with a postsynaptic localization. Considering the 
absence of colocalization of cGMP-immunoreactivity with synaptophysin, we conclude that 
sildenafil also acts postsynaptically. Recently, it was demonstrated that NO and cGMP act 
both pre- and postsynaptically during induction of a form of E-LTP (Wang et al. 2005). In ad-
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dition, a recent study (Lu and Hawkins 2002) showed that post synaptically localized cGMP 
contributes to L-LTP. To resolve this issue, studies are needed in which the PDE5 enzyme is 
localized at a subcellular level using a selective PDE5 antibody. 
Moreover, the present study focused on the effects of PDE5 inhibition on cGMP–IR 
and memory function in the hippocampus. However, although cGMP activity was shown in 
the hippocampal slices, the involvement of other brain regions, such as the cerebellum or the 
peri/post-rhinal cortex, cannot be excluded on basis of the present data.   
PDE5 inhibitors are known to result in vasodilatation, probably through cGMP in rats 
(Dundore et al. 1993; Dundore et al. 1992). Thus, the memory improving effect of PDE5 
inhibitors may alternatively result from the increased blood flow, and consequently glucose 
metabolism in the brain. However, the PDE5 inhibitor zaprinast clearly improved object 
memory in rats at 10 mg/kg (i.p.) but did not affect mean arterial blood pressure at this 
dosage (Prickaerts et al. 1997). Similar results on object memory and blood pressure have 
been observed for sildenafil administration in rats (Prickaerts et al. 2004). Taking this into 
account, it is unlikely that the memory enhancing effects of PDE5 inhibitors in mice can 
simply be explained through changes in blood flow or blood pressure (for a more detailed 
review see: (Prickaerts et al. 2004). So far, no studies have investigated the effects of PDE5 
inhibitors on arterial blood pressure and cerebral blood flow in mice.   
In conclusion, PDE5 inhibition is an effective way to improve object recognition memory 
in both rats and mice. Further experiments will be required to investigate the pathways under-
lying PDE5 inhibition and the localization of PDE5 and cGMP in the hippocampal neurons. 
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3 Rolipram reverses scopolamine-induced  and time-dependent memory 
deficits in object recognition 
by different mechanisms  
of action
K. Rutten, J. Prickaerts And A. Blokland.
Neurobiology of Learning and Memory (2006) 85: 132–138
In this study, the effect of the selective phosphodiesterase type 4 (PDE4) 
inhibitor rolipram on memory performance was investigated using the 
object recognition task. First, three doses of rolipram (0.01, 0.03 or 
0.1 mg/kg) were tested with a 24h delay between the learning (T1) and 
the test (T2) trial. Doses of rolipram were injected at different time points 
(30 min before T1, immediately after T1 or 3 h after T1). In a second ex-
periment, the effects of rolipram (0.03, 0.1 or 0.3 mg/kg) were tested in 
combination with scopolamine (0.1 mg/kg) applying a 1 h delay between 
trials. Both substances were administered 30 min before T1. Using a 24 h 
interval, rolipram showed an improvement in long-term memory per-
formance when injected 3 h after T1 at a dose of 0.03 mg/kg. Further, 
rolipram reversed the scopolamine-induced short-term memory deficit 
at a dose of 0.1 mg/kg. Although the improved memory performance 
in both conditions is likely to be explained by elevated cAMP levels, two 
separate working mechanisms might explain these effects.
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Introduction
Cyclic adenosine monophosphate (cAMP) plays an important role in intracellular signal-
ing (Bailey et al. 1996) and in processes of neuroplasticity such as long term potentia-
tion (LTP). Hippocampal LTP has been proposed to be a neurophysiological correlate of 
memory (Bliss and Collingridge 1993). LTP consists of two phases, an early phase (E-LTP), 
which does not require gene transcription and lasts less than 3 hours and a late phase 
(L-LTP) depending on gene transcription and protein synthesis and which lasts longer 
(>3 h). The postsynaptic cAMP/ protein kinase A (PKA)/cAMP responsive element bind-
ing protein (CREB) pathway, as well as the postsynaptic cGMP/PKG/CREB pathway, are 
involved in L-LTP (Frey et al. 1993; Impey et al. 1996; Lu and Hawkins 2002; Lu et al. 
1999; Slack and Walsh 1995).
Rolipram is a selective inhibitor of the phosphodiesterase type 4 (PDE4) enzyme, 
which hydrolyzes cAMP. Thus, PDE4 inhibition enhances the intracellular availability of ce-
rebral cAMP in the absence of direct stimulation of neurotransmitter receptors (Silvestre 
et al. 1999). Studies investigating PDE4 function using rolipram indicate that cAMP is in-
volved in neural processes that underlie learning and memory (Bach et al. 1999; Barad et 
al. 1998; Zhang and O’Donnell 2000). Accordingly, a substantial amount of studies have 
shown a positive effect of PDE4 inhibition on spatial memory (Bach et al. 1999; Gong et al. 
2004; Nagakura et al. 2002), inhibitory avoidance learning (Egawa et al. 1997; Ghelardini et 
al. 2002; Imanishi et al. 1997; Randt et al. 1982; Zhang et al. 2000; Zhang and O’Donnell 
2000), contextual fear conditioning (Barad et al. 1998; Gong et al. 2004) and object recog-
nition memory (Bourtchouladze et al. 2003). Moreover, several studies have shown an in-
volvement of PDE4 inhibitiors in working and reference memory (Egawa et al. 1997; Zhang 
et al. 2000; Zhang and O’Donnell 2000; Zhang et al. 2004).
Previous work showed that intra-hippocampal infusion of 8Br-cAMP improved memo-
ry performance when injected 3 or 6 h after one-trial training, but not when injected directly 
after the training trial (Bernabeu et al. 1997; Bernabeu et al. 1996; Prickaerts et al. 2002a). 
There is additional evidence that the late phase of memory consolidation is modulated by 
a cAMP/PKA signaling pathway in the hippocampus (Bernabeu et al. 1997). To our knowl-
edge, all studies that claim to improve memory performance via the cAMP/PKA pathway 
administered rolipram before the training trial. However, the late phase of memory consoli-
dation, in which the cAMP/PKA pathway is involved, occurs approximately three hours after 
training. At this time point cAMP levels are probably minimal due to its metabolic clearance 
(T1/2 = 1–3 h, Krause and Kuhne 1988). Therefore, another mechanism of action is prob-
ably responsible for the memory enhancing effects of rolipram when injected before T1. 
However, to our knowledge there is no profound evaluation of the effects of cAMP on early 
versus late consolidation. Furthermore, most cAMP evaluating studies have investigated 
the effects of cAMP via rolipram treatment in a scopolamine-induced short-term memory 
deficit model. Therefore, we decided to test the effects of rolipram on long-term memory 
performance by administering the drug at different time points. 
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To study the memory enhancing properties of rolipram we investigated its effects in an 
object recognition task (ORT) (Ennaceur and Delacour 1988). The ORT is a memory test that 
relies on a rat’s innate explorative behavior. In the first trial the animal is presented two ob-
jects. In the second trial, after a variable delay, one familiar and one new object are present-
ed. In both trials the amount of time spent exploring the objects is recorded. If an animal has 
memory of the objects presented in trial 1 (T1), it will explore the novel object more in the 
second trial (T2). Depending on the time of treatment, drug effects on acquisition, consoli-
dation or retrieval of object memory can be tested (Prickaerts et al. 2005). Treatments be-
fore the first trial influence acquisition or early consolidation processes, whereas treatments 
after T1 will affect early or late consolidation processes. The present study investigated the 
effects of different doses of rolipram on different long-term memory processes, i.e. acquisi-
tion (by injecting the drug 30 min before T1), early (by injecting the drug immediately after 
T1) and late (by injecting the drug 3 h after T1) consolidation, by using a 24h delay. In ad-
dition, rolipram was tested in the scopolamine model for short-term memory deficits using 
a 1h delay. This was done to replicate previous findings and for comparison of different dose-
response curves, i.e. long-term vs. short-term memory. Of note, the effects of rolipram on 
the scopolamine deficit model were never before examined in the object recognition task. 
Methods
Experiment 1: Effects of rolipram on long-term memory,  
using a 24 h interval in the ORT 
Animals
All experimental procedures were approved by the local ethical committee of the Maastricht 
University for animal experiments according to governmental guidelines. Twelve 5-month-
old male Wistar rats (Charles River, The Netherlands) were used (413–464g). The animals 
were housed individually in standard type 3 Makrolon cages on sawdust bedding in an air-
conditioned room (about 20° C). They were kept under a reversed 12/12-hour light/dark cy-
cle (lights on from 18.00 to 6.00 h) and had free access to food and water. Rats were housed 
in the same room as where the animals were tested. A radio, that played softly, provided 
background noise in all rooms. All testing was done between 9.00 and 17.00h. 
Object recognition memory
The object recognition test was performed as described elsewhere (Prickaerts et al. 2002a).
The apparatus consisted of a circular arena, 83 cm in diameter. Half of the 40 cm high wall 
was made of grey polyvinyl chloride, the other half of transparent polyvinyl chloride. A light 
bulb was switched on during testing only and provided a light intensity (20 lux) which was 
equal in the different parts of the apparatus. Two objects were placed in a symmetrical posi-
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tion about 10 cm away from the grey wall. We used four different sets of objects. The differ-
ent objects were: 1) a cone consisting of a grey polyvinyl chloride base (maximal diameter 
18 cm) with a collar on top made of brass (total height 16 cm), 2) a standard 1 l transpar-
ent glass bottle (diameter 10 cm, height 22 cm) filled with sand, 3) a massive metal cube 
(10.0 × 5.0 × 7.5 cm) with two holes (diameter 1.9 cm), and 4) a massive aluminum cube 
with a tapering top (13.0 × 8.0 × 8.0 cm). The objects could not be displaced by a rat.
In the first week, the animals were handled daily and were adapted to the procedure 
in two days, i.e., they were allowed to explore the apparatus (without any objects) twice for 
3 min each day. In the two following weeks the rats were adapted to the testing and i.p. 
administration procedure by a saline injection (0.4 ml) immediately after the first trial until 
they showed a stable discrimination performance, i.e., good object discrimination at a 1-h 
interval. Subsequently, testing of the drugs began.
A testing session comprised two trials. The duration of each trial was 3 min. During 
the first trial (T1) the apparatus contained two identical objects (samples). A rat was always 
placed in the apparatus facing the wall in the centre of the transparent front segment. After 
the first exploration period the rat was put back in its home cage. Subsequently, after a delay 
interval, the rat was put back in the apparatus for the second trial (T2), but now with two 
dissimilar objects, a familiar one (the sample) and a new one. The times spent exploring each 
object during T1 and T2 were recorded manually with a personal computer.
Exploration was defined as follows: directing the nose to the object at a distance of no 
more than 2 cm and/or touching the object with the nose. Sitting on the object was not 
considered exploratory behavior. In order to avoid the presence of olfactory trails the objects 
were always thoroughly cleaned. Moreover, each object was available in triplicate so neither 
of the two objects from the first trial had to be used as the familiar object in the second 
trial. In addition, all combinations and locations of objects were used in a balanced manner 
to reduce potential biases due to preferences for particular locations or objects.
Since we expected the drug treatments to improve long-term memory performance 
we needed a delay interval at which no more discrimination between the objects occurs. 
Therefore, we selected a delay interval of 24 h, since Wistar rats show virtually no discrimi-
nation between the two objects after this interval (Prickaerts et al. 2002b). In one week two 
testing sessions were given, one session comprised Monday and Tuesday and the other one 
comprised Thursday and Friday. 
In the first experiment we investigated the effects of rolipram on object recognition 
memory using a 24h delay interval and three different times of administration. 
Treatment with rolipram
Rolipram was freshly suspended in 5% ethanol, 1% tylose (methyl-cellulose) and 94% dis-
tilled water on every experimental day. The following doses of rolipram were tested: 0.01, 
0.03 or 0.1 mg/kg. Administrations were always i.p. (injection volume 2 ml/kg) at three 
different time points. First, effects of rolipram were investigated when injected 30 minutes 
before T1. Next, rolipram was injected immediately after T1 and in the final study injections 
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took place three hours after T1. Each dose condition was tested once. The order of the dose 
testing was randomly chosen.
Statistical analysis
The basic measures were the times spent by rats in exploring an object during T1 and 
T2. Table 1 shows the measures involved in the object recognition task (Prickaerts et 
al. 1997). e1 and e2 are measures of the total exploration time of both objects during 
T1 and T2 respectively. d2 was considered as index measures of discrimination between 
the new and the familiar objects. In fact, d2 is a relative measure of discrimination 
which corrects the difference between exploring the old and the novel object for ex-
ploration activity (e2). 
For all parameters the effects of the different dose conditions were analyzed with a one 
way ANOVA. Dose effects were analyzed in more detail with t-test using Duncan post hoc 
test correction. 
Table 1. Measures involved in the object recognition test
e1 is the measure of the time spent in exploring both identical objects (a1 and a2) in T1, and e2 is the 
measure of the time spent in exploring both the familiar (a) and new object (b) in T2; d2 is the measure of 
discrimination between the new and familiar objects.
Exploration Discrimination
e1 = a1 + a2 d2= b - a / e2
e2 = a + b
Experiment 2: Effect of rolipram on short-term memory in the 
scopolamine model for amnesia, using a 1 h delay in the ORT.
Animals
For this experiment twelve 4-month-old male Wistar rats (390–452g) were used. Housing 
conditions were identical to those described in Experiment 1.
Object recognition memory
The apparatus and procedures of the object recognition test were identical to those described 
in Experiment 1 (see above). However, the second experiment was based on a one hour delay 
interval between T1 and T2. Under normal conditions, Wistar rats show a good memory 
performance using this interval. Therefore, the effects of rolipram were investigated in a sco-
polamine-induced memory deficit model.
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Treatment with scopolamine and rolipram
Scopolamine (0.1 mg/kg in saline; s.c.) in combination with rolipram 0.03, 0.1 or 0.3 mg/kg 
in vehicle (see exp. 1; i.p.) were administrated 30 minutes before T1. Each treatment combi-
nation was tested once. The order of dose-testing was chosen randomly.
Statistical analysis
The parameters in the second experiment were identical to those described in Experiment 
1 (see above).  For all parameters the effects of the different dose conditions were analyzed 
with a one way ANOVA. Post-hoc comparisons were made in case of significance (LSD).  
Results 
Experiment 1: Effects of Rolipram in the 24h delay ORT 
Treatment: 30 minutes before T1
The results of treatment with rolipram 30 minutes before the first trial are summarized 
in Table 2A. No location preference was found in any of the treatment sessions (data not 
shown).  In T1 the total level of exploration was different between treatment conditions 
(e1: F(3,43) = 5.17, P < 0.01). Post-hoc comparisons showed that the level of exploration 
in the highest dose condition (0.1 mg/kg) was lower than in the other treatment condi-
tions (Duncan post-hoc). For T2 no difference between treatment sessions in the total level 
of exploration was observed (e2: F(3,43)= 2.34, n.s.). 
The effects of treatment with rolipram, 30 minutes before T1, on the d2 index are presented 
in Figure 1A. A between group comparison (ANOVA) showed no significant dose effect for 
d2 (d2: F(4,43) = 0.31; n.s.). There were no differences in discrimination performance be-
tween treatment conditions.
Treatment: immediately after T1
When rolipram was administered immediately after T1 no location preference was found 
in any of the treatment sessions (data not shown). In T1 there was a difference between 
treatment sessions in the total level of exploration (e1: F(3,46) = 5.63, P < 0.01) (Table 2B). 
In a post-hoc analysis we found that the level of exploration was higher for the 0.1 mg/kg 
dose condition than for the 0.03 mg/kg dose condition (Duncan test). There were no differ-
ences between the other dose conditions. It is very likely that the effect on e1 before rolip-
ram treatment is an incidental statistical effect which, cannot be linked to rolipram since 
it was given after T1. The level of exploration in T2 did not differ between treatment sessions 
(e2: F(3,46) = 1.51, n.s.). 
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The effects of treatment with rolipram, immediately after T1, on the d2 index are pre-
sented in Figure 1B. A between group comparison (ANOVA) showed no significant dose ef-
fect for d2 (d2: F(4,46) = 0.90; n.s.) when rolipram was injected immediately after T1. None 
of the treatment conditions differed in discrimination performance. 
Table 2. Results of treatment with rolipram on the exploration measures of the object recognition test. 
Wistar rats (n=12 per dose) received an i.p. injection of rolipram at doses of 0, 0.01, 0.03 or 0.1 mg/kg. 
The delay between the first and the second interval was 24 h. 
* P<0.05: different from vehicle (Duncan); # P<0.05: different from 0.03 mg/kg (Duncan)
Mean values (±S.E.M.) of total exploration time (s) during the first (e1) and second trial (e2)
VEHICLE 0.01 mg/kg 0.03 mg/kg 0.1 mg/kg
A) Injection 30 min before T1
e1 23.85 (4.07) 15.97 (3.18) 18.46 (2.52) 7.00 (1.48) *
e2 29.55 (3.78) 17.67 (1.89) 25.53 (3.24) 22.69 (3.42)
B) Injection immediately after T1
e1 15.63 (2.02) 18.38 (1.70) 11.93 (0.97) 21.86 (2.20) #
e2 15.73 (2.22) 20.51 (2.23) 20.43 (2.13) 16.61 (1.53)
C) Injection 3h after T1
e1 31.52 (2.95) 24.67 (2.72) 32.18 (3.14) 30.20 (2.39)
e2 33.24 (3.42) 27.27 (2.24) 27.62 (2.71) 31.82 (3.73)
Vehicle 0.01 0.03 0.1
-0.1
0.0
0.1
0.2
0.3
0.4
0.5
Vehicle 0.01 0.03 0.1
-0.1
0.0
0.1
0.2
0.3
0.4
0.5
Vehicle 0.01 0.03 0.1
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Figure 1: Effects of rolipram treatment on the discrimination performance in the object recognition task (means + S.E.M.). The delay 
between the learning trial (T1) and the test trial (T2) was 24 h. In the vehicle session, rats were treated with 5% ethanol, 1% tylose (methyl-
cellulose) solution (i.p.). In the drug session, rats were treated with doses of 0.01, 0.03 or 0.10 mg/kg. Rolipram, when injected 30 min 
before T1 (A) or immediately after T1 (B) did not improve the performance of the animals at any dose condition. (C) Administration of 
rolipram 3 h after T1 improved the performance of the animals at the dose of 0.03 mg/kg. Differences from the vehicle group are depicted 
as asterisks (One sample t-test; * P < 0.05).
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Treatment: 3 h after T1
The results of treatment with rolipram 3 hours after T1 are summarized in Table 2C. No 
location preference was found in any of the treatment conditions (not shown). There 
were no differences between treatment conditions in the total levels of exploration in T1 
(e1: F(3.47) = 1.47, n.s.). Furthermore, no differences were observed between the dose con-
ditions in the total level of exploration in T2 (e2: F(3,47) = 0.95, n.s.). 
The effects of treatment with rolipram, 3 h after T1, on the d2 index are present-
ed in Figure 1C. Between group analysis showed an effect of dose on the d2 values (d2: 
F(3,47) = 2.80; P < 0.05) When comparing the different doses with the vehicle group with 
a post-hoc test, the d2 value of the medium dose (0.03 mg/kg) was higher than that of the 
vehicle group (Duncan test). Thus, 24 hours after training, only the rats treated with 0.03 
mg/kg rolipram were able to discriminate between the objects.
Experiment 2: Effects of Rolipram on the scopolamine-induced 
memory impairment in the 1h delay ORT
The results of scopolamine treatment in combination with rolipram on the measures of ex-
ploration are shown in Table 3. When comparing between treatment groups an effect of 
dose on the levels of exploration in T1 was found (e1: F(4,53) = 2.70; P < 0.05). Post-hoc 
analysis showed that the level of exploration of the animals treated with the highest 
dose of rolipram (0.3 mg/kg) was lower than the other treatment conditions in T1 (LSD). 
The level of exploration in T2 did not differ between the different treatment conditions 
(e2: F(4,53) = 0.87; n.s.).
The effects of scopolamine and rolipram treatment on the d2 index for object recogni-
tion are shown in Figure 2. Between group analysis showed a tendency of dose–effect on the 
d2 values (F(4,53) = 1.86; n.s.). However, when comparing the different doses with post-hoc 
analysis, the d2 values of the medium dose (0.1 mg/kg) and the no drugs condition (saline/
vehicle) were significantly higher than the d2 value of the virtual group (LSD: P < 0.05). Thus, 
scopolamine clearly impaired memory performance in a one hour delay version of the ORT 
and 0.1 mg/kg rolipram effectively reversed this memory deficit (Figure 2).
Discussion
In the present study we found that rolipram reverses the time-dependent decreased memory 
performance in object recognition when injected 3 h after the acquisition trial. Since rolip-
ram did not improve memory when injected 30 min before T1 or immediately after T1 it is 
assumed that PDE4 inhibition improves late-phase consolidation. Corroborating previous 
studies, rolipram reversed the scopolamine-induced deficit.  Notably, the dose of rolipram 
required to reverse the scopolamine deficit (0.1 mg/kg) was higher when compared to the 
dose required to reverse the time-dependent deficit (0.03 mg/kg). 
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Rolipram increases intracellular cAMP levels in hippocampal slices (Barad et al. 1998). 
In the hippocampus cAMP is involved in L-LTP via the cAMP/PKA/CREB pathway (Bailey et 
al. 1996; Frey et al. 1993; Impey et al. 1996). Since the hippocampus plays an important role 
in long-term object recognition memory (Hammond et al. 2004; Prickaerts et al. 2002a), our 
results may imply an effect of rolipram in the process of hippocampal L-LTP, which is most 
effective when administered 3h after T1. This effect was also shown to be dose-dependent. 
Our data corroborate the findings of Bernabeu (1997) that intra-hippocampal injec-
tions of 8 Br-cAMP were only effective when administered 3 or 6 hours after training in 
the passive avoidance task. Along similar lines, administration of 8Br-cAMP was ineffective 
when given immediately after training in the ORT (Prickaerts et al. 2002a). Taking into ac-
count that the half-life of rolipram is approximately 1–3 h (Krause and Kuhne 1988), admin-
istering rolipram before or immediately after training in the object recognition task is not 
likely to enhance memory processes via cAMP. 
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Figure 2: Effects of rolipram treatment in combination with sco-
polamine on the discrimination performance in the object recogni-
tion task (means + S.E.M.). The delay between the learning trial (T1) 
and the test trial (T2) was 1 h. In the vehicle-vehicle session, rats 
were treated with 5% ethanol, 1% tylose (methyl-cellulose) solution 
(i.p.) or saline (s.c.). In the drug conditions, rats were treated with 
0.1 mg/kg scopolamine immediately followed by vehicle, 0.03, 0.1 
or 0.3 mg/kg rolipram. Rolipram, when injected 30 min before T1 
ameliorated the scopolamine deficit at the dose of 0.1 mg/kg. Differ-
ences from the vehicle group are depicted as asterisks (One sample 
t-test; * P < 0.05).
Table 3: Results of treatment with scopolamine in combination with rolipram on the exploration measures 
of the object recognition test. Wistar rats (n=12 per dose) received injections of scopolamine (0.1 mg/kg; 
s.c.) immediately followed by rolipram at doses of 0, 0.03, 0.1 or 0.3 mg/kg (i.p.). The delay between the 
first and the second interval was 1 h. * P<0.05: different from all other treatment conditions (LSD). 
Mean values (±S.E.M.) of total exploration time (s) during the first (e1) and second trial (e2)
Scopolamine 0 mg/kg 0.1 mg/kg 0.1 mg/kg 0.1 mg/kg 0.1 mg/kg
Rolipram 0 mg/kg 0 mg/kg 0.03 mg/kg 0.1 mg/kg 0.3 mg/kg
e1 19.46 (2.61) 16.25 (2.23) 24.01 (3.90) 17.90 (6.84) 5.80 (9.07) * 
e2 23.23 (2.69) 21.73 (2.70) 28.01 (4.42) 23.45 (3.19) 20.14 (2.10) 
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Mice carrying a truncated form of CREB-binding protein (CBP) show defective long-
term object recognition memory. Treatment of these CBP+/- mice with rolipram reverses the 
long-term memory deficits (Bourtchouladze et al. 2003).  In that study rolipram was admin-
istered 20 min before the first trial, thus possibly affecting acquisition or early consolidation 
processes. However, acquisition or early consolidation processes were not affected by rolip-
ram in our experiment applying a 24 h delay, since administration of rolipram 30 min before 
T1 or immediately after T1 did not improve object recognition memory. Most probably the 
effects in the CBP+/- mice cannot be explained by rolipram enhancing late-phase consolida-
tion. Thus, late consolidation occurs 3 h after T1 when rolipram levels are probably too low 
to affect cAMP levels in the brain. However, the effective dose for rolipram in that study was 
0.1 mg/kg, which is higher than the 0.03 mg/kg used in our time-dependent experiment. 
Therefore, it could be suggested that rolipram enhances neurotransmitter levels (see below) 
and this may explain the effects of rolipram on long-term memory in these mice. 
Several studies have shown an ameliorating effect of rolipram on the scopolamine-
induced memory deficit (Imanishi et al. 1997; Silvestre et al. 1999; Zhang and O’Donnell 
2000). In the present study we also investigated the effects of rolipram on a scopolamine-
induced deficit in the ORT. When rolipram (0.1 mg/kg) was administered together with sco-
polamine 30 minutes before training, rats were able to discriminate between the familiar 
and novel object. Several others have found ameliorating effects of rolipram on the scopol-
amine deficit in behavioral testing, using the similar doses of rolipram (Barad et al. 1998; 
Egawa et al. 1997; Imanishi et al. 1997; Silvestre et al. 1999; Zhang and O’Donnell 2000). 
However, this has never been shown before in the ORT. Since in this paradigm of the ORT 
short-term memory is examined, no gene transcription or protein synthesis is required. 
Thus, the cAMP/PKA/CREB pathway may not be involved. Of note, rolipram also affects 
the cholinergic system that is specifically disrupted by the treatment with scopolamine and 
this is mediated via an elevation of intracellular cAMP (Silvestre et al. 1999). Accordingly, 
cAMP analogues have been reported to promote the activity of cholinergic neurons and to 
potentiate acetylcholine (ACh) responses (Imanishi et al. 1997). Since, PDE4 inhibitors are 
able to increase cAMP levels and thus enhance ACh release and synthesis in the brain, it can 
be assumed that some of the pharmacological and behavioral effects of rolipram in the sco-
polamine model could be mediated by this neurotransmitter (Silvestre et al. 1999). 
From the literature it is known that rolipram can have sedative side-effects at higher 
doses, shown by dose-dependent hypo activity in the open field task (Griebel et al. 1991; 
Silvestre et al. 1999). Since the object recognition performance can only be determined 
if the animals show sufficient exploration (Sik et al. 2003), we also evaluated the exploration 
levels of the animals. In our time-dependent experiment with untreated animals, a dose 
of 0.1 mg/kg rolipram, given 30 min before T1, resulted in a substantial decrease in explor-
atory activity. This finding may be indicative of a sedative effect at this dose. However, in the 
second experiment in which the animals were treated with scopolamine as well, no effects 
on exploratory behavior were observed at this dose. These findings are in line with previous 
studies that do not report behavioral side effects of even higher rolipram doses (> 0.1 mg/kg) 
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in combination with similar doses of scopolamine (Imanishi et al. 1997; Silvestre et al. 
1999; Zhang and O’Donnell 2000). However, in our second experiment side effects were 
observed again at a dose of 0.3 mg/kg rolipram in the scopolamine model. Assuming that 
the side-effects are mediated by the neurotransmitter ACh, the cholinergic side-effects of 
this dose of rolipram are possibly no longer fully antagonized by scopolamine. Since the 
difference in doses between side effects and cognition enhancing effects of rolipram is only 
a factor three, this implies a steep dose-response curve for rolipram to affect neurotrans-
mitter levels or activating PKA. 
On the basis of the different dose-response curves of rolipram in both experiments, we 
assume that the effects of rolipram on memory performance might be mediated by two dif-
ferent processes. The first mechanism works via cAMP activated PKA, which plays a key role 
in the induction of L-LTP and long-lasting neuronal changes. The activation of the cAMP-
PKA system is specifically required at about 3 h after training. Thus during the process of late 
memory consolidation the cAMP-PKA pathway cascade is believed to trigger events, includ-
ing the activation of transcription factors such as CREB (Friedrich et al. 2004). 
The second mechanism by which rolipram could affect learning and memory is via 
its ability to influence different neurotransmitter systems. The effectiveness of rolipram 
is thought to be due to a stimulatory effect on cholinergic transmission by both enhance-
ment of cholinergic turnover presynaptically and inhibition of cAMP degradation postsyn-
aptically (Imanishi et al. 1997). Furthermore, elevated intracellular cAMP levels are thought 
to excite noradrenergic and dopaminergic (Schoffelmeer et al. 1985) neurotransmitter sys-
tems and thus increasing their availability, hence also enhancing synaptic transmission.
In summary, this study suggests that rolipram improves object recognition memory 
performance by two different mechanisms of action. Clearly, further neurochemical studies 
are required to support this notion.
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The present study investigated the time dependent memory enhancing 
properties of three selective phosphodiesterase inhibitors (PDE-I) varde-
nafil (PDE5-I), rolipram (PDE4-I) and BAY 60-7550 (PDE2-I) in the ob-
ject recognition task. In particular, the time-dependent involvement of 
cAMP and cGMP in memory consolidation were assessed by altering the 
time points of drug administration. Vardenafil (1 mg/kg, p.o.), rolipram 
(0.03 mg/kg, i.p.), and BAY 60-7550 (3 mg/kg, p.o.) were tested in rats 
with a 24h delay between the learning and the test trial. The PDE-Is were 
administered at different time points, i.e. directly after, 1h, 3h and 6h 
after the first trial. Using a 24 h interval, vardenafil only showed an ef-
fect on object memory when injected directly after trial 1, rolipram only 
showed an improvement when injected 3 h after trial1 and BAY 60-7550 
improved memory when injected either directly after or 3h after trial 1. 
No treatment effects were found when the compounds were administered 
1h or 6h after the first trial. Our results extend our previous data that dif-
ferent types of PDE-Is affect different stages of memory consolidation. 
Moreover, the present study provides further support that selective PDE-
Is can influence memory consolidation in a time dependant manner, 
assumingly by elevating central cAMP and cGMP levels.
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Introduction
Recently, evidence has been accumulating that the second messenger molecules, cyclic GMP 
(cGMP) and cyclic AMP (cAMP) are differentially involved in learning and memory pro-
cesses. In a one-trial learning paradigm intra-hippocampal infusions of 8-Br-cAMP directly 
after the first, i.e acquisition trial, did not improve memory performance in the second, i.e. 
retention trial. In contrast, infusions of 8-Br-cGMP directly after the first trial improved 
memory performance (Prickaerts et al. 2002a). Moreover, when 8-Br-cAMP was injected 
3h after trial 1, memory enhancement was observed but for 8-Br-cGMP this was not the 
case (Bernabeu et al. 1997). These findings imply different temporal effects of cGMP and 
cAMP on memory. It has been suggested that inhibition of phosphodiesterases (PDEs), 
which selectively hydrolyze cyclic nucleotides, may be a reliable method to enhance memory 
performance (Prickaerts et al. 2004). 
Eleven subclasses of PDEs have been identified so far, but hitherto only the PDE4, 5 and 
recently PDE2 have been demonstrated to be effective in memory enhancement (Blokland 
et al. 2006a). Selective PDE4 inhibitors (PDE4-I) selectively inhibit the hydrolysis of cAMP. 
Ample evidence suggests a role for the cAMP/PKA/CREB pathway in the cognition enhancing 
abilities of PDE4-I (Imanishi et al. 1997; Tully et al. 2003). In particular, the selective PDE4-I 
rolipram has been widely tested in cognition studies (for review see: Blokland et al. 2006a). 
A recent study from our group showed memory enhancement after rolipram (selective 
PDE4-I) treatment in the object recognition task (Rutten et al. 2006a). This effect was found 
when rolipram was injected 3h, but not when it was injected directly after trial 1, suggesting 
that the time of injection is of great importance in this respect. 
PDE5 inhibitors (PDE5-I) such as sildenafil (Viagra®) and vardenafil (Levitra®) have 
not only been shown to be effective in the treatment of erectile dysfunction, but they 
are also candidate drugs for cognition enhancement. For instance, the specific PDE5-Is 
sildenafil and vardenafil have been shown to improve object recognition memory when 
injected immediately following the first trial (Prickaerts et al. 2002b). PDE5-Is are as-
sumed to improve early processes of memory consolidation via either a presynaptic or 
a postsynaptic mechanism. The presynaptic mechanism acts through the Nitric Oxide 
(NO)-cGMP signalling pathway and the postsynaptic mechanism through the cGMP/
Protein Kinase G/cAMP Response Element Binding protein (cCMP/PKG/CREB) signal-
ling pathway (Prickaerts et al. 2004). 
Most recently another type of PDE-Is has been proposed for cognition enhancement, 
namely PDE 2 inhibitors (PDE2-I). PDE2 enzymes hydrolyze both cAMP and cGMP and 
therefore inhibition of PDE2 may selectively increase both cAMP and cGMP levels, which 
influence synaptic plasticity and memory formation. The novel selective PDE2 inhibitor 
2-(3,4-dimethoxybenzyl)-7-{(1R)-1-[(1R)-1-hydroxyethyl]-4-phenylbutyl}-5-methyl imid-
azo[5,1-f][1,2,4]triazin-4(3H)-one (BAY 60-7550) revealed cognition enhancing properties 
in one-trial learning tests, such as social and object recognition (Boess et al. 2004). In this 
study it was shown that BAY 60-7550 was effective when injected directly after trial 1. 
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Since PDE5-Is also improve memory when injected after trial 1 in an object recognition 
task, it was assumed that the effects of PDE2 inhibition were mediated via cGMP.
In the present study we investigated the time-dependent involvement of cAMP and 
cGMP in memory consolidation by directly comparing the effects of three different types of 
PDE-Is: PDE5, PDE4 and PDE2. By altering the time of drug administration, the differential 
temporal effects of the PDE-Is vardenafil, rolipram and BAY 60-7550 were assessed.
Materials and methods
Animals
All experimental procedures were approved by the local ethical committee of the Maas-
tricht University for animal experiments according to governmental guidelines. A total 
of 66 young adult male Wistar rats (Charles River, The Netherlands) were used in this 
study. The animals were divided into three experimental groups (n=22/group) for behav-
ioral drug testing. The animals were housed individually in standard type 3 Makrolon 
cages on sawdust bedding in an air-conditioned room (about 20°C). They were kept under 
a reversed 12/12-hour light/dark cycle (lights on from 18.00 to 6.00 h) and had free ac-
cess to food and water. Rats were housed in the room where they were tested. A radio 
that played softly provided background noise in all rooms. All testing was done between 
9.00 and 17.00h under red light conditions.
Object recognition memory
The object recognition test was performed as described elsewhere (Ennaceur and Delacour 
1988). The apparatus consisted of a circular arena, 83 cm in diameter. Half of the 40 cm high 
wall was made of grey polyvinyl chloride, the other half of transparent polyvinyl chloride. 
The light intensity (20 lux) was equal in the different parts of the apparatus. Two objects 
were placed in a symmetrical position about 10 cm away from the grey wall. We used four 
different sets of objects. The different objects were: 1) a cone consisting of a grey polyvinyl 
chloride base (maximal diameter 18 cm) with a collar on top made of brass (total height 16 
cm), 2) a standard 1 l transparent glass bottle (diameter 10 cm, height 22 cm) filled with 
sand, 3) a massive metal cube (10.0 × 5.0 × 7.5 cm) with two holes (diameter 1.9 cm), and 
4) a massive aluminium cube with a tapering top (13.0 × 8.0 × 8.0 cm). The objects could 
not be displaced by a rat.
In the first week, the animals were handled daily and were adapted to the observation 
arena on two successive days, i.e., they were allowed to explore the apparatus (without any ob-
jects) twice for 3 min each day. In the next two weeks the rats were adapted to the testing and 
intra peritoneal (i.p.) and oral (p.o.) administration procedures by a saline injection (0.4 ml) 
immediately after the first trial until they showed a stable discrimination performance, i.e., 
good object discrimination at a 1-h interval. Subsequently, testing of the drugs began.
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A testing session comprised two trials. The duration of each trial was 3 min. During the 
first trial the apparatus contained two identical objects (samples). A rat was always placed in 
the apparatus facing the wall in the centre of the transparent front segment. After the first 
exploration period the rat was put back in its home cage. Subsequently, after a delay inter-
val, the rat was put back in the apparatus for the second trial, but now with two dissimilar 
objects, a familiar one (the sample) and a new one. The times spent exploring each object 
during the first and the second trial were recorded manually using a personal computer.
Exploration was defined as follows: directing the nose to the object at a distance 
of no more than 2 cm and/or touching the object with the nose. Sitting on the object 
was not considered exploratory behaviour. In order to avoid the presence of olfactory 
trails the objects were thoroughly cleaned after each trial. Moreover, each object was 
available in triplicate so none of the two objects from the first trial had to be used as the 
familiar object in the second trial. In addition, all combinations and locations of objects 
were used in a balanced manner to reduce potential biases due to preferences for par-
ticular locations or objects.
Since we expected the drug treatments to improve long term memory performance 
we needed a delay interval at which rats did not discriminate between the objects above 
chance level. Therefore, we selected a delay interval of 24 h, since Wistar rats show no 
discrimination between the two objects after this interval (Prickaerts et al. 2002b). Each 
week two testing sessions were given, one session comprised Monday (trial 1) and Tues-
day (trial 2) and the other one comprised Thursday (trial 1) and Friday (trial 2). 
Treatments 
All substances were dissolved in their vehicles and were administered at one of four time 
points per condition. The time points of administration for each substance were: immedi-
ately after the first trial , or 1h, 3h, or 6h after the first trial. The order of treatment condi-
tions was randomly chosen.  Each time point of administration was tested once in all 22 
animals. Each of the three different PDE-Is was tested in a separate group of 22 animals.
The PDE5-I vardenafil was prepared daily and dissolved in 1% tylose (methyl-
cellulose) and 99% distilled water on every experimental day. The substance was test-
ed at an optimal dose of 1 mg/kg (Prickaerts et al. 2002b), administered orally (p.o.) 
by means of a canule in an application  volume of 2 ml/kg. 
The PDE4–I rolipram was freshly suspended in 5% ethanol, 1% tylose (methyl-
cellulose) and 94% distilled water on every experimental day. Rolipram was tested 
at the dose of 0.03 mg/kg. This is the most optimal dose for a memory enhancing ef-
fect when injected 3 h after the first trial  (Rutten et al. 2006a). Rolipram was always 
administered i.p. in an application volume of 2 ml/kg.
The PDE2–I Bay 60-7550 was prepared daily and dissolved in 10% solutol, 5% 
ethanol and 85% distilled water. Bay 60-7550 was tested at a dose of 3 mg/kg because 
this dose was shown to be effective in the object recognition test when injected im-
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mediately after the first trial (Boess et al. 2004). The compound was administered p.o. 
in an injection volume of 5 ml/kg. 
Statistical analysis
The basic measures were the times spent by rats in exploring an object during trial 1 
and trial 2. Table 1 shows the measures involved in the object recognition task (Prick-
aerts et al. 1997). e1 and e2 are measures of the total exploration time of both objects 
during trial 1 and trial 2 respectively. D2 was considered as index measure of discrimi-
nation between the new and the familiar objects. In fact, d2 is a relative measure of 
discrimination which corrects the difference between exploring the old and the novel 
object for exploration activity (e2). Animals that did not explore sufficiently in the 
second trial (i.e. less than 5s) were excluded from the data analysis for that particular 
delay condition.
For all parameters the effects of the different administration time points (vehi-
cle, directly after trial 1 vs. drug, directly after trial 1, or 1-, 3-, or 6-hours after trial 1) 
were analyzed with a one way ANOVA. Drug effects with respect to vehicle treatment 
were analyzed in more detail using the Bonferroni post hoc t-test.
Table 1. Measures involved in the object recognition test
Exploration Discrimination
e1 = a1 + a2 d2= b - a / e2
e2 = a + b
e1 is the measure of the time spent in exploring both identical objects (a1 and a2) in T1,
e2 is the measure of the time spent in exploring both the familiar (a) and new object (b) in T2;
d2 is the measure of discrimination between the new and familiar objects.
Results
PDE5 inhibition
The results of treatment with the PDE5 inhibitor vardenafil on exploration times are shown 
in Table 2A. In the first trial differences in exploration times were observed between the dif-
ferent administration conditions (e1: F(4,108) = 5.83; P < 0.01). Post-hoc analysis showed 
that the level of exploration for animals treated 3h after trial 1 was higher than all other 
treatment conditions except when the animals were treated directly after trial 1.
Also, in the second trial there were differences between treatment conditions in the 
level of exploration (e2: F(4,108) = 5.35; P < 0.01). The animals in the vehicle condition ex-
plored less than the animals treated with vardenafil one or three hours after the first trial. 
Figure 1 (left panel) shows the time dependent effects of vardenafil treatment on ob-
ject recognition performance. Differences between treatment conditions on the discrimi-
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nation index were observed (d2: F(4,108) = 3.00; P< 0.05). Post-hoc analysis showed that 
vardenafil, administered directly the first trial improved the object recognition performance; 
whereas injection of vardenafil at other time points had no effect on recognition memory. 
Table 2. Results of treatment with three different PDE inhibitors on the exploration measures (in s) of 
the object recognition test.
VEHICLE DRUG DRUG DRUG DRUG
T1 + 0h T1 + 0h T1 +1h T1 + 3h T1 + 6h
 A) Vardenafil (PDE5 inhibitor)
e1 15.73 (1.05) 20.19 (1.35) 17.05 (1.42) 23.28 (1.50)a 15.90 (1.44)
e2 18.04 (1.15) 24.52 (2.22) 24.37 (1.31)a 28.54 (1.82)a 22.82 (1.65)
 B) Rolipram (PDE4 inhibitor)
e1 16.54 (0.77) 20.01 (1.13) 18.95 (1.47) 17.70 (1.27) 18.79 (1.43)
e2 21.69 (1.12) 29.38 (1.94)a 20.43 (1.72) 24.79 (1.24) 27.39 (1.76)
C) BAY 60-7550 (PDE2 inhibitor)
e1 19.58 (1.59) 19.40 (1.33) 20.44 (2.02) 17.48 (1.67) 21.70 (1.01)
e2 20.93 (1.76) 18.40 (1.65) 27.64 (1.93)a 21.39 (1.30) 26.16 (2.15)a
Wistar rats (n=22 per drug group) received drug administrations at different time points after T1. The delay between the first and the 
second interval was 24 h. Entries are means (±S.E.M.) (a depicts differences from vehicle, P<0.05 Bonferonni t-tests).
PDE4 inhibition
Effects of administering rolipram at different time points on the exploration times are pre-
sented in Table 2B. Exploration in the first trial was unaffected (e1: F(4,109) = 1.14; n.s.). 
However, differences in exploration time were observed in the second trial (e2: F(4,109) = 
5.60; P < 0.01). Post-hoc analysis showed that the level of exploration was higher when the 
animals were injected with rolipram directly after the first trial than when the animals were 
treated with vehicle or with rolipram 1h after the first trial. The effects of rolipram adminis-
tered at different time points after the first trial on the memory performance are depicted in 
Figure 1 (center panel). A between treatment time points analysis of the d2 values showed 
a time-dependent effect (d2: F(4,109) = 2.80; P < 0.05). Post-hoc comparisons between the 
different drug administration time points and the vehicle condition showed that only the 
animals treated 3h after trial 1discriminated between the novel and the familiar object.
PDE2 inhibition
The results of treatment with the PDE2 inhibitor, Bay 60-7550 on the exploration times 
are summarized in Table 2 (right panel). The total level of exploration during the first trial 
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was similar between sessions (e1: F(4,106) = 1.01; n.s.). In the second trial there was a dif-
ference between the treatment conditions (e2: F(4,106) = 4.98; P < 0.01). Post-hoc analysis 
showed that the level of exploration for the group that was administered directly after trial 
1 was lower than the groups that were administered 1h or 6h after trial 1. The results of 
Bay 60-7550 treatment on the d2 index of object discrimination are depicted in Figure 1C. 
The d2 indices were affected by the different time points of drug administration (F(4,106) = 
4.91; P < 0.01). Post-hoc analysis revealed that the d2 values were higher than those of the 
vehicle condition, when the rats were injected with the PDE2-I directly after, or 3h after trial 
1, but not when injected 1h or 6h after trial 1.
Discussion
In the present study we found that PDE2-, 4- and 5 inhibitors can reverse the time-
dependent forgetting in the object recognition test in rats. However, the efficacy 
of the different PDE-Is appeared to depend on the time point of administration after 
acquisition (trial 1).
When injected with vehicle, all three groups of Wistar rats had no memory of the 
familiar object in the second trial. In a previous time-dependent study with rolipram, we 
found that the dose of 0.03 mg/kg was the optimal dose in the object recognition task, 
when injected 3h after the first trial (Rutten et al. 2006a). The present study confirmed this 
earlier finding. When rolipram was injected directly after, 1h or 6h after trial 1, no memory 
enhancement was observed. As expected, a dose of 1 mg/kg vardenafil administered direct-
ly after the first trial improved memory, corroborating our earlier findings (Prickaerts et 
al. 2002b). However, when vardenafil was administered at a later time point after training 
(i.e. 1h, 3h, or 6h after trial 1) no memory enhancing effects were observed. Finally, 
we examined the effects of the selective PDE2-I BAY 60-7550 in the object recognition task. 
A previous study showed that the effective dose when injected directly after the first trial 
Figure 1: Effects of three PDE inhibitors on the discrimination performance in the object recognition task (means + S.E.M.). The delay 
between the learning trial (trial 1) and the test trial (trial 2) was 24 h. Rats were treated with PDE inhibitors at four different points of 
administration after the first trial. The time points were directly after trial 1, 1h after trial 1, 3h after trail 1 or 6h after trial 1. (left panel) 
Treatment with the PDE5 inhibitor vardenafil (1 mg/kg), (center panel) Treatment with the PDE4 inhibitor rolipram (0.03 mg/kg) and 
(right panel) Treatment with the PDE2 inhibitor Bay 60-7550 (3 mg/kg). Differences from the vehicle condition are depicted as asterisks 
(Bonferroni t-test; * P < 0.05).
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was 3 mg/kg (Boess et al. 2004). The present study corroborates these findings and shows 
that this PDE2-I is also active when injected 3h after trial 1. Surprisingly, when BAY 60-7550 
was injected 1h after trial 1 or 6h after trial 1 no effects on object recognition memory were 
found. These findings may be explained by the underlying mechanisms of action and the 
pharmacokinetics of these different drugs. 
PDE5 inhibition
There is ample evidence that cGMP and cAMP are differentially involved in the memory con-
solidation processes (Prickaerts et al. 2004). Several studies have found memory enhancing 
effects of PDE5-Is when injected before or directly after training (e.g. Campbell and Edwards 
2006; Devan et al. 2006; Devan et al. 2004; Prickaerts et al. 2005; Prickaerts et al. 1997; Rut-
ten et al. 2005). Initially, cGMP was thought to act mainly pre-synaptically in the early phase 
of long term potentiation, via the NO/sGC/cGMP pathway. This form of long term potentia-
tion lasts less than 3h and requires no gene transcription or protein synthesis. Alternatively, 
the cGMP/PKG pathway has repeatedly been proposed as the underlying mechanism of ac-
tion for early memory consolidation (Izquierdo and Medina 1997; Prickaerts et al. 2002b; 
Zhuo et al. 1994). Recently, it has been shown that the cGMP/PKG/CREB pathway is also 
involved in late phase long term potentiation, which lasts longer than 3h (Lu and Hawkins 
2002; Lu et al. 1999). This pathway may also be involved in early consolidation processes and 
may thus be mediated by sustained elevated cGMP levels in the object recognition task, i.e. 
cGMP is only effective when administered immediately after one-trial learning (Bernabeu et 
al. 1997; Prickaerts et al. 2002a). At present, it is unclear which pathway is underlying the 
memory enhancing effects of selective PDE5 inhibition. Studies are underway to localize the 
PDE5 enzyme at the subcellular level.
No data are currently available about the half-life of vardenafil in rats. Since in 
humans vardenafil and sildenafil have similar half lives (approximately 4 h), after oral 
administration (Corbin and Francis 2002), it is assumed that half lives of these two com-
pounds are similar in rats. Considering the short half life of sildenafil, approximately 0.4h 
in male rats (Walker et al. 1999) we speculate that the time window for modulating the 
early consolidation processes via cGMP is narrow (between 0 and 1h). When vardenafil 
was injected directly after learning memory enhancement was observed, but when the 
injection was delayed (1, 3, or 6h) memory was not affected, which is in agreement with 
the active time window of cGMP.
PDE4 inhibition
The data of rolipram are assumed to be related to elevated cAMP levels (Barad et al. 1998). 
cAMP is involved in late phase long term potentiation via the cAMP/PKA/CREB pathway 
(Bailey et al. 1996; Frey et al. 1993; Impey et al. 1996). Furthermore, it has been suggested 
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that specifically late consolidation processes are affected by cAMP at 3 h after acquisition 
(Bernabeu et al. 1997; Prickaerts et al. 2002a). The findings of the present study support 
this notion. The half life of i.p. injected rolipram is approximately 1-3h (Krause and Kuhne 
1988) and since rolipram has no effect on memory when injected earlier than the 3h time 
point (immediately after or 1h after the first trial) or later than 3h (i.e. 6h), the time window 
of rolipram for influencing the late consolidation processes of memory is quite specific, as is 
also the case for the active time window of cAMP.
PDE2 inhibition
In vitro studies have shown that BAY 60-7550 increased both cGMP and cAMP levels in hip-
pocampal slices (Boess et al. 2004). We found an effect of BAY 60-7550 on object memory 
when it was given directly after training. This might be related to elevated cGMP levels, 
as the effect was observed at a drug administration time point where vardenafil affected rec-
ognition memory. In addition, improved object memory was observed when the PDE2-I was 
injected 3h after training. Similar to the results of the rolipram study, these effects might 
be mediated by the elevation of cAMP levels and the process of late consolidation. When 
the short elimination half life of approximately 45 min after p.o. injection of BAY 60-7550 
in rats (unpublished data) is taken into account, it appears once again that time windows 
for influencing early consolidation processes, possibly via cGMP and late consolidation pro-
cesses, possibly through cAMP, are specific and narrow. The results from the experiment 
with this PDE2-I support the notion of a specific and time-critical role of cGMP and cAMP 
in memory consolidation and are consistent with the results obtained after treatment with 
rolipram or vardenafil. 
Most probably, the dissociable effects of the three different classes of PDE-Is are not 
due to differences in pharmacokinetics, but to differences in the underlying mechanisms 
of action. All three PDE-Is have a relatively low half-life. This ensures that they affect 
processes during a restricted time window after drug administration and enables investi-
gation of time-critical processes during the consolidation process. We believe that PDE5 
inhibition (i.e. elevated cGMP levels) has an effect on early consolidation processes either 
pre-synaptically (through the cGMP/NO/sGC pathway) or post-synaptically (through the 
cGMP/PKG/CREB pathway). PDE4 inhibition generates its effects through elevated cAMP 
levels and the late consolidation processes of cAMP/PKA/CREB. PDE2-Is exert their effect 
both via cGMP and cAMP. This explains why the PDE2 inhibitor is effective when injected 
directly after (early consolidation) and 3h after (late consolidation) the first trial. In addi-
tion, studies with intra-hippocampal infusions of cAMP and cGMP analogues have shown 
comparable behavioral effects (Bernabeu et al. 1997; Bernabeu et al. 1996; Prickaerts et al. 
2002a) and underscore the notion that these intracellular second messengers have a time 
dependent role in memory consolidation. 
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Conclusions
Summarizing, the timing of treatment modulates the effects on memory and strongly sup-
ports a role for cGMP in early stages of memory formation whereas for cAMP a role in the 
late stages of memory formation is presumed. Our study of time dependent administra-
tion of three different PDE-Is advocates specific roles of cAMP and cGMP in the long term 
memory consolidation processes within narrow time windows. Further, our data suggest 
that different types of PDE-Is can affect different stages of memory consolidation.
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5 The PDE4 inhibitor rolipram reverses object memory impairment induced  
by acute tryptophan 
depletion in the rat
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Psychopharmacology (2007) in press
Rationale: The selective type IV phosphodiesterase (PDE) inhibitor, ro-
lipram, has been shown to improve long-term memory and can reverse 
the cholinergic deficit caused by scopolamine. However underlying mech-
anisms of action of rolipram remain obscure. OBJECTIVES: The present 
study investigates the effect of rolipram in a serotonergic deficit model 
of acute tryptophan depletion (ATD). In addition, the levels of plasma 
tryptophan (TRP) were compared to object recognition performance. 
Materials and methods: The experiments were conducted using male 
Wistar rats. The time dependent effect of ATD treatment (a gelatin based 
protein mixture) on plasma TRP levels (0, 1, 3 and 6 h after injection) and 
object recognition (ORT) performance (0.5, 1, 3 and 6 h after ATD treat-
ment) was examined. The effect of rolipram (0, 0.01, 0.03 and 0.1 mg/kg, 
i.p.) was tested in the condition in which ATD induced a clear memory 
deficit. Results: ATD significantly lowered the plasma TRP ratio (TRP/
∑LNAA) with a maximum of 48%, approximately 1 h after administra-
tion. Furthermore ATD impairs ORT performance when administered 
3 h before testing. Rolipram (0.1 mg/kg) reversed the memory deficit 
induced by ATD in a dose dependent manner. Conclusions: On basis of 
previous studies and the ability to reverse a serotonergic deficit we sug-
gest that rolipram may act through elevation of cAMP levels and subse-
quent increase in neurotransmitter release.
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Introduction
Inhibition of phosphodiesterase type 4 (PDE4) leads to an increase in intracellular cyclic ad-
enosine monophosphate (cAMP) availability (Silvestre et al. 1999). cAMP is an important 
second messenger molecule in the process of intracellular signal transduction mechanisms 
(Bailey et al. 1996). Several studies have shown that rolipram, a selective PDE4 inhibitor, 
improves cognitive performance in young rats (Blokland et al. 2006a; Imanishi et al. 1997; 
Rose et al. 2005; Zhang et al. 2000; Zhang et al. 2004) and ameliorates scopolamine-in-
duced memory deficits (Egawa et al. 1997; Imanishi et al. 1997; Rutten et al. 2006a; Zhang 
and O’Donnell 2000). 
In a previous study we have shown that rolipram reversed a scopolamine-induced deficit in 
an object recognition task in male Wistar rats (Rutten et al. 2006a). It was suggested that 
these effects may be related to the effects of elevated cAMP levels on neurotransmitter re-
lease. There is also evidence that there is a link between PDE4 inhibition and serotonergic 
neurotransmission (Schoffelmeer et al. 1985; West and Galloway 1996). The adenylate cy-
clase activator forskolin as well as 8-bromo-cyclic AMP can enhance the electrically evoked 
release of 3H-5-hydroxytryptamine (Schoffelmeer et al. 1985). Thus elevating cAMP levels 
by a selective PDE4 inhibitor could exert a general facilitatory effect on 5-HT release.  Based 
on these findings we argued that rolipram may also reverse memory deficits induced by 
a lowered 5-HT neurotransmission.
Acute tryptophan depletion (ATD) is a well established model to assess the role of serotonin 
in cognitive and affective functioning (Booij et al. 2003). The neurotransmitter serotonin 
is synthesized from its amino acid precursor tryptophan (TRP), which is obtained from 
our food. Free TRP is transported into the brain across the blood-brain barrier but has to 
compete for entrance with five other large neutral amino acids (LNAAs: valine, leucine, 
isoleucine, phenylalanine, and tyrosine). The ratio of TRP and these other LNAAs (TRP/
∑LNAA ratio) is thought to be a more sensitive index of brain TRP availability (Fernstrom 
1981; Wurtman et al. 1980). Since 5-HT is synthesized from TRP,  through the rate limit-
ing enzyme TRP-hydroxylase, the availability of TRP in the brain determines the amount 
of central 5-HT (Wurtman et al. 1980). Due to its reversible and non-intrusive effects, the 
method of ATD can be repeatedly used in animals and humans. 
In humans acute tryptophan depletion (ATD) has a negative effect on memory consoli-
dation (Park et al. 1994; Riedel et al. 1999; Schmitt et al. 2000). Furthermore, memory 
impairments in the object recognition task (ORT) have been observed in rats after ATD 
(Lieben et al. 2005b; Lieben et al. 2004b). Therefore, we hypothesized that rolipram could 
reverse an ATD induced memory deficit in rats by elevating 5-HT release in the brain. 
73
The PDE4 inhibitor rolipram reverses object memory impairment 
induced by acute tryptophan depletion in the rat
In addition to this aim of the study, we further examined the relation between peripheral 
TRP and memory performance. We investigated the effects of different pretreatment times 
of the TRP depleted mixture on object recognition memory. These data should provide more 
experimental support for a relation between plasma TRP, and consequently central 5-HT, 
and memory performance.
Methods
Animals
All experimental procedures were approved by the local ethical committee of the Maastricht 
University for animal experiments according to governmental guidelines. A total of forty-two 
4-month-old male Wistar rats (Charles River, The Netherlands) were used (410-450 g). Rats 
were randomly assigned to either the biochemistry (n=18) or the behavior group (n=24). In the 
biochemistry groups the animals were randomly subdivided over three treatment groups, i.e. 
saline, TRP+, or TRP- (n=6/group). The animals were housed individually in standard type 3 
Makrolon cages on sawdust bedding in an air-conditioned room (about 20° C). They were kept 
under a reversed 12/12-hour light/dark cycle (lights on from 18.00 to 6.00 h) and had free ac-
cess water. Rats were housed in the same room as where they were tested. A radio, that played 
softly, provided background noise in all rooms. All testing was done between 9.00 and 17.00 h. 
Drugs and chemicals
The Gelatin hydrolysate (Solugel C) was obtained from PB Gelatins (Tessenderlo, Belgium). 
Glucodry 210 was obtained from the Amylumgroup (Koog aan de Zaan, The Netherlands). 
L-tryptophan and rolipram was obtained from Sigma-Aldrich (Zwijndrecht, The Nether-
lands). Kaliumchloride (KCl), calciumchloride-dihydrate (CaCl2·2H2O) and 5-sulfosalicylic 
acid dihydrate were purchased from Merck (Darmstadt, Germany).
Treatment
During a period of two weeks preceding the experiment, the rats were handled and habitu-
ated to oral injections with normal tap water (10 ml/kg). On experimental days, the rats 
were fasted 14 h prior treatment until the testing period was completed. This was done to 
minimize the availability of TRP from food which would counteract the effects of the ATD 
treatment. The rats were orally treated with a protein-carbohydrate mixture containing TRP 
(TRP+ group; in which 0.28% TRP of the total protein was added to the mixture) or one lack-
ing TRP (TRP- group; no TRP added to the mixture), or with saline. The composition of the 
nutritional mixture is shown in Table 1. 
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In every experiment, each dose contained 4.0 g Solugel C/kg and 2.0 g Glucodry/kg of 
the body weight and was given in a volume of 10 ml/kg between 8.30 and 12.30 h. Blood 
samples were taken at baseline (20 min before treatment) and 60 min, 180 min, and 360 
min after the first treatment. For the behavioral studies in the object recognition task, the 
mixture was administered at different time points (see below).
Rolipram was freshly suspended in 5% ethanol, 1% tylose (methyl-cellulose) and 94% 
distilled water on every experimental day. The following doses of rolipram were tested 0, 
0.01, 0.03 or 0.1 mg/kg always in combination with the TRP- mixture (3h before T1). Rolip-
ram was always administered 30 min before T1 (i.p., injection volume 2 ml/kg). 
Table 1: Composition of mixture and determination of the amino acids in gelatin-based protein (mol).
Protein (Solugel) in 100 ml water 100g
Aspartic acid 4.8
Glutamic acid 10.3
Hydroxyproline 11.4
Serine 3.4
Glycine 23.2
Histidine 0.8
Arginine 10.0
Threonine 2.0
Alanine 10.4
Proline 12.0
Tyrosine 0.4
Valine 2.2
Methionine 0.7
Isoleucine 1.0
Leucine 2.5
Hydroxylysine 0.9
Phenylalanine 1.1
Lysine 2.9
Carbohydrate (Glucodry 210) in 80 ml water 50.0
KCl 0.094
CaCl2.2H2O 2.32
L-tryptophan (TRP- group) 0
L-tryptophan (TRP+ group) 0.28
The composition of the mixture (g) used in this experiment is described in bold. The amino acid 
spectrum (%) of the Solugel protein was obtained from PB Gelatins, Tessenderlo, Belgium.
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Biochemistry
For the determination of plasma amino acid levels blood samples were taken at resting 
values and repeated at several points in time. Blood sampling was done via a tail-incision 
method (Fluttert et al. 2000). Promptly after collection of blood in sodium heparin tubes 
(Microvette® CB 300, Sarstedt, Germany), the samples were kept on ice. After centrifugation 
of the blood samples (at 4° C for 15 min at 3000 g in a Hettich EBA 12 centrifuge), plasma 
was deproteinised with cups containing dry 5-sulfosalicylic acid (6 mg/100µl plasma) and 
the protein was spun down. Samples were frozen in liquid nitrogen and stored at -80° C. 
Before analysis, samples were thawed at 4° C, vortex-mixed vigorously and centrifuged at 
50,000 g in a Hereaus Model Biogufe Stratos for 10 min at 4° C. From the clear superna-
tant 20 µl was mixed with 1960 µl water and 20 µl norvaline and stored in the cooled (7° C) 
sample compartment until analysis. 
In addition to total plasma TRP, the concentrations of several other amino acids were 
determined with a fully automated high-performance liquid chromatrography (HPLC) sys-
tem after precolumn derivatization with ophthaldialdehyde (OPA) (Van Eijk et al. 1993). 
OPA-AA derivates were quantified with fluorescence detection. The concentrations of the 
total plasma amino acids were expressed as µmol/l. 
Object recognition memory
The object recognition test was performed as described elsewhere (Prickaerts et al. 2002a).
The apparatus consisted of a circular arena, 83 cm in diameter. Half of the 40 cm high wall 
was made of grey polyvinyl chloride, the other half of transparent polyvinyl chloride. A light 
bulb was switched on during testing only and provided a light intensity (20 lux) which was 
equal in the different parts of the apparatus. Two objects were placed in a symmetrical posi-
tion about 10 cm away from the grey wall. We used four different sets of objects. The differ-
ent objects were: 1) a cone consisting of a grey polyvinyl chloride base (maximal diameter 
18 cm) with a collar on top made of brass (total height 16 cm), 2) a standard 1 l transpar-
ent glass bottle (diameter 10 cm, height 22 cm) filled with sand, 3) a massive metal cube 
(10.0 × 5.0 × 7.5 cm) with two holes (diameter 1.9 cm), and 4) a massive aluminum cube 
with a tapering top (13.0 × 8.0 × 8.0 cm). The objects could not be displaced by a rat.
In the first week, the animals were handled daily and were adapted to the procedure 
in two days, i.e., they were allowed to explore the apparatus (without any objects) twice for 
3 min each day. In the two following weeks the rats were adapted to the testing and i.p. ad-
ministration procedure by a saline injection (0.4 ml) 30 min before the first trial until they 
showed a stable discrimination performance, i.e., good object discrimination (a d2 value 
of about 0.30, see below) at a 1 h interval on two successive sessions. Subsequently, testing 
of the drugs began.
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A testing session comprised two trials. The duration of each trial was 3 min. During 
the first trial (T1) the apparatus contained two identical objects (samples). A rat was always 
placed in the apparatus facing the wall in the centre of the transparent front segment. After 
the first exploration period the rat was put back in its home cage. Subsequently, after a delay 
interval, the rat was put back in the apparatus for the second trial (T2), but now with two 
dissimilar objects, a familiar one (the sample) and a new one. The times spent exploring each 
object during T1 and T2 were recorded manually with a personal computer.
Exploration was defined as follows: directing the nose to the object at a distance 
of no more than 2 cm and/or touching the object with the nose. Sitting on the object was 
not considered exploratory behavior. In order to avoid the presence of olfactory trails the 
objects were always thoroughly cleaned with alcohol (70%). Moreover, each object was 
available in triplicate so neither of the two objects from the first trial had to be used as the 
familiar object in the second trial. In addition, all combinations and locations of objects 
were used in a balanced manner to reduce potential biases due to preferences for particular 
locations or objects.
Since we expected ATD to impair memory performance we needed a delay interval at 
which normal rats discriminate between the novel and familiar object. Therefore, we selected 
a delay interval of 1 h, since Wistar rats show good discrimination between the two objects 
after this interval (Rutten et al. 2006a). Furthermore we hypothesized that rolipram may 
reverse deficits induced by ATD in a 1h delay ORT. In one week three testing sessions were 
given with a 48 h washout period in between. Tests were always conducted on Mondays, 
Wednesdays and Fridays. 
In the first behavioral experiment we investigated the effects of administration with TRP+ 
or TRP- mixture at different time points (i.e. 30 min, 1 h, 3 h or 6 h) before testing in the 
ORT.  Each rat always participated in each condition and the order of test conditions was 
decided at random.
The second behavioral experiment examined the effect of rolipram (30 min before T1) 
on object recognition performance in combination with the TRP- mixture at the most ef-
fective time-point (i.e. 3 h before T1). Thus, 5 treatment conditions were tested, i.e. saline, 
vehicle and TRP-, rolipram 0.01 mg/kg and TRP-, rolipram 0.03 mg/kg and TRP-, and rolip-
ram 0.1 mg/kg and TRP-. Each rat was tested in each condition and the order of treatment 
conditions was decided at random.  The same animals (n=24) were used for both behavioral 
experiments, thus control conditions (TRP+) from experiment 1 can and saline from experi-
ment 2 can be compared to each other. 
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Statistical analysis
Biochemistry
The mean concentrations of plasma amino acids were determined for each treatment and 
time condition separately. The extent of reduction (expressed in absolute values and in per-
centage decline from resting values) was calculated for total plasma TRP concentrations and 
for the TRP/∑LNAA ratio. Extreme values, as determined by an extremity test (see Dixon 
1959), were excluded from statistical analysis. Differences in plasma amino acid concentra-
tions were analyzed with GLM, with main factor ‘treatment’ and repeated measure factor 
‘time’. Separate one way analyses of variance (ANOVA) were performed to analyze differ-
ences between treatment conditions per time point. A post-hoc Bonferroni test was used 
to further characterize the differences between treatment conditions. Differences were re-
garded as statistically significant if p<0.05.
Behavior
The basic measures were the times spent by rats exploring an object during T1 and T2. Table 
2 shows the measures involved in the object recognition task (Prickaerts et al. 1997). e1 and 
e2 are measures of the total exploration time of both objects during T1 and T2 respectively. 
d2 was considered as index measures of discrimination between the new and the familiar 
objects. d2 is a relative measure of discrimination which corrects the difference between ex-
ploring the old and the novel object for exploration activity (e2), and appears to be indepen-
dent of the total exploration times (see Sik et al. 2003). In the object recognition task, results 
are not reliable if an animal explores both objects in the second trial for less than 5 s (Sik et 
al. 2003). Therefore in every session, animals that explored less than 5 s in the second trial 
(i.e. e2 < 5) were excluded from analysis. For all parameters the effects of the different treat-
ment, time and interactions were analyzed with univariate ANOVA for the first experiment 
and one-way ANOVA for the second experiment. Significant effects were analyzed in more 
detail using the Bonferroni correction. To compare control conditions, i.e the TRP+ (3h before 
the first trial) condition of the first experiment with the saline condition of the second experi-
ment a t-test was performed. Differences were regarded as statistically significant if p<0.05.
Table 2. Measures involved in the object recognition test. e1 is the measure of the time spent in exploring 
both identical objects (a1 and a2) in T1, e2 is the measure of the time spent in exploring both the familiar 
(a) and new object (b) in T2; d2 is the measure of discrimination between the new and familiar objects.
Exploration Discrimination
e1 = a1 + a2 d2= b - a / e2
e2 = a + b
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Results
Plasma TRP values
The plasma TRP/∑LNAA ratio is shown in Figure 1. TRP/∑LNAA levels changed over the 
6 hours (F(3,60) = 4.92; P < 0.01). There was a treatment effect for TRP/∑LNAA ratio 
(F(2,60) = 36.72, P < 0.01). Post hoc analysis showed that the TRP- condition was signifi-
cantly different than the TRP+ and the saline condition (Bonferroni, P<0.05). In addition, the 
Time x Treatment interaction was also significant for the TRP/∑LNAA ratio (F(6,60) = 7.80; 
P < 0.01). Separate one-way ANOVA analyses for each treatment time point showed differ-
ences between treatment conditions at the 1 h time point (F(2,17) = 31.44; P < 0.01) and the 
3 h time point (F(2,16) = 6.79; P < 0.01). However, no differences between treatment con-
ditions were observed at the baseline time point (-20 min) (F(2,15) = 2.03; n.s.) or the 6 h 
time point (F(2.17)= 3.33; n.s.) (see Figure1). Furthermore, post hoc analysis showed that the 
TRP/∑LNAA ratio of the TRP- treated animals was lower than the TRP+ or saline treated ani-
mals at the 1 h time point (Bonferroni; P<0.01) and the 3 h time point (Bonferroni; P<0.05). 
Behavioral experiment 1
The effects of ATD on ORT performance are shown in Figure 2 and Table 3. There was a gen-
eral treatment effect on ORT performance (F(1,165) = 36.44 ; P < 0.01). In addition, a time 
effect was observed on ORT performance (F(3,165) = 2.86; P < 0.05. The Time x Treatment 
interaction was also significant for the memory performance in the ORT (F(3,165) = 4.47; 
P < 0.01). Separate analysis per treatment condition showed that there was a significant time 
effect for the TRP- condition (F(3,87) = 5.41; P < 0.01) in memory performance, but not for 
Figure 1: The effects of treatment time on the ratio plasma TRP/∑LNAA (mean values and SEM). Percentages indicate the difference from 
baseline levels in the TRP- conditions. Asterisks indicate significant differences from baseline (* P<0.05; ** P<0.01)
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the TRP+ condition (F(3,84) = 1.77; P= n.s.). Post-hoc analysis showed that object recogni-
tion performance was significantly impaired when the TRP- mixture was administered 3h 
before the first trial.  
Table 3: Exploration times in the object recognition task at baseline and after ATD. * indicates significant 
differences to the baseline group, P < 0.05
T1 - 30 min T1 - 1h T1 - 3h T1 - 6h
A) TRP +
e1 26.62 (2.09) 32.30 (1.37) 27.82 (2.06) 29.00 (2.50)
e2 33.64 (2.40) 49.78 (3.11)* 28.61 (2.39) 28.37 (2.15)
B) TRP -
e1 26.97 (2.11)` 30.39 (1.78) 29.29 (1.66) 24.98 (1.53)
e2 39.26 (4.17) 37.32 (2.40) 30.06 (1.77) 28.91 (2.69)
Behavioral experiment 2
The effects of ATD in combination with rolipram on object recognition performance are 
depicted in Figure 3 and Table 4. A dose dependent increase in discrimination performance 
was observed after treatment with rolipram (F(4,104) = 6.85; P < 0.01). Post-hoc analysis 
showed that a dose of 0.1 mg/kg rolipram reversed the effects of TRP- treatment (P<0.05). 
Rolipram treatment decreased exploration times in the first trial (F(4,106) = 16.24; P < 0.01), 
but had no effect on exploration times the second trial (F(4,106) = 1.53; n.s.; see Table 4). 
Figure 2: The effects of treatment time of TRP+ or TRP- on the performance in object recognition task. Asterisks indicate a significant 
impairment in object recognition performance (* P<0.05).
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Post hoc analysis showed that for all of the rolipram doses the exploration in the first trial 
was lower than the saline control condition. 
A comparison between the d2 values of the control groups of the first and second 
experiment (TRP+ 3 h vs. saline) showed that there was no difference between these two 
control groups (t(38) = 0.906; n.s.). 
Table 4: Exploration times in the object recognition task after treatments with rolipram and TRP- mix-
ture. * indicates significant differences to the baseline group, P < 0.05
 Saline Vehicle 0.01 mg/kg 0.03 mg/kg 0.1 mg/kg
 Saline TRP- TRP- TRP- TRP-
e1 28.72 (2.52) 26.18 (1.72) 19.15 (1.66)* 18.68 (1.35)* 12.02 (1.53)*
e2 28.73 (1.42) 27.43 (1.80) 21.68 (1.96) 27.89 (2.63) 27.29 (2.70)
Discussion
The present study shows that acute tryptophan depletion results in reliable lowering of plas-
ma TRP and the TRP/∑LNAA ratio. When rats were administered one dose (10 ml/kg) of 
the TRP- mixture, depletion was maximal (48%) one hour after the treatment. The present 
data provide strong evidence that blood TRP levels predict object recognition performance 
and that ATD has only temporary effects on TRP levels and memory performance. When 
injected 3 h before T1 object recognition was maximally impaired. This is in support of the 
Figure 3: The effects of rolipram treatment on ATD induced deficits in the object recognition task. Asterisks indicate a significant differ-
ence in object recognition performance compared with the TRP- and vehicle condition (** P<0.01). The 0.1 mg/kg dose of rolipram reverses 
the ATD effect.
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results from the blood TRP values (see above). Thus, TRP levels in the blood seem to be re-
lated with behavioral performance in rats. Since previous studies have shown (Lieben et al. 
2004a) a clear relation between plasma TRP and central 5-HT, these data provide further 
support that ATD can be used as a serotonergic deficit model in the object recognition task. 
In the study by Lieben at al. (2004) two doses of the TRP- mixture (10 ml/kg) were adminis-
tered, which resulted in a 70% drop of the TRP/∑LNAA ratio and in memory impairment in 
the ORT. In contrast, the present study showed that one dose of the TRP- mixture resulted 
in a 48% drop in the TRP/∑LNAA ratio, which was found to induce memory impairment 
in the ORT. These findings suggest that a 50% reduction in plasma TRP levels is sufficient 
to impair object memory in rats.
In the first behavioral experiment, no effects on exploration times in the ORT were observed, 
except from an increase in exploration time in the second trial of the TRP+ 1 h before T1 
group. However, in the second experiment a dose dependent decrease in the exploration 
time of T1 was observed after treatment with rolipram. Previous work from our group has 
shown that as long as exploration in trial 1 is higher than 10 s a reliable discrimination index 
(d2) can be calculated (Sik et al. 2003). Furthermore, as can be seen when exploration times 
are compared to d2 values, effects in exploration time are independent of effects in d2 values 
(Sik et al. 2003).  Rolipram is known to have some sedative side effects (at higher dosages 
>0.1 mg/kg) (Griebel et al. 1991; Silvestre et al. 1999), nevertheless the low dosages used 
in the present study improved memory performance. 
Rolipram has shown its pro-cognitive effects in several behavioral models. We have shown 
that rolipram treatment increases object memory in a time dependent forgetting paradigm 
(Rutten et al. 2006a). In addition, rolipram attenuated cholinergic deficits caused by scopol-
amine in several behavioral tasks (Imanishi et al. 1997; Rutten et al. 2006a; Silvestre et al. 
1999; Zhang and O’Donnell 2000). When rolipram (0.1 mg/kg) was administered in com-
bination with the TRP- mixture (i.e. TRP- 3 h before T1 and rolipram 30 min before T1), we 
found that it reversed the effects of ATD. These are the first data suggesting that rolipram 
can reverse a serotonergic induced memory deficit in rats.
Our previous study indicated that rolipram can reverse the cholinergic deficit caused 
by scopolamine in the ORT (Rutten et al. 2006a). Remarkably, a similar dose of 0.1 mg/kg 
rolipram was capable of reversing the serotonergic and cholinergic deficits in the object 
recognition task, which might be explained by a non-specific working mechanism of ro-
lipram.  Although the underlying mechanisms of action of the memory enhancing effects 
of rolipram in these models remain to be determined, the present data could be explained 
via an enhanced cholinergic and serotonergic turnover by rolipram (Imanishi et al. 1997; 
Schoffelmeer et al. 1985).
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Alternatively, the effects of rolipram could also be explained in terms of only a choliner-
gic mechanism of action. Thus, previous studies have shown that the acetylcholinesterase 
(AChE) inhibitor metrifonate ameliorates the effects of ATD as well and improves perfor-
mance in scopolamine deficit models of the ORT (Lieben et al. 2005b). This suggests that the 
cholinergic and serotonergic systems act in a synergistic manner in memory performance 
(see Lieben et al. 2005b for a detailed discussion). Clearly, further research is needed to scru-
tinize the mechanism of action rolipram in the different animal models of memory.
Another mechanism of action of rolipram that could explain the present data is related to 
the intracellular signaling in long-term potentiation (LTP). In the hippocampus, rolipram 
has shown to improve LTP through activation of the cAMP/PKA/CREB pathway (Frey et al. 
1993; Impey et al. 1996). Moreover, these mechanisms have been linked to behavioral im-
provement in several behavioral tasks (Barad et al. 1998; Bernabeu et al. 1997; Blokland et 
al. 2006a; Rutten et al. 2006a). Consequently, it could be argued that the present data could 
be explained by the effects of rolipram on the cAMP/PKA/CREB pathway. However, a recent 
study by our group showed that the administration time of rolipram was of critical relevance. 
Rolipram was only effective in the 24 h interval ORT when administered 3 h after T1 (Rutten 
et al. 2006a) and the mechanism of late LTP was proposed to explain these effects. However, 
in the present study a 1 h interval in the ORT was examined, in which no gene transcription 
or protein synthesis is required. Therefore, we assume that the cAMP/PKA/CREB pathway 
cannot explain these effects. 
A recent PET study used radioactive rolipram as a measure for PDE4 binding and as an indi-
rect index of cAMP signaling (Lourenco et al. 2006). Acute elevation of synaptic neurotrans-
mitter levels (noradrenaline, 5-HT and histamine) resulted in elevated cAMP levels that in 
turn elevated (R)-[11C] rolipram binding to PDE4 (Lourenco et al. 2006). According to this 
rationale, elevation of cAMP levels through inhibition of PDE4 can reverse cAMP mediated 
deficits in behavior that occur due to a shortage of 5-HT, ie, reversing the ATD induced 
object recognition impairment. Since rolipram non-selectively facilitates several neurotrans-
mitter systems, a broad mechanism of action can be expected. This can be favorable because 
influencing multiple systems increases the likelihood that several aspects of behavior could 
be enhanced. This may explain previous reports that rolipram was effective in depression 
models (Bobon et al. 1988; Norman et al. 1992b; Weishaar et al. 1985b). On the downside, 
the broad mechanism of action increases the risks for negative side effects, e.g. emesis, seda-
tion and nausea.
Summarizing, the method of ATD can be used as a reliable method for inducing object 
memory impairment in rats. The selective PDE4 inhibitor rolipram was able to reverse this 
serotonergic deficit, which could be explained by different mechanisms of action. These data 
provide further support that PDE4 inhibition could be considered as a potential target to 
improve memory performance. 
83
The PDE4 inhibitor rolipram reverses object memory impairment 
induced by acute tryptophan depletion in the rat
References
Bailey CH, Bartsch D, Kandel ER (1996) Toward a molecular definition of long-term memory storage. Proc. Natl. 
Acad. Sci. USA 93: 13445–13452
Barad M, Bourtchouladze R, Winder DG, Golan H, Kandel E (1998) Rolipram, a type IV-specific phosphodiesterase 
inhibitor, facilitates the establishment of long-lasting long-term potentiation and improves memory. Proc. 
Natl. Acad. Sci. USA 95: 15020–15025
Bernabeu R, Bevilaqua L, Ardenghi P, Bromberg E, Schmitz P, Bianchin M, Izquierdo I, Medina JH (1997) Involve-
ment of hippocampal cAMP/cAMP-dependent protein kinase signaling pathways in a late memory consoli-
dation phase of aversively motivated learning in rats. Proc. Natl. Acad. Sci. USA 94: 7041–7046
Blokland A, Schreiber R, Prickaerts J (2006) Improving Memory: A role for Phosphodiesterases. Curr. Pharm. Des. 
12: 2511–2523
Bobon D, Breulet M, Gerard-Vandenhove MA, Guiot-Goffioul F, Plomteux G, Sastre-y-Hernandez M, Schratzer M, 
Troisfontaines B, von Frenckell R, Wachtel H (1988) Is phosphodiesterase inhibition a new mechanism of 
antidepressant action? A double blind double-dummy study between rolipram and desipramine in hospital-
ized major and/or endogenous depressives. Eur. Arch. Psychiatry Neurol. Sci. 238: 2–6
Booij L, Van der Does AJ, Riedel WJ (2003) Monoamine depletion in psychiatric and healthy populations: review. 
Mol. Psychiatry. 8: 951–973
Dixon WJ (1959) Analysis of extreme values. Ann. Math. Stat. 21: 488–506
Egawa T, Mishima K, Matsumoto Y, Iwasaki K, Fujiwara M (1997) Rolipram and its optical isomers, phosphodies-
terase 4 inhibitors, attenuated the scopolamine-induced impairments of learning and memory in rats. Jpn. 
J. Pharmacol. 75: 275–281
Fernstrom JD (1981) Dietary precursors and brain neurotransmitter formation. Annu. Rev. Med. 32: 413–425
Fluttert M, Dalm S, Oitzl MS (2000) A refined method for sequential blood sampling by tail incision in rats. Lab. 
Anim. 34: 372–378
Frey U, Huang YY, Kandel ER (1993) Effects of cAMP simulate a late stage of LTP in hippocampal CA1 neurons. 
Science 260: 1661–1664
Griebel G, Misslin R, Vogel E, Bourguignon JJ (1991) Behavioral effects of rolipram and structurally related com-
pounds in mice: behavioral sedation of cAMP phosphodiesterase inhibitors. Pharmacol. Biochem. Behav. 
39: 321–323
Imanishi T, Sawa A, Ichimaru Y, Miyashiro M, Kato S, Yamamoto T, Ueki S (1997) Ameliorating effects of rolipram on 
experimentally induced impairments of learning and memory in rodents. Eur. J. Pharmacol. 321: 273–278
Impey S, Mark M, Villacres EC, Poser S, Chavkin C, Storm DR (1996) Induction of CRE-mediated gene expression 
by stimuli that generate long-lasting LTP in area CA1 of the hippocampus. Neuron 16: 973–982
Lieben CK, Blokland A, Şık A, Sung E, van Nieuwenhuizen P, Schreiber R (2005) The selective 5-HT6 receptor 
antagonist Ro4368554 restores memory performance in cholinergic and serotonergic models of memory 
deficiency in the rat. Neuropsychopharmacology 30: 2169–2179
Lieben CK, Blokland A, Westerink B, Deutz NE (2004a) Acute tryptophan and serotonin depletion using an opti-
mized tryptophan-free protein-carbohydrate mixture in the adult rat. Neurochem. Int. 44: 9–16
Lieben CK, van Oorsouw K, Deutz NE, Blokland A (2004b) Acute tryptophan depletion induced by a gelatin-based 
mixture impairs object memory but not affective behavior and spatial learning in the rat. Behav. Brain. Res. 
151: 53–64
Lourenco CM, Kenk M, Beanlands RS, DaSilva JN (2006) Increasing synaptic noradrenaline, serotonin and hista-
mine enhances in vivo binding of phosphodiesterase–4 inhibitor (R)-[11C]rolipram in rat brain, lung and 
heart. Life. Sci. 79: 356–364
Norman TR, Judd FK, Burrows GD (1992) New pharmacological approaches to the management of depression: 
from theory to clinical practice. Aust N Z J Psychiatry 26: 73–81
Park SB, Coull JT, McShane RH, Young AH, Sahakian BJ, Robbins TW, Cowen PJ (1994) Tryptophan depletion 
in normal volunteers produces selective impairments in learning and memory. Neuropharmacology 33: 
575–588
Prickaerts J, de Vente J, Honig W, Steinbusch HW, Blokland A (2002) cGMP, but not cAMP, in rat hippocampus 
is involved in early stages of object memory consolidation. Eur. J. Pharmacol. 436: 83–87
Prickaerts J, Steinbusch HW, Smits JF, de Vente J (1997) Possible role of nitric oxide-cyclic GMP pathway in object 
recognition memory: effects of 7-nitroindazole and zaprinast. Eur. J. Pharmacol. 337: 125–136
Riedel WJ, Klaassen T, Deutz NE, van Someren A, van Praag HM (1999) Tryptophan depletion in normal volun-
teers produces selective impairment in memory consolidation. Psychopharmacology (Berl) 141: 362–369
Rose GM, Hopper A, De Vivo M, Tehim A (2005) Phosphodiesterase inhibitors for cognitive enhancement. Curr. 
Pharm. Des. 11: 3329–3334
Rutten K, Prickaerts J, Blokland A (2006) Rolipram reverses scopolamine-induced and time-dependent memory 
deficits in object recognition by different mechanisms of action. Neurobiol. Learn. Mem. 85: 132–138
Schmitt JA, Jorissen BL, Sobczak S, van Boxtel MP, Hogervorst E, Deutz NE, Riedel WJ (2000) Tryptophan deple-
tion impairs memory consolidation but improves focussed attention in healthy young volunteers. J. Psycho-
pharmacol. 14: 21–29
Schoffelmeer AN, Wardeh G, Mulder AH (1985) Cyclic AMP facilitates the electrically evoked release of radio-
labelled noradrenaline, dopamine and 5-hydroxytryptamine from rat brain slices. Naunyn Schmiedebergs 
Arch. Pharmacol. 330: 74–76
Şık A, van Nieuwehuyzen P, Prickaerts J, Blokland A (2003) Performance of different mouse strains in an object 
recognition task. Behav. Brain. Res. 147: 49–54
Silvestre JS, Fernandez AG, Palacios JM (1999) Preliminary evidence for an involvement of the cholinergic system 
in the sedative effects of rolipram in rats. Pharmacol. Biochem. Behav. 64: 1–5
Van Eijk HM, Rooyakkers DR, Deutz NE (1993) Rapid routine determination of amino acids in plasma by high-
performance liquid chromatography with a 2–3 microns Spherisorb ODS II column. J. Chromatogr. 620: 
143–148
Weishaar RE, Cain MH, Bristol JA (1985) A new generation of phosphodiesterase inhibitors: multiple molecular 
forms of phosphodiesterase and the potential for drug selectivity. J. Med. Chem. 28: 537–545
West AR, Galloway MP (1996) Regulation of serotonin-facilitated dopamine release in vivo: the role of protein 
kinase A activating transduction mechanisms. Synapse 23: 20–27
Wurtman RJ, Hefti F, Melamed E (1980) Precursor control of neurotransmitter synthesis. Pharmacol. Rev. 32: 
315–335
Zhang HT, Crissman AM, Dorairaj NR, Chandler LJ, O’Donnell JM (2000) Inhibition of cyclic AMP phosphodiester-
ase (PDE4) reverses memory deficits associated with NMDA receptor antagonism. Neuropsychopharmacol-
ogy 23: 198–204
Zhang HT, O’Donnell JM (2000) Effects of rolipram on scopolamine-induced impairment of working and reference 
memory in the radial-arm maze tests in rats. Psychopharmacology (Berl) 150: 311–316
Zhang HT, Zhao Y, Huang Y, Dorairaj NR, Chandler LJ, O’Donnell JM (2004) Inhibition of the phosphodiesterase 
4 (PDE4) enzyme reverses memory deficits produced by infusion of the MEK inhibitor U0126 into the CA1 
subregion of the rat hippocampus. Neuropsychopharmacology 29: 1432–1439
6 Behavioral effects  of PDE4-D and PDE4-B  knock-out mice in models  
of learning and memory
Kris Rutten, Melissa Works, Arjan Blokland,  
Luca Santarelli, Tanya Wallace-Boone
Awaiting clearance from Roche Palo Alto for submission 
Sustained activation of cyclic adenosine monophosphate (cAMP) and subsequent phosphory-
lation of cAMP responsive element binding protein (CREB) is believed to be a critical mediator 
of long-term memory (LTM) formation.  Consistent with this hypothesis, pharmacological 
inhibition at the level of the phosphodiesterase 4 (PDE4), the primary enzyme responsible for 
the breakdown of cAMP results in memory enhancement in several cognitive behavioral tasks 
across multiple species.  Currently, four isoforms of the PDE4 enzyme (A, B, C and D) have 
been identified, yet the requisite involvement of each of these isoforms in mediating LTM has 
yet to be elucidated, in part because selective small molecule isoform inhibitors have not been 
characterized.  The intent of the present study was to use genetic knockout mice to investigate 
the involvement of two of the PDE4 isoforms that have high brain expression, namely D and 
B, in in vivo models of learning and memory.  Adult, male PDE4-D and PDE4-B knock-out mice 
were first characterized in an associative learning paradigm using the fear conditioning model 
(FC) at two time points, 24 hours for long term memory (LTM), and 1 hour for short term 
memory (STM).  Interestingly, whereas the PDE4 B knock out mice demonstrated equivalent 
LTM and STM as compared to wildtype mice, the PDE4-D knock-out animals exhibited sig-
nificant deficits in LTM as compared with their control littermates.  The impairment in LTM 
observed in the PDE4D knockout mice could not be attributed to differences in acquisition of 
the FC task (i.e., STM), alterations in locomotor activity or effects on shock sensitivity, as there 
were no significant genotype effects in any of these measures.  Neither the PDE4B or PDE4D 
mice showed any alterations in MWM performance (acquisition or retention) as compared 
to wildtype controls.  Whereas the deficit in LTM observed in the PDE4D knockout mice was 
not expected, and may be explained by adaptive responses occurring because of constitutive 
inactivity of this isoform throughout development, it does suggest that the PDE4D isoform, 
possibly more so than PDE4B may be of importance in learning and memory.
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Introduction
Activation of the cAMP (cyclic adenosine monophosphate)/protein kinase-A (PKA) /CREB 
pathway has been proposed to mediate long term potentiation (LTP) and memory (Ahi 
et al. 2004; Barco et al. 2003; Bernabeu et al. 1997; Bourtchouladze et al. 2003; Comery 
et al. 2005; Frey et al. 1993).  In particular, cAMP plays an important role in intracellular 
signaling (Bailey et al. 1996) and in processes of neuroplasticity and is believed to be in-
volved in the processes of late phase LTP and late memory consolidation (Rose et al. 2005; 
Rutten et al. 2006a). The degradation of cAMP and cGMP cyclic guanine monophosphate, 
a closely related cyclic nucleotide, is regulated by phosphodiesterase (PDE) enzymes. The 
family of PDEs is relatively large and eleven different isozymes have been identified thus 
far. Several studies have shown memory enhancing effects of phosphodiesterase inhibitors 
(PDE-Is) in many different species and in a large array of memory tasks (for review see 
Blokland et al. 2006, in press). At present, the studies that describe effects of selective 
PDEs on memory performance have concentrated on inhibitors of PDE4 (i.e. Rose et al. 
2005), PDE5 (i.e. Prickaerts et al. 2004) and more recently PDE2 (i.e. Boess et al. 2004). 
PDE4 and PDE5 are specific inhibitors of cAMP or cGMP, respectively, whereas PDE2 hy-
drolyzes both cAMP and cGMP.
Within the PDE4 family, four PDE4 subtypes have been characterized, namely PDE4 A, 
B, C, and D. Whereas PDE4 is ubiquitously expressed in the brain, the PDE4-B and D isoforms 
are more widely expressed than PDE4 A and C (Perez-Torres et al. 2000).  In particular, PDE4-
B and PDE4-D are present in cortex, hippocampus, hypothalamus, midbrain and cerebellum, 
with PDE4-B being specifically enriched in the striatum (Blokland et al. 2006, in press). In the 
amygdala and the hippocampus PDE4-B and D are both expressed but not equally.
At present, it is unknown which PDE4 isoform (s) is involved in mediating synaptic 
plasticity and cognitive enhancing effects.  Previous studies showed that intra-hippocampal 
infusions of cAMP analogs (e.g., 8-Br-cAMP, sp-cAMPs) improved learning in memory in an-
imals models of cognition (Bernabeu et al. 1997; Bernabeu et al. 1996). Similar results were 
observed after infusions of 8-Br-cGMP in the rat hippocampus in another one trial learning 
task, the object recognition task (Prickaerts et al. 2002a). The most widely characterized 
PDE4 inhibitor, rolipram, has demonstrated cognitive enhancing properties in several ani-
mal models of learning and memory (Bourtchouladze et al. 2003; Rutten et al. 2006a; Zhang 
et al. 2000; Zhang et al. 2005; Zhang et al. 2004). In addition, PDE4 inhibitors can reverse 
memory impairments in several mouse models of disease (e.g., Alzheimer’s disease) (Bourt-
chouladze et al. 2003; Comery et al. 2005; Gong et al. 2004).  
Whereas PDE4 inhibitors are enticing targets for the treatment of cognitive impairing 
disease such as Alzheimer’s, it has been very difficult to circumvent the adverse effects that 
often accompany the beneficial effects of the PDE4-Is.  Thus, one approach to minimize the 
adverse effects would be to develop selective PDE4 isoform inhibitors depending on the 
characterization and understanding of which isoform (s) was involved in learning/memory. 
It was the intent of the present study to use genetic knock out mice with selective deletions 
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of either the PDE4B or PDE4D isoform to identify whether either or both of these subtypes 
is involved in mediating LTM.  Characterization of specific isoform functions can provide 
better understanding of the mechanism for cognitive enhancement of PDE4 inhibition and 
the augmentation of pro-cognitive drugs. 
Methods
Generation of PDE4-D & B KO mice
The generation of the PDE4-D- and PDE4-B-deficient mice has been described previously (Jin 
et al. 2005).  For both lines the effect of the null PDE4 allele was tested on mice of a mixed 
background (C57BL/6 x 129/Ola) using wild-type littermates as controls. Colonies were es-
tablished and maintained by out-breeding heterozygous pairs and genotyping the offspring. 
A total of 184 young adult male (25–30g) transgenic, PDE4-D (n = 92) and PDE4-B (n = 92) 
mice, were used in the characterization experiments. The mice used in the present studies 
were all adults between the ages of 10-23 weeks of age.  All animals were housed in stan-
dard Allentown mouse cages on corncob bedding (n = 1–8/cage, depending on littermate 
availability) in a temperature controlled room (about 20° C). They were kept under a regular 
12/12-hour light/dark cycle (lights on from 6.00h to 18.00h) and had free access to food and 
water.  All experimental procedures were approved by the Institutional Animal Care and Use 
Committee (IACUC) of Roche Palo Alto and were in accordance with NIH guidelines.  
Apparatus:
Fear Conditioning
Training took place in 8 identical mouse fear conditioning boxes (Coulbourn Instruments, 
Allentown, PA).   The floor was a metal grid (17.8 cm long × 17.8 cm wide × 30.5 cm high) 
connected to a shock generator (model H13-15) used to administer foot shocks (0–1.0 mA). 
Each fear conditioning box was dimly lit (3–8 lux) by a single house light and was enclosed 
by a sound attenuating chamber. The boxes were equipped with a 24V speaker and on top of 
each box a digital camera was mounted which was connected to a computer system that au-
tomatically monitored freezing behavior (Freezeframe, Coulbourn Instruments, Allentown, 
PA). The threshold for detecting freezing was set at 15 and was based on empirically col-
lected data comparing manual and automatic scoring measurements.  Freezing was defined 
as a total lack of movement except for respiration.
On the day of training and testing mice were brought into the test room with free ac-
cess to food and water. The animals were then weighed and acclimated to the test room for 
60 min. The fear conditioning test consisted of a training phase and a test phase conducted 
24 h later. Before each training and testing session the conditioning boxes were cleaned with 
an 85% ethanol solution.
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On the training day, each mouse was placed in a conditioning box and was allowed to 
explore the new environment for 120s.  Next a tone (CS, 3000Hz, 85dB) was presented for 
30s that co-terminated with a 2s foot shock (0, 0.4 or 1 mA) (US). A second CS/US pairing 
was presented after an inter stimulus interval (ISI) of 120s. After the second shock the mice 
remained in the training box for 30 seconds before being returned to their home cages. 
 On the test day, conducted 1 hr (short-term memory) or 24 hr (long-term memo-
ry) after training, mice were returned to the testing room and each mouse was placed in 
the same chamber used for training and the association between the context and the aver-
sive US (foot shock) was measured by means of freezing behavior over a 5 minute period 
(i.e., context test). Freezing behavior was monitored automatically.
Approximately, one hour after contextual fear testing, the environmental conditions 
of the testing room were changed in preparation for the cue test, in which an altered context 
was created. Cue tests were conducted in standard mouse cages with sawdust bedding and 
covered with filter tops. The boxes were scented with orange extract and the testing room 
itself was cleaned with a different disinfectant (Lysol instead of 85% ethanol) to minimize 
similarity to the original conditioning environment. During the cue test a radio provided soft 
background noise and the test room was divided into a smaller segment as compared to the 
original conditioning session by a black curtain.  Next, the association between the auditory 
cue (CS) and the aversive foot shock (US) were measured manually by monitoring freezing 
behavior (i.e., altered context/cue test).  In this test, four mice were scored simultaneously by 
a blinded observer at 4 second intervals each mouse was judged as either freezing or active. 
For the altered context (cue) test, baseline freezing was scored for the first 120s (pre-CS).
Morris water maze (MWM)
The testing room consisted of a circular, galvanized steel pool 1.42 meters in diameter, paint-
ed white, filled with 22° C water and 250 mL of white, latex indoor house paint to make the 
water opaque. The pool was surrounded by curtains that could be drawn, and around the 
room, bright and bold visual cues were displayed on the walls. These extra-maze cues were 
kept constant throughout the training and testing period. The pool was divided into four 
quadrants (North, West, South, East) and a 13 cm white, circular platform was placed 1.5 cm 
below the surface of the water in the North quadrant. Centered above the pool, a camera 
(Panasonic, Secaucus, NJ) was connected to an HP computer loaded with a visual tracking 
program (Noldus Ethovision, Leesburg, VA).  
Mice were subjected to the following testing schedule for MWM: spatial navigation 
with acquisition and probe trials (days 1–5), reversal learning (days 6 & 7), and cued naviga-
tion (day 8).  Acquisition of spatial navigation (days 1–4) consisted of 4 trials per day with 
a 10-minute inter-trial interval where mice were trained to use spatial cues to reach a hid-
den platform. Each trial started with the mouse facing the wall of the pool and ended when 
the mouse reached the platform, or 60 seconds, which ever came first. Starting positions 
were balanced in a Latin Square design so that no mouse started the trials in the same loca-
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tion order. If the mouse failed to find the platform, it was guided to the platform location 
with a prop (an immobilized paint roller). At the end of the trial, the mouse was allowed to 
stay on the platform for approximately 10 seconds and was then taken off the platform via 
the prop. On day 3, 1.5 hours after the last acquisition trial, and day 5, 24 hours after the 
last acquisition trial, the platform was removed from the tank and the mouse was allowed 
to swim in the tank for 60 seconds. Reversal learning (days 6 and 7) consisted of 4 trials 
per day with a 10-minute inter-trial interval in which the platform was moved to the East 
quadrant. Starting positions were balanced in a Latin Square design. The mouse was given 
60 seconds to find the platform and allowed to stay on the platform for approximately 10 
seconds. Cued navigation (day 8), which tested swimming ability and visual acuity, consisted 
of 4 trials per day with a 10-minute inter-trial interval. The curtains were closed around the 
pool and the platform was placed in the center of the pool. An object was placed in the center 
of the platform to act as a “cue”. Starting positions were balanced in a Latin Square design. 
The mouse was given 60 seconds to find the platform and allowed to stay on the platform 
for approximately 10 seconds. Comparisons of path length (cm) in acquisition, reversal, and 
cued tests, and percent distance in each quadrant in probe trials were performed between 
KO and WT mice.
Learning Capacity Test in Morris Water Maze
In modified version of the Morris water maze, another group of mice were tested for learn-
ing capacity. In this test, mice had a maximum of 8 (60-second) trials per day to locate the 
hidden platform using spatial cues. If the mouse was able to reach the platform in an average 
of 21 seconds over three consecutive trials (i.e., reached “criteria”), then testing ended for 
the day. The next day, the platform was moved to a new location and the mouse was given 
another 8 trials. If the mouse did not reach criteria on a given day, testing ended after 8 trials 
and the platform was placed in the same location the next day. For any given trial location, 
subjects were allowed a maximum of 4 days, or 32 trials, before the platform was moved to 
the next location automatically. Mice experienced a maximum of 10 platform locations. Half 
of the mice experienced the platforms locations in the order of 1 to 10, while the other half 
experienced the platforms in the order of 10 to 1, in order to account for platform location 
order bias. The platform locations were dispersed throughout the pool to account for quad-
rant bias. Average trials to criterion and number of platforms experienced were compared 
between KO and WT mice.
Locomotor activity (LMA)
Loco-motor activity was measured in 10 identical test chambers. The chambers were square 
(l x b x h) and equipped with laser beams and photocells that were aligned to create a grid. The 
boxes were connected to a computer system that automatically tracked an animal’s move-
ment and calculated the total distance moved (Med Associates, St. Albans, VT).  Mice were 
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placed inside a test chamber (27.9 cm × 27.9 cm) equipped with 16 infrared beam arrays to 
monitor distance traveled, and were allowed to explore the chamber freely for 60 min. Before 
and after each session the boxes were cleaned with 85% ethanol solution. The dependent 
measure in this task was the total distance traveled (cm).  
Shock sensitivity
Tests for sensitivity to shock were conducted inside the fear conditioning chambers. A mouse 
was placed in a test chamber and was administered five foot shocks of increasing amplitude 
(0, 0.2, 0.4, 0.8 and 1.0 mA) with an ITI of 30s. An observer, blinded to genotype, scored 
shock sensitivity in the PDE4-D and B mice, based on three behavioural categories: flinch-
ing, running/jumping and vocalizing. For each mouse individual, scores from naïve KO and 
naïve WT animals were averaged and compared. The dependent measure in this task was the 
average amplitude to first detect flinching, running/jumping or vocalizing.
Statistical analysis
For all behavioral experiments, scores were averaged per genotype and compared in a be-
tween subjects design. A correlation analysis was performed to assess the effect of shock 
amplitude on freezing behavior in the shock response curve experiment for both automatic 
and manual scoring. Analysis of the shock dependent freezing experiment for the PDE4-D 
and B wild-types, a one-way ANOVA test was performed with shock intensity as factor and 
freezing behavior as dependent variable. A Bonferroni post hoc test was performed in case 
of statistical significant effects. Furthermore, differences between genotypes (wild-type vs. 
knock-out for both PDE4-B and –D) in LTM, STM, LMA and shock sensitivity were assessed 
by means of independent sample t-tests (p < 0.05 = significant result). Differences between 
genotypes in MWM were assessed by two-way repeated measures ANOVA (day and geno-
type) for acquisition and reversal and two-way ANOVA (zone and genotype) for probe trials. 
Differences between the genotypes in the learning capacity test were assessed by two-way 
repeated measures ANOVA (trials to criterion and genotype) and two-way ANOVA (average 
trials to criterion and genotype; number of platforms experienced and genotype). A Bonfer-
roni post hoc test was performed in case of statistically significant effects.  
Results
Figure 1 shows the effect of shock intensity (0, 0.4 or 1mA) on context and cue depen-
dent freezing for PDE4-D and PDE4-B wild-type mice. For the PDE4-D mice a difference 
in freezing behavior was observed between different shock amplitudes (F(2,41) = 42.47; 
P < 0.01) (Figure 1A). As expected, the sham group was significantly lower as compared 
to the 0.4 and 1 mA group (Bonferroni, P<0.01). Furthermore a shock dependent increase 
in freezing behavior in the context test was observed. Moreover, the cue test for all shock 
groups showed a significant increase between pre and post cue freezing (T0mA(13) = -3.75; 
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T0.4mA (13) = -5.50, T1mA (13) = 5.52; P < 0.01). An increase in freezing during the CS is in-
dicative of a learned association of the CS with the US. Furthermore, the PDE4-B wild-type 
animals showed similar results as the PDE4-D wild-type animals (Figure 1B). Differences be-
tween freezing levels were observed between shock amplitudes (F(2,41) = 12.86; P < 0.01). 
Freezing behavior in both 0.4 mA and 1 mA conditions was higher than the 0mA condition 
(Bonferroni, P < 0.01). The cue test for all shock groups showed a significant increase between 
pre and post cue freezing (T0mA(13) = -3.75; T0.4mA (13) = -8.48, T1mA (13) = -6.86; P < 0.01). 
A strong correlation in shock dependent freezing behavior exists between C57/Bl control 
animals and the PDE4-D (r = 0.72) and PDE4-B(r = 0.78) wild-types (data not shown).
Characterization of PDE4 KO mice
Previous work showed that wild-type littermates of the PDE4-D and B knock-out strains 
performed equal to C57/Bl6 mice in the fear conditioning paradigm (data not shown).
To characterize the effects of the isoform specific knock-out on learning and memory 
as assessed by fear conditioning, we chose a shock intensity (0.4 mA) that would enable mea-
suring effects on enhancement (i.e., freezing) and on impairment (i.e., decrease in freezing) 
of memory. The results for the long and short term memory fear conditioning for PDE4-D 
Figure 1: Shock amplitude dependent increases in freezing behavior for context test and cue test. A) Freezing behavior for PDE4-D wild-
type mice (n= 14/group). B) Freezing behavior for PDE4-B wild-type mice (n=14/group).
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mice are depicted in Figure 2A and 2B. No differences between genotypes were observed in 
the training session of the fear conditioning task (data not shown). For the PDE4-D mice 
differences were observed on basis of genotype in the context test, 24h after training with 
2 CS/US pairings of 0.4mA (t(28) = 3.58; P < 0.01). PDE4-D KO mice exhibited a significant 
deficit in LTM compared to WT animals. In addition, it was of interest to characterize how 
PDE4-D mice acquired the association between the CS-US as compared to wild-type mice 
by measuring freezing levels at 1 hr after training.  The right panel of Figure 3A shows, that 
PDE4-D KO and WT mice equally obtained the association between tone and shock (tWT(28)= 
-9.78; tKO(29) = -6.72; P < 0.01). There were no differences in freezing behavior between KO 
and WT in the (post)cue test (t(28) = -0.98; P = n.s.) Heterozygous animals showed simi-
lar results as the wild-type animals (data not shown). Figure 3B shows the comparison of 
genotypes in the short term memory task of fear conditioning. No differences were observed 
between PDE4-D KO and WT mice for contextual freezing (t(4) = 0.53; P = n.s) and neither 
for (post)cue freezing (l.t(4)=0.51; P = n.s.). Both groups did show a significant increase of 
cue associated freezing (tWT(10)= -8.24; tKO(4) = -9.35; P < 0.01).
No differences between knock-outs and wild-types were observed for the PDE4-B mice 
in LTM fear conditioning test (Figure 3). Training with 2CS/US pairings with 0.4 mA (t(13)= 
0.27; P = n.s.) did not reveal any differences in context test. The (post)cue test did not reveal 
any differences between genotypes (t(13)= 1.10; P = n.s). However, the difference between 
pre and post cue freezing indicates that both genotypes learned the association between CS 
and US (tWT(13) = -8.48; tKO(15)= -7.24; P < 0.01).
Figure 2: Freezing behavior of PDE4-D wild-types vs. knock-outs in context and cue test after training with 2 CS/US pairings (0.4 mA).  A) 
Long term memory fear conditioning (24h between training and testing) n=16/group, B) Short term memory fear conditioning (1h between 
context and testing) n=8/group.
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Comparison of PDE4-B wild-types and knock-outs in the short term memory fear 
conditioning task showed no differences in contextual freezing (t(7) = 0.04; P = n.s.) and 
neither for cue freezing (t(7) = 0.04; P = n.s.) Thus, the KO mice performed equal to the WT 
mice in the short term version of fear conditioning in both strains. The difference between 
pre and post cue freezing indicates that both genotypes learned the association between 
CS and US (tWT(7) = -8.37; tKO(7) = -585; P < 0.01). 
Locomotor activity for both PDE4-D and PDE4-B mice is shown in Figure 4. When 
comparing between genotypes (wild-type and knock-out) no significant differences in 
LMA were found on basis of genotype in neither the PDE4-D (t(13)= 1.8, P = n.s.) nor the 
PDE4-B (t(13) = -2.12, P = n.s.) animals. The general activity level of the PDE4-B mice was 
higher than the PDE4-D mice for both wild-types (t(13)=-3.41; P < 0.01) and knock-outs 
(t(13)= -6.60; P < 0.01). 
To determine that PDE4-D and PDE4-B knock-out mice showed equal sensitivity 
to the shock stimulus as compared to the wild-type littermates, naïve mice underwent 
delivery of brief (1s), ascending shocks from (0 mA to 1.0 mA). The average amplitude to 
first detect flinching, running/jumping or vocalizing behavior was calculated (Figure 5). 
The lower shock amplitudes generally elicited flinching behavior, whereas the higher shock 
amplitudes induced running and jumping behavior. Vocalizing occurred on average from 
0.3 mA and up for both groups. No differences between WT and KO animals were ob-
served in the different categories of shock sensitivity for either the PDE4-D or PDE4-B 
animals (see Table 1 for statistics) 
Figure 3: Freezing behavior of PDE4-B wild-types vs. knock-outs in context and cue test after training with 2 CS/US pairings (0.4 mA). 
A) Long term memory fear conditioning (24h between training and testing) n=16/group, B) Short term memory fear conditioning (1h 
between context and testing) n=8/group.
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Table 1: T-values and degrees of freedom belonging to the independent samples T-tests comparing WT 
to KO on each behavioral level of the shock sensitivity test, for PDE4D and PDE4B animals. No significant 
T-values were found.
PDE4-D PDE4-B
t-values df t-values df
Flinching -1.00 26 -0.85 14
Running/Jumping -0.74 24 0.08 14
Vocalizing 0.56 26 0.31 14
Figure 4: Loco-motor activity. Left: Total distance moved forPDE4-D wild-types vs.. knock-outs (n=16/group), and Right: distance moved 
forPDE4-B wild-types vs.. knock-outs (n=16/group).
Figure 5: Sensitivity to the foot shock for PDE4-D and PDE4-B animals. The bars indicate the average required shock amplitude to generate 
flinching, running/jumping, or vocalizing behavior. Wild-types were compared to knock-outs for both PDE4-D (left) and PDE4-B (right) 
animals. 
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No significant differences between knock-outs and wild-types were observed for either 
the PDE4-D or the PDE4-B mice (Figure 6) in the acquisition phase of spatial navigation. 
Post hoc Bonferroni tests revealed a significantly longer path length on day 1 (P < 0.001) 
compared to days 2 (t = 5.656), 3(t = 4.667), and 4 (t = 4.221) in the PDE4-B mice.  Post hoc 
tests also revealed a significantly longer path length on day 1 (P< 0.001) compared to days 3 
(t = 6.3646) and 4 (t = 5.807) in the PDE4-D mice. 
In the probe trials on day 3 and 5, there were no significant differences in percent 
distance in zone in the PDE4-D (Figure 7). PDE4-B mice on the day 3 probe trial showed 
a significantly higher percent distance traveled in the target (North) quadrant compared 
to all other quadrants. Post-hoc tests revealed that percent total distance spent in the 
North quadrant for PDE4-B knock-outs was significantly higher than the South (t=5.907, 
P<0.001), East (t=3.664, P<0.05), and West (t=3.664, P<0.01), and for PDE4-B wild-types 
was significantly higher than the South (t=6.161, P<0.001), East (t=4.595, P<0.001), and 
West (t=3.427, P<0.01). PDE4-B knock-out and wild-type mice did not differ within zone, 
between genotype in the day 3 probe trial. There were no significant differences observed 
for PDE4B mice on the day 5 probe trial. 
In reversal learning, PDE4-D mice did not show significant differences in learn-
ing across days or genotype (Figure 8). PDE4-B mice showed a significant decrease 
in path length across day in reversal learning (t = 4.288, P<0.001) and there were 
significant differences in path length between PDE4-B knock-out and wild-type mice 
on day 2 (t = 2.464, P<0.05). 
Figure 6: Acquisition of spatial navigation in Morris water maze for PDE4-D and PDE4-B animals. Wild-types were compared to knock-
outs for both PDE4-D (left) and PDE4-B (right) animals. 
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Figure 7: Probe trial of spatial navigation in Morris water maze for PDE4-D and PDE4-B animals. Wild-types were compared to knock-outs 
for both PDE4-D (top) and PDE4-B (bottom) animals.
Figure 8: Reversal trial of spatial navigation in Morris water maze for PDE4-D and PDE4-B animals. Wild-types were compared to knock-
outs for both PDE4-D (left) and PDE4-B (right) animals.
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In cued navigation, both PDE4-D (Figure 9) and PDE4-B showed decreasing path lengths 
to reach the platform across trials and no differences were observed between knock-out and wild-
type mice.
No significant differences between knock-outs and wild-types were observed for either PDE4-
D or PDE4-B mice in the learning capacity test.  Between PDE4-D and PDE4-B mice, there were no 
significant differences in trials to criterion (Figure 10) or number of platforms experienced. 
Figure 9: Cued navigation in Morris water maze for PDE4-D and PDE4-B animals. Wild-types were compared to knock-outs for both PDE4-
D (left) and PDE4-B (right) animals.
Figure 10: Learning capacity test in Morris water maze for PDE4-D and PDE4-B animals. Wild-types were compared to knockouts in aver-
age trials to criterion (left) and total number of platforms experienced (right) in PDE4-D (top) and PDE4-B (bottom) animals.
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Discussion
In the present study we characterized the effects on cognition of two specific PDE4 isoforms 
(PDE4-D and PDE4-B). PDE4 knockout mice were behaviorally tested in the context and cue 
test of a fear conditioning task and in a water maze task. In the fear conditioning paradigm 
found a shock dependant increase of freezing behavior in the context and cue test. Wild-type 
animals of both PDE4-B and PDE4-D strains learned to make an association between the 
delivered foot shock and the testing environment (context learning). In addition, the animals 
associated the tone to the aversive foot shock in the altered context condition (cue learn-
ing). These two (context and cue) forms of associative learning have shown to have different 
underlying neuronal mechanisms (LeDoux 2000). Lesions of the amygdala interfered with 
the conditioning of fear responses to both the cue and the context, whereas lesions of the 
hippocampus interfered with conditioning to the context but not to the cue. These findings 
suggest an associative role for the amygdala and a sensory relay role for the hippocampus in 
fear conditioning (Phillips and LeDoux 1992). 
In the Morris water maze, a hippocampus-dependent task, both strains were able to learn the 
platform location. PDE4-D and PDE4-B mice showed a decrease in path length over acquisi-
tion trials indicating successful spatial navigation. There were no differences in path length 
in acquisition between knock-outs and wild-types in either PDE4-D or PDE4-B mice. In the 
probe trial on day 3, a short-term spatial memory test, both knock-out and wild-type PDE4-B 
mice showed a preference for the target quadrant over all other quadrants, whereas the PDE4-
D mice showed equal preference for all quadrants. In reversal learning trials, PDE4-D mice did 
not show an improvement in spatial navigation over time. While the PDE4-B mice showed 
an overall improvement in navigation in reversal learning, this effect was largely driven by a 
significant decrease in path length for the wild-type mice. Within the second day of reversal 
learning, PDE4-B knock-out mice had significantly longer path lengths compared to wild-type 
mice. In the learning capacity test, both PDE4-D and PDE4-B mice demonstrated a similar 
number of trials to reach criterion and experienced the same average number of platforms.
The localization of PDE4-D and PDE4-B mRNA has been extensively described for many 
species including human, monkey and rat, however, to our knowledge, PDE4 isoform local-
ization in the brain of mice has not been described yet (Perez-Torres et al. 2000). According 
to Perrez-Torres et al. (2000), PDE4-D mRNA is more abundant than PDE4-B mRNA in CA1, 
CA2 and CA3 areas of the hippocampus and in the granule cell layer of the dendate gyrus 
in rats. In addition, more mRNA activation was observed in the entorhinal and perirhinal 
cortex for PDE4-D than for PDE4-B. In contrast, PDE4-B mRNA was observed more in the 
caudate nucleus, putamen and nucleus accumbens. In the amygdaloid complex, PDE4-D 
mRNA was observed more in the bed nucleus of the accessory tract and the anterior cortical 
amygdaloid nucleus whereas PDE4-B mRNA was observed more in the basolateral amygda-
loid nucleus (Perez-Torres et al. 2000).
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Neurons of the lateral amygdala show synaptic LTP and this may be the site for long term 
memory in cue fear conditioning. Increases in spike firing in the LA after fear condition-
ing are CS dependent, since unpaired US-CS (i.e. only the tone) showed extinction of fear 
responses (Maren and Quirk 2004). The PDE4-B isoform is more pronounced in the lateral 
amygdala areas than the PDE4-D isoform (as described above). However, no effects were ob-
served after isoform knock-out on the cue-test in either of the strains. Since the hippocam-
pus is believed to encode and process contextual cues in the fear conditioning task (Phillips 
and LeDoux 1992), this may indicate that the observed impairment might be originated in 
hippocampal areas, whereas the amygdala remains unaffected. 
Moreover when tested in a short term memory version of the FC task with a 1 h delay be-
tween training and testing, no differences between genotypes were observed neither in the 
context version nor the cue version of the task. Thus, PDE4-D KO mice were impaired on long 
term memory but not on short term memory in context fear conditioning. Furthermore, for 
both context and cue test, PDE4-B animals learned the associations to the foot shock and no 
differences between genotypes were observed on long-term or short-term fear conditioning. 
The short-term memory task shows that the animals did acquire the task and that there were 
no baseline differences between the genotypes in the ability to learn the task. 
A possibility was that the observed differences between genotypes in the PDE4-D mice were 
caused by differences in baseline activity levels or differences in shock perception. However, 
a loco-motor analysis showed that there were no differences between knock-out and wild-
type mice in general activity measures. Moreover, no differences were observed between the 
genotypes in the reaction to the foot shocks. Thus, differences between WT mice and KO 
mice could not be explained by differences in loco-motor activity or shock perception. 
When comparing the PDE4-D and PDE4-B animals on long term fear conditioning, it was 
observed that the PDE4-B wild-type animals had lower freezing scores than the PDE4-D 
wild-type mice. In the PDE4-B mice we did not see impairment after training with a 0.4 mA 
shock. Also, in the LMA experiment it was observed that PDE4-D animals were less active 
then PDE4-B animals, this might explain the higher baseline freezing levels between the 
wild-types of both strains. The reduced activity of PDE4-D mice as compared to PDE4-B’s 
might be explained by developmental differences. For example, PDE4-D knockout mice have 
lower birth weights than wild-type littermates. From the above described results it might be 
concluded that PDE4-B and -D isoforms are differently involved in memory for FC. While 
PDE4-D knock-out mice show impairment in long term memory in the fear conditioning 
task the PDE4-B KO seem unaffected by the missing gene. The PDE4-D enzyme seems to 
influence processes in the long term acquisition of context memory in the FC paradigm.
 Earlier pharmacological studies with PDE4 inhibitors showed memory improvement in sev-
eral behavioral tasks in rats and mice (Gong et al. 2004; Imanishi et al. 1997; Rutten et al. 
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2006a; Zhang et al. 2005). Inhibition of PDE4 causes elevation of cAMP and this is believed 
to improve LTP and long term memory via the cAMP/PKA/CREB pathway. Therefore we 
expected PDE4 KO to perform better than WT animals. However, this was not the case, 
PDE4-D knock-out mice even showed memory impairment in the fear conditioning task. 
Unpublished results have demonstrated LTP in PDE4-D knock-out mice and LTD in PDE4-
B knock-out mice. How to explain the observed impairment for the PDE4-D KOs remains 
speculative. A possible explanation could be that developmental changes occur in these mice 
that cause the deficit. These knock-out mice show lower birth weights as compared with 
wild-type littermates. Another explanation could be that adaptive changes to the missing 
enzyme have occurred in the brain and as a result baseline enzyme and neurotransmitter 
levels are altered. Furthermore, knock-out of the PDE4-D gene may cause an up-regulation 
of other PDEs that result in impaired fear conditioning performance. Due to these devel-
opmental differences of PDE4-D knockout mice no clear conclusions can be drawn at this 
point. Ongoing studies with specific local gene-silencing techniques rule out these develop-
mental deficits and will provide more isoform specific information on the influence of PDE4 
in depression and cognition.  
Since no effects were observed in PDE4-B knock-out animals a specific role for the PDE4-D 
gene in cognition might be expected. A previous experiment with these PDE4-D knock-out 
mice showed an antidepressant-like effect for these animals (Zhang et al. 2002), however 
cognition was not assessed in this study. The present study for the first time investigated 
the effects of PDE4-D and PDE4–B knockout on hippocampus and amygdala dependant 
cognitive behavior. 
Finally, inhibition of PDE4, for example by the PDE4 inhibitor rolipram, has shown to have 
pro-cognitive and antidepressive effects in several behavioral models (Blokland et al. 2006, 
in press; Mizokawa et al. 1988; Overstreet et al. 1989; Rose et al. 2005). However, severe 
side effects, such as emesis, have always been a dose limiting factor for clinical use of rolip-
ram as an antidepressant or cognitive enhancer (Dyke and Montana 2002; Hebenstreit et al. 
1989; Norman et al. 1992a; Overstreet et al. 1989). The PDE4-D isoform has been described 
to be involved in emesis, one of the dose-limiting factors in treatment with PDE4 inhibitors 
(Robichaud et al. 2002). However, mice deficient in other PDE4 isoforms have not been 
tested. Thus, targeting specific PDE4 isoforms could reduce the limiting side effects of the 
presently available PDE4 inhibitors and dissociate between side effects and procognitive or 
antidepressant effects. To further elucidate the role of the different subtypes of PDE4 genes 
in cognition and to further comprehend the present results and apply them to pro-cognitive 
drug development more specific PDE4 isoform studies are required.
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7 Selective PDE inhibitors sildenafil and rolipram improve object retrieval 
performance in unimpaired 
adult Cynomolgus macaques
K. Rutten,  J. L. Basile, J. Prickaerts,  
A. Blokland, J. A. Vivian
Psychopharmacology (submitted)
Rationale: Selective phosphodiesterase (PDE) inhibitors have been 
shown to improve long-term memory in several rodent models of cogni-
tion. However, studies evaluating the effects of PDE inhibition on cogni-
tion in unimpaired primates are very scarce. OBJECTIVES: The present 
study investigates the effect of the PDE4 inhibitor rolipram and the PDE5 
inhibitor sildenafil on object retrieval (OR) performance. OR is a prefrontal 
cortical mediated task, which is likely to capture attention and response 
inhibition. Materials and methods: Adult male cynomolgus macaques 
were trained in the OR task. The effects of rolipram (0, 0.003, 0.01 and 
0.03 mg/kg, i.m.) and sildenafil (0, 0.3, 1 and 3 mg/kg, i.m.) treatment 
on the percentage correct first reaches, which is 50% correct in difficult tri-
als, were investigated. Results: Rolipram dose-dependently increased cor-
rect first reaches during difficult trials, reaching significance at 0.01 mg/kg 
and maximal performance of 71% correct at the dose of 0.03 mg/kg. Silde-
nafil dose-dependently increased correct first reaches during difficult tri-
als, reaching significance at 1 mg/kg. At the highest dose tested (3 mg/kg), 
correct reaches were increased to 73%. Conclusions: Both rolipram and 
sildenafil significantly improved performance in the OR task. These find-
ings complement and extend to the cognition-enhancing effects of cAMP 
and cGMP via PDE inhibition. However, the underlying mechanism of ac-
tion and cellular pathways remain elusive.
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Introduction
Second messenger cyclic nucleotides, i.e cyclic adenosine monophosphate (cAMP) and cyclic 
guanosine monophosphate (cGMP), have been strongly implicated in processes of synaptic 
long term potentiation (LTP) (Frey et al. 1993; Zhuo et al. 1994) and have cognition enhanc-
ing  properties (Bernabeu et al. 1996; Blokland et al. 2006b; Prickaerts et al. 2005). cAMP 
and cGMP are hydrolyzed by phosphodiesterase (PDE) enzymes. Cognition enhancing ef-
fects of cAMP and cGMP are widely studied by administration of PDE inhibitors (PDE-Is) in 
animal models of cognition. In this field, research has focused on PDE4 and PDE5 inhibitors 
(Blokland et al. 2006b; Rose et al. 2005; Rutten et al. 2006a), and more recently PDE2 (Boess 
et al. 2004; Rutten et al. 2007b) and PDE10 (Rodefer et al. 2005) inhibitors. Rodent studies 
have shown that inhibition of PDE2, 4 and 5 can improve memory in the object recognition 
task (Boess et al. 2004; Prickaerts et al. 2004; Rutten et al. 2007b). Moreover, the cAMP-
selective PDE4-I rolipram is an effective performance enhancer in the passive avoidance task 
(Egawa et al. 1997; Imanishi et al. 1997), fear conditioning test (Barad et al. 1998) and radial 
arm maze (Zhang and O’Donnell 2000). 
The cyclic-GMP (cGMP) selective PDE5-I sildenafil has been shown to not only effective-
ly enhance performance in the object recognition task, but also in the T-Maze and spatial plus 
maze (Devan et al. 2006; Devan et al. 2004; Patil et al. 2006; Prickaerts et al. 2004). In addition, 
sildenafil improved object recognition memory in mice (Rutten et al. 2005) and another PDE5-
I, zaprinast, improved performance in a passive avoidance task in neonate chicks (Campbell 
and Edwards 2006). Human experiments with PDE5-Is in memory tasks are being performed 
and also preclinical trials with PDE4-Is are ongoing. PDE-Is can be seen as a an effective target 
for cognitive enhancement in several neuropathological diseases, such as Alzheimer’s disease, 
Parkinson’s disease, and amnesia (Blokland et al. 2006b; Weishaar et al. 1985a).
The current literature of PDE inhibition in cognition has mainly focused on learning 
and memory functioning in rodents. However, the effects of PDE-I on prefrontal, executive 
functions have not been evaluated previously. The present study shifts attention from ro-
dents to non-human primates and focuses on possible cognition-enhancing effects of PDE 
inhibition in a task of prefrontal behavior, namely the object retrieval task. Object retrieval 
in primates (OR; also known in the literature as the object detour task) is a prefrontal corti-
cal mediated behavior, which is likely to capture attention, response inhibition and planning 
(executive function) (Diamond et al. 1989). Successful completion of the OR task requires 
various hypothetical steps, including: resolution of contradictory signals conveyed by vi-
sual and tactile inputs, suppression of the incorrect signal, representation of the incorrect 
approach stored in a short term memory system that may be retrieved, and expression in 
the ‘detour’ test of an innate species-characteristic tendency of perseveration toward a sus-
tained sensory stimulation. (Lipina and Colombo 2001). Deficits in motor planning and 
in the ability to inhibit certain behavioral responses have been demonstrated in humans 
with Parkinson’s disease, in patients with frontal lobe lesions and in children with attention 
deficit hyperactivity disorder (ADHD) (Schneider and Roeltgen 1993). Furthermore, deficits 
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in OR tasks have been documented in primates after treatment with MPTP (Schneider and 
Roeltgen 1993; Taylor et al. 1990a; Taylor et al. 1990b), phencyclidine (PCP) (Jentsch et al. 
2000; Jentsch et al. 1999a; Jentsch et al. 1999b), and after excitotoxic lesioning with quino-
linic acid of the prefrontal cortex (Roitberg et al. 2002). The effect of PDE-Is in the OR have, 
to our knowledge, never been evaluated before in unimpaired primates. Of note, Ramos et 
al. (2003) found improved spatial working memory performance of the prefrontal cortex af-
ter treatment with rolipram in young Rhesus monkeys and performance impairment in aged 
Rhesus monkeys in a spatial delayed response task. 
Based on previous studies with PDE-Is in rodents, the objective of the current study 
was to characterize the potential cognition-enhancing effects of PDE-Is in a frontally-medi-
ated behavior capturing executive function. We hypothesized that not only memory but also 
executive functions and response inhibition might be improved by inhibition of PDEs. The 
PDE4 enzyme is omnipresent throughout the brain and PDE5 is found in the hippocampus, 
throughout the cortex and in the cerebellum (See van Staveren et al. 2004). Thus, eleva-
tion of cAMP and cGMP in the prefrontal cortex, through PDE4-Is or PDE5-Is respectively, 
could therefore be a possible way to improve cognitive performance in a prefrontal task. The 
present study investigated the pro-cognitive effects of two selective PDE-Is in non-human 
primates. The effects of sildenafil (PDE5-I) and rolipram (PDE4-I) were assessed in the OR 
task in unimpaired adult cynomolgus macaques.
Methods
Subjects
A total of 14 adult male cynomolgus macaques (Macaca fascicularis) were housed in same-
sex pairs in a colony room maintained at 21 ± 2° C, 40 ± 10% humidity, and on a normal 12 h 
light/dark cycle (lights on 7.00 am). Food (Purina High Protein #5045) and water were avail-
able ad lib. All experimental procedures were approved by the Institutional Animal Care and 
Use Committee (IACUC) of Roche Palo Alto and were in accordance with NIH guidelines.
Object retrieval task
The object retrieval task has been previously described by Diamond et al. (1989), and revised 
by Basile & Vivian (publication in prep). Briefly, this task requires a monkey to reach into 
a clear acrylic box (dimensions: 5 cm × 5 cm × 5 cm) with one open side, to retrieve a food 
treat (cubes of apple or pear (1–2 cm2)). The box was positioned in front of the monkey and 
outside of the home cage, with the open side facing left, right, or centered (i.e., in front of) 
relative to the monkey. Food treats were placed on the outer edge, inner edge, or deep within 
the box. A test session consisted of 17 trials with 9 “easy” food retrievals (i.e., placement of 
the food reward on the inner or outer edges of the box, or when the opening is centered rela-
tive to the monkey) and 8 “difficult” food retrievals (i.e., placement of the food reward deep 
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within the box and the open side facing left or right, see Figure 1). The order of presentation 
never varied (Table 1), and trials were terminated if there were no reaches within 3-min. 
Note that there were no contingencies for incorrect reaches (i.e., monkeys typically acquired 
the treat after the incorrect reach) or dropped treats, and the box was cleaned diligently 
between trials to minimize barrier cues which could influence the task and subsequent task 
performance. After an initial period (1 week) to acclimate the monkeys to the apparatus, and 
familiarize them with the procedures, tests were conducted twice a week. 
Table 1: Primate Object Retrieval: Trial Order
Trial # Description Level
1 LOS – Line of Sight Easy
2 LOS – Line of Sight Easy
3 RO – Right Outside Easy
4 RD – Right Deep Difficult
5 RO – Right Outside Easy
6 RI – Right Inside Easy
7 RD – Right Deep Difficult
8 LO – Left Outside Easy
9 LD – Left Deep Difficult
10 LO – Left Outside Easy
11 LI – Left Inside Easy
12 LD – Left Deep Difficult
13 LD – Left Deep Difficult
14 RD – Right Deep Difficult
15 LD – Left Deep Difficult
16 RD – Right Deep Difficult
17 LOS – Line of Sight Easy
Drugs
easy difficult
Line of sight Figure 1: A schematic overview of possible trials in the object retrieval (detour reaching) task. 
The left panel shows easy trials and the right panel shows difficult trials.
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Sildenafil (0.3, 1 and 3 mg/kg; Sequoia Research Products Limited, Pangbourne, UK) and rolip-
ram (0.003, 0.01, 0.03 and 0.1 mg/kg; Sigma Chemicals, St Louis, MO) were prepared fresh daily 
in a suspension of 10% cremaphore/90% saline, and administered 60 or 30 min prior to testing, 
respectively. All drugs were administered intramuscular (i.m.) in a volume of 0.1 ml/kg.
Data Analysis
The mean percent correct first reaches for easy and difficult food retrievals were analyzed 
with a one-factor (DOSE) repeated measures analysis of variance (ANOVA). When signifi-
cant effects were demonstrated, a post-hoc Dunnett analysis was performed, comparing dose 
conditions to vehicle performance. For all tests, the significance level was 0.05, two-tailed. 
Results
In object retrieval test sessions involving vehicle administration, monkeys readily reached 
for the food treats, successfully acquiring the treat on the first reach 100 ± 0% during easy 
trials, and 52 ± 3% during difficult trials. Over the course of the experiment (2 months), 
there were no changes in vehicle performance.
The PDE-4 inhibitor rolipram (0.003-0.1 mg/kg, i.m.) dose-dependently increased 
correct first reaches during difficult trials [F(3,55) = 13.5, p < 0.05], reaching significance 
at 0.01 mg/kg, i.e. different from vehicle (Figure 2a). At 0.03 mg/kg, the percentage correct 
first reaches were increased to 71 ± 3 %. Note that at 0.1 mg/kg (data not shown), emesis 
was observed in all but two monkeys, these results were therefore excluded from analysis. 
The PDE-5 inhibitor sildenafil (0.3–3 mg/kg, i.m.) dose-dependently increased correct 
first reaches during difficult trials [F(3,50) = 8.6, p < 0.05], reaching significance at 1 mg/kg. 
At the highest dose tested (3 mg/kg), correct reaches were increased to 73 ± 3%, and no un-
toward signs were observed (Figure 2b).
Figure 2: The effects of PDE-I on Object Retrieval (OR) performance (mean values and SEM).a) The effects of the PDE5 inhibitor sildenafil 
(a) and the PDE4 inhibitor rolipram (b) on the percentage correct first reaches on difficult trials in the OR task. Asterisks indicate significant 
differences from baseline (P<0.05)
The Effects of Phosphodiesterase Inhibition on Memory 
108
Neither rolipram nor sildenafil altered performance during the easy trials, with the 
exception of the high dose of rolipram (0.1 mg/kg), in which monkeys failed to perform the 
task (data not shown) because of emetic side-effects.
Discussion
The present study demonstrates performance-enhancing effects of two selective PDE-
Is on object retrieval in unimpaired monkeys. The object retrieval task is generally used 
as a measure for prefrontal functioning after induced damage to the frontal cortex or fronto-
striatal pathways. The prefrontal cortex and its dopaminergic and cholinergic innervation 
pathways are involved in attention processes, working memory processes, and response in-
hibition in rodents and primates. Thus, the current results complement and extend cogni-
tion-enhancing effects of PDE inhibition.  
Previous studies have repeatedly shown that PDE-Is can have pro-cognitive effects 
in healthy unimpaired rodents. PDE4 inhibition improved long term memory in the object 
recognition task (Rutten et al. 2006a), in passive avoidance learning (Zhang et al. 2005), 
and fear conditioning (Barad et al. 1998). Furthermore, PDE4-Is have shown to be effective 
in numerous deficit models (for a review see Blokland et al. 2006b). Compared to PDE4 in-
hibition, the cognition enhancing effects of PDE5 inhibition have not been studied as exten-
sively. However, a growing amount of studies have shown pro-cognitive effects of PDE5-Is 
in different species and various behavioral tasks. PDE5-Is improved cognitive performance 
in inhibitory and passive avoidance task (Baratti and Boccia 1999; Shafiei et al. 2006), ele-
vated plus maze (Singh and Parle 2003), and object recognition (Prickaerts et al. 2005; Prick-
aerts et al. 2004; Prickaerts et al. 2002b; Rutten et al. 2005). In addition, a couple of studies 
have shown ameliorating effects of PDE5-Is in deficit models (Devan et al. 2006; Devan et al. 
2004; Patil et al. 2006). The underlying mechanisms of PDE-Is and cognition enhancement 
are still elusive, but several possible pathways have been described (see below).
A possible mechanism of action for rolipram in cognition enhancement is the cAMP-Protein 
kinase A (PKA) pathway. This pathway was shown to enhance performance in hippocampal 
short-term memory tasks (Ahi et al. 2004; Bernabeu et al. 1997; Frey et al. 1993; Friedrich et 
al. 2004). A recent study showed that activation of the cAMP-PKA signaling pathway, through 
rolipram, improves spatial working memory in the prefrontal cortex in young rats (delayed 
alternation in a T-maze) and monkeys (special delayed response task) (Ramos et al. 2003).
In addition, the effects of rolipram on prefrontal functioning in the OR may be ex-
plained by its stimulatory effect on neurotransmission. Since rolipram is independent 
of a specific receptor system it is suggested that rolipram may ameliorate physiological ab-
normalities that occur secondary to alterations in dopaminergic, glutamatergic, serotonergic 
and/or adrenergic transmission (Maxwell et al. 2004; Rutten et al. 2007a). Both enhanced 
cholinergic turnover pre-synaptically and inhibition of cAMP degradation post-synaptical-
ly, could enhance cholinergic signaling and increase attention and behavioral performance 
(Imanishi et al. 1997). In addition, elevated cAMP levels are thought to excite noradrener-
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gic and dopaminergic neurotransmitter systems (Schoffelmeer et al. 1985), thus enhancing 
their availability, hence also enhancing synaptic transmission. 
What is known about the possible mechanism underlying our observed pro-cognitive ef-
fects of sildenafil related to prefrontal cortex function? Current concepts on the working 
mechanism of cGMP and nitric oxide (NO) in strengthening synaptic contacts define a pre-
synaptic effect of NO, in conjunction with the retrograde messenger role of NO (Garthwaite 
and Boulton 1995).  NO activates soluble Guanylate Cyclase (sGC) pre-synaptically, which 
in turn catalyzes cGMP production and enhances neurotransmission (Bernabeu et al. 1996; 
Prickaerts et al. 1997; Son et al. 1998). The enhanced neurotransmission might be caused 
by cGMP-mediated Protein Kinase G (PKG) activation (Zhuo et al. 1994) or by stimulation 
of cGMP-gated ion channels (Zufall 1996). In addition, cGMP- PKG activation has also been 
suggested for long term memory enhancement in hippocampus dependent tasks via CREB 
activation (Lu and Hawkins 2002). Thus, PDE5-I can have an effect, via elevated cGMP levels, 
on memory processes either pre-synaptically (through the sGC/cGMP pathway) or post-syn-
aptically (through the cGMP/PKG/CREB pathway). A very recent study by Matsumoto et al. 
(2006) suggested another pathway through which cGMP can influence cognitive processes. 
This study showed that the NO/cGMP pathway directly stimulates the cAMP/PKA/CREB 
pathway, which is known to be involved in long-term memory as well  (Matsumoto et al. 
2006). Thus, both cGMP and cAMP can activate the PKA/CREB cascade and induce long last-
ing changes in neuronal signaling and may thereby improve learning and memory.
Similar to rolipram, sildenafil is a drug that is not linked to specific neurotransmitter 
systems. Modulatory activity of sildenafil was suggested on central dopaminergic pathways 
and, possibly, on nitric oxide production (Ferrari et al. 2002). Hence, activation of cGMP 
may improve dopaminergic turnover and prefrontal functioning. Thus far, it remains unclear 
which of these above mentioned mechanisms are involved in the prefrontal cortex and how 
they explain cognition enhancement by inhibition of PDEs in the object retrieval task. 
Of note, in aged monkeys and rats, rolipram decreased working memory performance 
of the prefrontal cortex (Arnsten et al. 2005; Ramos et al. 2003). The behavioral tasks 
used, i.e. delayed alternation in a T-maze for rats and delayed response task in Rhesus 
monkeys, rely heavily on working memory processes. The object retrieval task, used in the 
present study, does not involve working memory but requires attention and response inhi-
bition (Diamond et al. 1989). Furthermore, the animals tested in the former studies were 
age impaired animals as compared to the adult unimpaired monkeys used in the present 
study. Our findings corroborate the findings by Ramos et al (2003) that rolipram tended 
to improve spatial working memory in the frontal cortex at a similar dose of rolipram 
(10 µg/kg) in young adult monkeys. However in aged monkeys rolipram impaired working 
memory performance and opposite profiles between the hippocampus and the prefrontal 
cortex were suggested with advancing age to explain these results: the prefrontal cortex 
showed indices of increase PKA activity, while the hippocampus exhibited evidence of de-
creased PKA activity (Ramos et al. 2003). 
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Dopaminergic dysfunction in prefrontal cortex may subserve at least a component of 
the impaired object retrieval/detour performance in deficit models (Jentsch et al. 1999a). 
Moreover, serotonin depletions of the orbitofrontal cortex in the common marmoset result 
in deficits in the acquisition of the OR task (Walker et al. 2006). On one hand, the increase 
in neurotransmitter signaling by both elevation of cAMP and cGMP might be the underly-
ing mechanism of the effects of PDE-I on OR performance. On the other hand, the cellular 
pathway theories of cAMP/PKA, sGC/cGMP or cGMP/PKG are considered very important 
mechanisms for learning and memory processes in the hippocampus and these could also be 
effective in prefrontal cortical areas.  
Summarizing, the present study shifts the focus of PDE4 and 5 inhibition from a ro-
dent hippocampal task to a primate prefrontal task and it showed that, in unimpaired adult 
monkeys, rolipram and sildenafil have pro-cognitive effects. Underlying mechanisms of ac-
tion for these drugs remain to be further elucidated.
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General discussion and conclusion
Although the underlying mechanisms of learning and memory are not yet explained or fully 
understood, experimental results from morphology, electrophysiology, biochemistry, and 
behavioral experiments point towards critical roles for cAMP and cGMP in this process. 
These second messengers play an important role in intracellular signaling (Bailey et al. 1996; 
Son et al. 1998) and in processes of neuroplasticity such as long term potentiation (LTP). 
Hippocampal LTP has been proposed to be a neurophysiological correlate of memory (Bliss 
and Collingridge 1993). The studies presented in this thesis investigated the effects of dif-
ferent PDE inhibitors on memory performance in several test models (object recognition, 
fear conditioning and object retrieval) and species (mice, rats and cynomolgus macaques). 
The results from these studies support the importance of the role of the second messengers 
cAMP and cGMP in learning and memory processes. 
As described previously, two important studies showed specific and time dependent roles 
of cAMP and cGMP in memory (Bernabeu et al. 1996; Prickaerts et al. 2002a). Intra-hip-
pocampal injections of a cAMP analogue (8Br-cAMP) enhanced memory performance only 
when injected 3 h after learning, whereas injections of a cGMP analogue (8Br-cGMP) was 
only effective when administered directly after the learning trial. These findings advocate 
specific roles for cGMP and cAMP in memory processes and imply differential cellular 
underlying pathways. 
A large part of this thesis investigated the effects of specific PDE-Is on long-term mem-
ory performance and the time dependent differences between cAMP- and cGMP selective 
PDEs in the object recognition task (ORT) (chapters 2–4). Furthermore, the effects of PDEs 
on short-term memory were investigated in deficit models (chapters 3 and 5). Next, the 
effects of specific isoform knock-out of the PDE4 enzyme (i.e. PDE4B or PDE4D) on fear 
conditioning memory were investigated in a knock-out mouse model (Chapter 6). Finally, 
the effects of PDE4 and PDE5 inhibition were investigated in a non-human primate model 
of cognition, the object retrieval task (chapter 7). 
Effects of PDE inhibition on unimpaired long-term memory
PDE5 Inhibition
Previous studies showed memory enhancing effects of PDE5-I on long-term memory in 
rats directly after the learning trial in the ORT (Prickaerts et al. 2004). We investigated 
the effects of sildenafil directly after the first trial in the C57/Bl6 mouse. The effects of 
PDE5-I were never before investigated in the mouse object recognition paradigm. Sildenafil 
(1 mg/kg) improved ORT performance in these mice and also enhanced cGMP immunore-
activity (cGMP-IR) in varicosities of the CA3 region of the hippocampus (See Chapter 2 or 
Rutten et al. 2005). Evidence has been presented that behavioral improvement of memory 
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performance after sildenafil treatment might in part be mediated by an effect on E-LTP 
(Ingram et al. 1996). The pre-synaptic action of NO/sGC/cGMP is assumed to be part of the 
mechanism of E-LTP. Since our behavioral results were observed 24 h after learning, they 
outlast the period of E-LTP (i.e. maximally 3 h), but it is possible that E-LTP is converted 
into L-LTP, as has been observed recently (Pang et al. 2004). Of note, the latter has been 
associated with a post-synaptic localization. Considering the absence of colocalization of 
cGMP-immunoreactivity with synaptophysin in our immunucytochemical study, it could be 
concluded that sildenafil also acts post-synaptically. Nevertheless, it might also be the case 
that the used detection methods are not sensitive enough to pick up a pre-synaptic signal. 
Recently, it was demonstrated that NO and cGMP act both pre- and post-synaptically during 
induction of a form of E-LTP (Wang et al. 2005). In addition, Lu and Hawkins (2002) showed 
that post-synaptically localized cGMP contributes to L-LTP. To resolve this issue, studies are 
needed in which the PDE5 enzyme is localized at a sub-cellular level using a selective PDE5 
antibody. At present a selective PDE5 antibody has been generated in our laboratory and we 
are awaiting the first immunohistochemical results.
To further investigate the role of the treatment time of different PDEs on object memory, we 
administered the PDE5-I vardenafil directly after, 1 h, 3 h or 6 h after learning in rats (See 
chapter 4 or Rutten et al. 2006b). We observed that only when administered directly after 
learning the PDE5-I was effective in ORT performance corroborating the previous finding of 
a role of PDE5-I in early consolidation processes (Prickaerts et al. 2004). Since in the same 
study the PDE4-I rolipram was not active directly after learning, but only 3 h after learning 
we suggest different working mechanisms for cAMP or cGMP dependent PDE-Is. This will 
be discussed in more detail below. 
PDE4 inhibition
Based on the finding that intra-hippocampal injections of cAMP only enhanced memory 
when injected 3 h after training we assumed that rolipram would only affect late consolida-
tion processes. In a first study we tested the effects of rolipram in the ORT when administered 
before learning (i.e. acquisition), immediately after learning (early consolidation) and 3 h af-
ter learning (late consolidation). As expected we found that rolipram was effective only when 
injected 3 h after the learning trial (see Chapter 3 and Rutten et al. 2006a). Thus, rolipram had 
no effect on acquisition or early consolidation, but enhanced late consolidation processes. 
This finding was repeated in a second study that further examined the time-dependent 
effects of PDE-Is on object recognition memory. Rolipram was administered directly, 1 h, 
3 h or 6 h after the learning trial and was only effective 3 h after learning (see Chapter 4 and 
Rutten et al. 2006b). These findings again suggest a role for rolipram in late consolidation 
processes. The underlying mechanisms of PDE4-I and memory enhancement are not yet 
fully understood. However, evidence suggests that elevation of cAMP activates the cAMP/
PKA/CREB pathway that is involved in the process of L-LTP. This process leads to gene tran-
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scription and physical long lasting changes at the level of the synapse. The activity of ro-
lipram reported across a range of different models and experimental conditions in rodents 
is remarkable and suggests that PDE4-Is possess robust cognitive-enhancing properties. 
PDE2 inhibition
The PDE2 enzyme hydrolyses both cAMP and cGMP. To our knowledge, BAY 60-7550 is the 
only selective PDE2-I that has been tested in learning and memory models (Boess et al. 2004; 
Rutten et al. 2006b). In this thesis, the effects of BAY 60-7550 (3 mg/kg, p.o.) on object recog-
nition memory were investigated and the effect of time of treatment was studied (Chapter 3 
and Rutten et al. 2006b). We found an effect of BAY 60-7550 on object memory when it was 
given directly after training. This might be related to elevated cGMP levels, as the effect was 
observed at a drug administration time point where vardenafil affected recognition memory 
in the same study. In addition, improved object memory was observed when the PDE2-I was 
injected 3h after training. Similar to the results of the rolipram study, these effects might be 
mediated by the elevation of cAMP levels and the process of late consolidation. 
The results from the experiment with this PDE2-I support the notion of a specific and 
time-critical role of cGMP and cAMP in memory consolidation and are consistent with the 
results obtained after treatment with rolipram or vardenafil. Based on this study and previ-
ous studies with PDE4 and PDE5 inhibitors we suggest a role for cGMP in early consolida-
tion processes and cAMP for late consolidation processes of memory. 
Effects of PDE inhibition in deficit models of short-term memory 
In the literature, short-term memory effects of PDE4-Is are predominantly measured in 
pharmacological deficit models (see Table 3 of introduction). To also evaluate the effects of 
rolipram in memory deficit models two more experiments were performed, which were de-
scribed in the present thesis. The first study showed ameliorating effects of rolipram (0.1 mg/
kg) in the scopolamine deficit model when both were administered 30 min before learning 
(see Chapter 3 and Rutten et al. 2006a). This is in concordance with the literature that has 
repeatedly shown that rolipram reverses the deficit caused by scopolamine. The second study 
tested the effects on memory performance of rolipram in combination with an acute dose of 
a tryptophan free mixture. Acute tryptophan depletion (ATD) has shown to impair memory 
performance in both humans and rodents (Lieben et al. 2005a; Lieben et al. 2004c; Park 
et al. 1994; Riedel et al. 1999; Sambeth et al. in press; Schmitt et al. 2000). We found that 
rolipram reversed the memory deficit caused by ATD. In this experiment the tryptophan 
depleted mixture was administered 3 h before learning and rolipram 30 min before learn-
ing (See Chapter 5 and Rutten et al. in press). The effective dose of rolipram was similar 
(0.1 mg/kg) as in the scopolamine study. Thus, PDE4-I can ameliorate both a serotonergic 
and a cholinergic deficit in object recognition performance. However, the precise underlying 
mechanisms of action are still unknown. Since in these deficit models of the ORT short-
term memory is examined, no gene transcription or protein synthesis is required. Thus, the 
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cAMP/PKA/CREB pathway may not be involved. Possibly, rolipram ameliorates the effects 
of scopolamine through enhancement of cholinergic, noradrenergic and/or dopaminergic 
turnover (Imanishi et al. 1997; Schoffelmeer et al. 1985). The same could be true for ame-
lioration of the serotonergic system. PDE4 is involved in beta-adrenergic receptor mediated 
cAMP signaling, which has been shown to mediate some effects of antidepressants (Ye and 
O’Donnell 1996).
Thus, PDE4 inhibitors can improve short-term memory by enhancement of cAMP lev-
els, likely via modulation of neurotransmitter activity, whereas improvements in acquisition 
and consolidation processes of long-term memory are likely mediated by increased cAMP 
levels, which activate the cAMP/PKA/CREB pathway. 
Role of PDE4 isoforms: a genetic model
Whereas PDE4 inhibitors are enticing targets for the treatment of cognitive impairing dis-
ease such as Alzheimer’s, it has been very difficult to circumvent the adverse effects that 
often accompany the beneficial effects of the PDE4-Is.  Thus, one approach to minimize the 
adverse effects would be to develop selective PDE4 isoform inhibitors depending on the char-
acterization and understanding of which isoform (s) was involved in learning/memory. The 
objective of this experiment was to determine whether either or both of the brain enriched 
isoforms, B or D, were involved in mediating associative memory as assessed by the delayed 
fear conditioning and morris water maze test using selective PDE4 gene knock-out mice.  
Unpublished results showed that LTP was enhanced in PDE4-D knock-out mice and 
LTD was enhanced in PDE4-B knock-out mice. We expected PDE4 KO to perform better 
than WT animals, since these animals are believed to have higher cAMP levels. However, 
this was not the case; PDE4-D knock-out mice even showed memory impairment in the 
fear conditioning task, whereas PDE4-B knock-out mice showed no differences in perfor-
mance as compared to wild type littermates. How to explain the observed behavioral im-
pairment for the PDE4-D KOs remains speculative. A possible explanation could be that 
developmental changes occur in these mice that cause the deficit. These knock-out mice 
show lower birth weights and are encountered with harmful differences in maternal be-
havior as compared with wild-type littermates. Another explanation could be that adap-
tive changes to the missing enzyme have occurred in the brain and as a result baseline 
enzyme and neurotransmitter levels are altered. Furthermore, knock-out of the PDE4-D 
gene may cause an up-regulation of other PDEs that result in impaired fear conditioning 
performance. Due to these developmental differences of PDE4-D knock-out mice no clear 
conclusions can be drawn at this point. Nevertheless, specific PDE4 isoform research is 
necessary since rolipram is currently an invalidated clinical target because of side effects. 
Severe side effects, such as emesis, have always been a dose limiting factor for clinical use of 
rolipram as an antidepressant or cognitive enhancer (Dyke and Montana 2002; Hebenstreit 
et al. 1989; Norman et al. 1992a; Overstreet et al. 1989). The PDE4-D isoform has been 
implied to produce emesis (Robichaud et al. 2002), which is one of the most prominent 
negative side effects of treatment with PDE4 inhibitors. Thus, targeting specific PDE4 iso-
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forms could reduce the dose-limiting side effects of the presently available PDE4-I. SiRNA 
is a recently developed technique which is used to silence genes (Xia et al. 2002) and could 
therefore be an interesting alternative for KO animals.
Indirect evidence suggests that PDE4-A and PDE4-B are involved in signaling path-
ways involved in affective behavior (Ye et al. 2000) and memory  processes (Ahmed and Frey 
2003), respectively. Recently, the antidepressant potential of PDE4-A in the hippocampus 
has been found to be related to specific splice variants of this PDE4 isoform (D’Sa et al. 
2005). The same probably holds for PDE4-B and memory (Ahmed and Frey 2005). To our 
knowledge, there are no selective PDE4 inhibitors available for the three PDE4 isoforms yet. 
Thus, the role of the different PDE4 isoforms in the hippocampus with respect to affective 
and cognitive behavior could be evaluated directly using a novel technique such as SiRNA. 
Finally, using SiRNA techniques, there are no developmental aspects involved as is the case 
in the PDE4 KO mice.
Effects of PDE inhibition in higher species
Non-human primates
Notwithstanding these intriguing findings in rodents, PDE4 is clinically not validated 
as a target for the treatment of cognitive disorders and the rationale would be strengthened 
if more data in higher species such as non-human primates became available (Blokland et al. 
2006, in press). In a first study, a trend was found for rolipram to improve delayed respond-
ing performance in young unimpaired rhesus monkeys, although performance in aged, im-
paired monkeys was decreased (Ramos et al. 2003). The primate task involved activity of the 
prefrontal cortex and it is possible that PDE4 inhibitors possess differential effects in hip-
pocampal/amygdala-mediated tasks and frontal cortex-mediated tasks. Further, Ramos et al 
(2003) observed a disinhibited cAMP/PKA pathway in the prefrontal cortex of aged animals, 
suggesting that prefrontal cortex cAMP levels should be inhibited instead of elevated to im-
prove cognitive functions. In this thesis, we investigated the cognition enhancing properties 
of rolipram in the object retrieval task in non-human primates. 
To our knowledge, PDE5-I have never before been evaluated in primate models of cog-
nition. This thesis presented the first study in which the cognitive effects of PDE5-Is were 
investigated in a non-human primate model. The object retrieval task requires prefrontal 
functioning and is likely to capture attention and response inhibition (Diamond et al. 1989). 
Rolipram and sildenafil were administered to cynomolgus macaques 1 h prior to the OR 
task. In our experiment we found that both rolipram and sildenafil effectively improved pre-
frontal performance in adult monkeys (see Chapter 7). Although the underlying pathways 
are not yet fully understood, these results further strengthen the possibility of PDE4-I and 
PDE5-I as a clinical targets for cognitive improvement. 
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Humans
To our knowledge, the effects of PDE-I have not been investigated in humans yet. How-
ever unpublished data suggest some effects of PDE5-I on human memory. In this double 
blind placebo controlled study, two groups of people were treated with the PDE5-I sildenafil 
and their memory performance was evaluated. The first group consisted of students from 
the department of psychology of the Maastricht University; the second group consisted of 
subjects older than 60 years. Preliminary results suggested no general effect on memory of 
the PDE-I. However, post-hoc analysis showed that when subjects were divided into good 
and bad performers based on the memory performance in the vehicle condition, the group 
of bad performers benefited from the sildenafil treatment in both age groups. Thus, when 
people with poor memory were treated with sildenafil their memory performance increased 
significantly. These results are preliminary and further investigation will be required. An on-
going study will screen subjects on memory performance first and then administration 
of sildenafil will be investigated.
PDE4-Is have not been tested in humans yet, possibly because the most used PDE4-I 
rolipram produces severe emetic side effects.
Central vascular effects of PDEs
PDE-Is, in particular PDE5-Is, are known to have peripheral effects on vasodilatation. It 
has not yet been fully determined whether PDE-Is may also have central effects on blood 
flow and glucose metabolism. A possible alternative explanation to all experiments de-
scribed above could be that PDE-Is enhance central blood flow and glucose metabolism 
and thereby enhance cellular functioning in, for example, the hippocampus, and thus 
memory performance.  However, studies by Prickaerts et al (1997) showed that the PDE5 
inhibitor zaprinast clearly improved object memory in rats at 10 mg/kg (i.p.) but did not 
affect mean arterial blood pressure at this dosage (Prickaerts et al. 1997). Similar results 
on object memory and blood pressure have been observed for sildenafil administration 
in rats (Prickaerts et al. 2004). Taking this into account, it is unlikely that the memory 
enhancing effects of PDE5 inhibitors can simply be explained through changes in blood 
flow or blood pressure (for a more detailed review see: (Prickaerts et al. 2004). In an on-
going study by our group and the University of Edinburgh in Scotland, the effects rolip-
ram (0.03 mg/kg) and vardenafil (1 mg/kg) are studied on central blood flow and glucose 
metabolism. The results from this study were not yet available at the time of submitting 
the present thesis. Nevertheless, on the basis of the available data we do not expect that 
the memory enhancing effects of PDEs can be explained by a simple increase in glucose 
metabolism. We hope that the data on cerebral blood flow and glucose metabolism can 
confirm our notion.
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Final evaluation of PDEs in cognition
Taken together, the results presented in the present thesis show convincing cognitive en-
hancing properties of PDE-Is. The enhancing effects of PDE-I on memory performance have 
been shown in rats, mice and primates. Evidence suggests differential time dependent ef-
fects of cGMP or cAMP selective PDEs. It appears that cGMP is mainly involved in early 
consolidation processes and cAMP in late consolidation processes. The underlying pathways 
are yet to be fully explained, although cellular processes that are related to LTP seem to be 
a possible mechanism. The cGMP/PKG/CREB pathway for early consolidation processes and 
the cAMP/PKA/CREB pathway for late consolidation processes might be the most probable 
mechanisms underlying the observed behavioral effects. In addition, the pre-synaptic NO/
sGC/GMP pathway may also exert effects on short-term memory, but this has not yet been 
investigated at present. Furthermore, cAMP may also be involved in short-term memory 
processes through enhanced neurotransmitter release. Finally, the understanding of the un-
derlying mechanisms of PDE-Is and cognition can be further complicated, since evidence 
has shown that E-LTP can be converted to L-LTP. 
Isoform specific studies are promising new ways to further investigate the underly-
ing mechanisms of cognition enhancement in animal models. Genetic knock-out models 
for PDE4 show behavioral differences in cognition and depression, but developmental defi-
cits in these animals might confound the outcome of these studies. Novel techniques, such 
as gene silencing, could further increase our understanding of the mechanisms of PDE-Is 
in cognition and might provide more selective targets for cognitive enhancement.
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Summary
This thesis describes studies investigating the effects of phosphodiesterase (PDE) inhibi-
tors on learning and memory. During the last decennia, our understanding of the neuro-
biological processes underlying learning and memory has continuously improved, leading 
to the identification of targets for the development of memory-enhancing drugs. PDEs are 
enzymes that hydrolyze cyclic AMP (cAMP) and cyclic GMP (cGMP) in the body and the 
brain. Recently, evidence has been accumulating that these second messenger molecules 
cGMP and cAMP are very important in learning and memory processes. This thesis adds 
to the growing public interest into the effects of PDE- on cognition. The studies described 
in thesis show memory enhancing properties of different PDE-Is in different animal species 
and in different behavioral tests and models. 
Chapter 1: An introduction is provided into the basics of the human memory system, animal 
models of learning and memory and possible underlying pathways that involve long term 
potentiation (LTP). Furthermore, an overview is given of the different PDEs that are known 
at present and we focus on three PDEs which have been identified as possible relevant tar-
gets for memory improvement: PDE2, PDE4 and PDE5. Finally, an extensive review of the 
literature on PDE-I and putative memory enhancement in behavioral models is presented. 
Chapter 2: The effects of the in vivo application of the PDE5-I sildenafil on object recognition 
memory are described in relation to its administration in vitro using hippocampal slices in Swiss 
mice. To investigate a possible presynaptic underlying mechanism of action for PDE5-I we tried 
to co-localize cGMP immunoreactivity (cGMP-IR) with the pre-synaptic marker synaptophysin. 
Sildenafil improved memory performance in the ORT and cGMP-IR was increased in varicosi-
ties and some fibers in the CA1 area of the hippocampus. Furthermore, failed co-localization 
of cGMP with synaptophysin implies that either cGMP is not elevated at the presynaptic level 
(and thus does not work via a presynaptic mechanism of action), or that our mechanisms for 
measuring cGMP-IR are not sensitive enough to pick up small fluctuations in cGMP concentra-
tions. Future studies with specific PDE5 antibodies will further elucidate these results.
Chapter 3: The effect of the selective PDE4-I rolipram on memory performance in rats was 
investigated using the object recognition task. Since, previous studies showed that intra-
hippocampal injections of 8Br-cAMP enhanced long-term memory only when administered 
3h after training, we wanted to investigate the time dependent administration of rolipram 
on long-term memory. Furthermore we investigated the effects of rolipram in a short-term 
memory deficit model, i.e. the scopolamine model in 1h interval ORT. Using a 24 h inter-
val in the ORT, rolipram showed an improvement in long-term memory performance only 
when injected 3 h after training, not when injected 30 min before or immediately after train-
ing. Furthermore, rolipram reversed the scopolamine-induced short-term memory deficit. 
Although the improved memory performance in both conditions is likely to be explained by 
elevated cAMP levels, two separate working mechanisms might explain these effects. 
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Chapter 4: The time-dependent memory enhancing properties of three selective PDE-Is varde-
nafil (PDE5-I), rolipram (PDE4-I) and BAY 60-7550 (PDE2-I) were investigated in the ORT. In 
particular, the time-dependent involvement of cAMP and cGMP in memory consolidation was 
assessed by altering the time points of drug administration. Vardenafil, rolipram, and BAY 60-
7550 were tested in rats with a 24 h delay interval in the ORT. The PDE-Is were administered at 
different time points, i.e. directly after, 1 h, 3 h and 6 h after T1. Vardenafil only showed an ef-
fect on object memory when injected directly after T1, rolipram only showed an improvement 
when injected 3 h after T1 and BAY 60-7550 improved memory when injected either directly 
after or 3 h after. No treatment effects were found at the 1 h or 6 h administration time points. 
These results suggest that different types of PDE-Is can affect different stages of memory con-
solidation. Moreover, time dependent administration of three different PDE-Is advocates spe-
cific roles of cAMP and cGMP in the long term memory consolidation processes.
Chapter 5: Previous studies showed that rolipram can reverse the cholinergic deficit caused by 
scopolamine. However underlying mechanisms of action remain obscure. This study investi-
gated the effect of rolipram in a serotonergic memory deficit model of acute tryptophan deple-
tion (ATD). First, the effects different treatment times of ATD on plasma tryptophan (TRP) 
values and ORT performance were investigated. ATD significantly lowered the plasma TRP ra-
tio (TRP/∑LNAA) to a maximum of 48%, approximately 1 h after administration. Furthermore 
ATD impaired ORT performance when administered 3 h before testing. Rolipram (0.1 mg/kg) 
reversed the ATD induced serotonergic deficit. Possible mechanisms of action act through el-
evation of cAMP levels and downstream up-regulations of neurotransmitter systems.
Chapter 6: Currently, four isoforms of the PDE4 enzyme (A, B, C and D) have been identi-
fied, yet the requisite involvement of each of these isoforms in mediating LTM has yet to be 
elucidated.  The intent of the present study was to use genetic knock-out (KO) mice to inves-
tigate the involvement of two of the PDE4 isoforms that have high brain expression, namely 
D and B, in in vivo models of learning and memory.  Adult, male PDE4-D and PDE4-B KO 
mice were first characterized in an associative learning paradigm using the fear conditioning 
model (FC) at two time points, 24 h for long term memory (LTM), and 1 h for short term 
memory (STM).  Interestingly, whereas the PDE4 B KO mice demonstrated equivalent LTM 
and STM as compared to wild-type mice, the PDE4-D KO animals exhibited significant defi-
cits in LTM as compared with their control littermates.  Neither the PDE4-B or PDE4-D mice 
showed any alterations in Morris water maze (MWM) performance (acquisition or retention) 
as compared to wild-type controls.  Whereas the deficit in LTM observed in the PDE4-D KO 
mice was not expected, and may be explained by adaptive responses occurring because of con-
stitutive inactivity of this isoform throughout development, it does suggest that the PDE4-D 
isoform, possibly more so than PDE4-B may be of importance in learning and memory.
Chapter 7: Selective PDE-Is have been shown to improve long-term memory in several ro-
dent models of cognition. However, studies evaluating the effects of PDE-I on cognition 
in unimpaired primates are very scarce. This study investigated the effect of the PDE4-I 
rolipram and the PDE5-I sildenafil on object retrieval (OR) performance. OR is a prefrontal 
cortical mediated task, which is likely to capture attention and response inhibition.  Young 
adult male Cynomolgus macaques were trained in the OR task. Both rolipram and sildenafil 
significantly improved performance in the OR task. These findings complement and extend 
to the cognition-enhancing effects of cAMP and cGMP via PDE-I. However, the underlying 
mechanism of action and cellular pathways remain elusive.
Chapter 8: In the final chapter a general discussion of the findings in this thesis. Taken 
together, the results presented in the present thesis show convincing cognitive enhancing 
properties of PDE-Is. The enhancing effects of PDE-I on memory performance have been 
shown in rats, mice and primates. Evidence suggests differential time-dependent effects of 
cGMP or cAMP selective PDEs. It appears that cGMP is mainly involved in early consolida-
tion processes and cAMP in late consolidation processes. The underlying pathways are yet 
to be fully explained, although cellular processes that are related to LTP seem to be a possi-
ble mechanism. The cGMP/PKG/CREB pathway for early consolidation processes and the 
cAMP/PKA/CREB pathway for late consolidation processes might be the most probable 
mechanisms underlying the observed behavioral effects. In addition, the pre-synaptic NO/
sGC/cGMP pathway may also exert effects on short-term memory, but this has not yet been 
investigated at present. Furthermore, cAMP may also be involved in short-term memory 
processes through enhanced neurotransmitter release. Finally, the understanding of the un-
derlying mechanisms of PDE-Is and cognition can be further complicated, since evidence 
has shown that E-LTP can be converted to L-LTP. Future studies with specific antibodies for 
PDEs have to elucidate the pre or postsynaptic localization of PDEs and could further illumi-
nate the underlying mechanisms of action. Recently our lab has developed a specific PDE5 
antibody and the first immunohistochemical are expected in due course.
PDE-Is, in particular PDE5-Is, are known to have peripheral effects on vasodilatation. It has 
not yet been fully determined whether PDE-Is may also have central effects on blood flow 
and glucose metabolism. In this chapter we discussed why based on the literature it is not 
very likely that our memory enhancing effects of PDE-I are explained by central vascular 
effects. 
Isoform specific studies are promising new ways to further investigate the underlying mech-
anisms of cognition enhancement in animal models. Genetic KO models for PDE4 show be-
havioral differences in cognition and depression, but developmental deficits in these animals 
might confound the outcome of these studies. Novel techniques, such as gene silencing, 
could further increase our understanding of the role of PDE (isoform) enzymes in cognition 
and might provide more selective targets for cognitive enhancement.
10 Samenvatting
The Effects of Phosphodiesterase Inhibition on Memory 
128
Samenvatting
De studies die beschreven worden in dit proefschrift tonen de effecten van phosphodies-
terase (PDE) remmers op leren en het geheugen. De afgelopen jaren is onze kennis van de 
onderliggende processen van leren en het geheugen steeds beter geworden. Dit heeft geleid 
tot de identificatie van mogelijke targets voor de ontwikkeling van geheugenverbeterende 
medicijnen. PDEs zijn enzymen die in ons lichaam en in het brein cyclisch AMP (cAMP) 
en cyclisch GMP (cGMP) hydrolyseren. Steeds meer bewijs toont aan dat deze secundaire 
‘messenger’ moleculen cAMP en cGMP een belangrijke rol spelen in geheugenprocessen. 
Dit proefschrift draagt bij aan de groeiende interesse in PDE remmers en cognitie. De in dit 
proefschrift beschreven experimenten tonen geheugen verbeterende effecten van PDE rem-
mers in verschillende diersoorten en in verschillende gedragstaken en modellen. 
Hoofdstuk 1: Er wordt een introductie gegeven van de basale opbouw van het menselijke 
geheugen systeem, dierexperimentele modellen voor leren en geheugen en de mogelijke on-
derliggende mechanismen, waaronder long term potentiatie (LTP). Verder wordt een over-
zicht gegeven van de op dit moment bekende PDEs en we gaan dieper in op drie PDEs die 
gekenmerkt zijn als mogelijke targets voor geheugenverbetering: PDE2, PDE4 en PDE5. Ten 
slotte wordt een uitgebreid overzicht van de literatuur over PDE remmers en mogelijke ge-
heugenverbeterende effecten in diermodellen gegeven.
Hoofdstuk 2: De effecten van in vivo toediening van de PDE5 remmer sildenafil op het 
geheugen in de objectherkenningstaak (ORT) worden onderzocht in relatie tot de in vitro 
toediening op hippocampale coupes van Swiss muizen. Om een mogelijk presynaptisch on-
derliggend werkingsmechanisme van PDE5 remmers te onderzoeken werd geprobeerd om 
immunoreactiviteit van cGMP (cGMP-IR) te co-localiseren met de presynaptische marker 
synaptophysine. Sildenafil verbeterde het ORT geheugen in muizen en cGMP-IR werd waar-
genomen in varicositeiten en enkele vezels van het CA1 gebied van de hippocampus. Er werd 
verder geen co-localisatie gevonden tussen cGMP-IR en synaptophysine. Dit kan betekenen 
dat cGMP niet verhoogd actief is in presynaptische gebieden (en het dus niet via een pre-
synaptisch mechanisme werkt), of dat onze meettechnieken niet gevoelig genoeg zijn om 
kleine cGMP fluctuaties op te pikken.
Hoofdstuk 3: De effecten van de selectieve PDE4 remmer rolipram op het geheugen van 
ratten werden onderzocht in de ORT. Omdat eerdere studies lieten zien dat intra-hippo-
campale injecties van 8Br-cAMP het lange termijn geheugen alleen verbeterden wanneer 
de injecties 3 uur na training plaatsvonden, wilden we de effecten van tijd van toediening 
van rolipram op het lange termijn geheugen onderzoeken. Daarnaast werden de effecten van 
rolipram onderzocht in een model voor korte termijn geheugen, namelijk het scopolamine 
model met 1 uur interval in de ORT. Bij een 24 uur interval in de ORT verbeterde rolipram 
het lange termijn geheugen alleen wanneer het 3 uur na de training werd toegediend en niet 
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wanneer het een half uur voor of direct na de training werd toegediend. Verder hief rolipram 
het korte termijn geheugen defect door scopolamine op. De gevonden geheugenverbete-
ringen van rolipram in beide condities worden waarschijnlijk veroorzaakt door verhoging 
van de cAMP concentraties, maar wij denken dat verschillende werkingsmechanismen deze 
effecten verklaren.
Hoofdstuk 4: De geheugenverbeterende effecten en de tijd van toediening van drie selec-
tieve PDE remmers: vardenafil (PDE5 remmer), rolipram (PDE4 remmer) en BAY 60-7550 
(PDE2 remmer) werden onderzocht in de ORT. De tijdsafhankelijke betrokkenheid van 
cAMP en cGMP bij de consolidatie van het geheugen werd onderzocht door de tijd van toe-
diening te variëren. Vardenafil, rolipram en BAY 60-7550 werden in ratten getest met een 
24 uur interval ORT. De PDE remmers werden op verschillende tijdspunten toegediend, 
namelijk: direct na, 1 uur, 3 uur of 6 uur na trial 1 (T1). Vardenafil verbeterde alleen het ge-
heugen wanneer het direct na T1 werd toegediend, rolipram werkte alleen wanneer het 3 uur 
na T1 werd toegediend en BAY 60-7550 verbeterde het geheugen wanneer het of direct, 
of 3 uur na T1 werd toegediend. Geen effecten werden gevonden wanneer de drugs 1 uur of 
6 uur na T1 werden toegediend. Deze resultaten suggereren dat verschillende PDE remmers 
verschillende fases van consolidatie processen beïnvloeden. Met andere woorden, de tijdsaf-
hankelijke toediening van drie verschillende PDE remmers pleit voor specifieke betrokken-
heid van cAMP en/of cGMP in consolidatie processen van het lange termijn geheugen.
Hoofdstuk 5: Eerder onderzoek toonde aan dat rolipram het cholinerge defect dat door 
scopolamine wordt veroorzaakt kan opheffen. Maar de onderliggende mechanismen zijn 
nog niet volledig bekend. In deze studie werden de effecten van rolipram onderzocht in een 
serotonerg defect model, namelijk dat van acute tryptofaan depletie (ATD). Allereerst wer-
den de effecten van verschillende toedieningtijden van het ATD mengsel op de ORT pres-
tatie en de tryptofaan (TRP) waarden in het bloedplasma bepaald. ATD zorgde voor een 
significante verlaging van de TRP ratio (TRP/∑LNAA) in het bloed tot maximaal 48%, onge-
veer 1 uur na de toediening. Daarnaast verslechterde ATD de geheugenprestatie in de ORT 
wanneer het mengsel 3 uur voor de training werd toegediend. Rolipram was in staat het 
serotonerge geheugendefect op te heffen. Een mogelijke verklaring voor deze effecten is dat 
PDE4 remming via een verhoging van cAMP niveaus, de activiteit van diverse neurotrans-
mitter systemen versterkt. 
Hoofdstuk 6: Tot heden zijn er vier isovormen van het PDE4 enzym bekend (A, B, C en D) 
maar de respectievelijke betrokkenheid van elk van deze isovormen in de vorming van lange 
termijn geheugen moeten nog onderzocht worden. Het doel van deze studie was om de 
betrokkenheid te bestuderen van twee PDE4 isovormen die veel in het brein voorkomen, na-
melijk D en B, in in vivo modellen voor leren en geheugen. Hierbij werd gebruik gemaakt van 
genetische knock-out (KO) muizen. Volwassen mannelijke PDE4-D en PDE4-B KO muizen 
werden eerst gekarakteriseerd in een associatieve leertaak. Hierbij werd gebruik gemaakt 
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van de fear conditioning (FC) test voor lange termijn geheugen (24 uur interval) en korte 
termijn geheugen (1 uur interval). De PDE4-B dieren toonden geen verschillen tussen KOs 
en wild-type muizen op korte en lange termijn geheugen. De PDE4-D KO muizen toonden 
echter wel een significante verslechtering in lange termijn geheugen in vergelijking met de 
controle wild-type muizen. Zowel de PDE4-D als de PDE4-B KO muizen lieten geen verschil-
len zien in de spatiële Morris water maze (MWM) test (acquisitie en retentie) ten opzichte 
van de wild-types. Hoewel de verslechtering bij de PDE4-D muizen onverwacht was en mo-
gelijk verklaard kan worden door aanpassingsreacties die optreden door de constante inacti-
viteit van deze isovorm tijdens de ontwikkeling, suggereert dit wel dat de PDE4-D isovorm 
misschien nog wel meer dan de PDE4-B isovorm belangrijk kan zijn in leren en geheugen.
Hoofdstuk 7: In diverse knaagdier modellen voor leren en geheugen is aangetoond dat 
selectieve PDE remmers het lange termijn geheugen verbeteren. Er zijn echter maar zeer 
weinig studies waarin de effecten van PDE remmers op cognitie in gezonde primaten werd 
onderzocht. Dit hoofdstuk beschrijft de effecten van de PDE4 remmer rolipram en de PDE5 
remmer sildenafil op ‘object retrieval’ (OR) prestatie. De OR taak is een taak die aangestuurd 
wordt door de prefrontale cortex en processen als aandacht en respons inhibitie worden 
ermee gemeten. Jonge volwassen Cynomolgus makaken werden getraind in de OR taak. 
Zowel rolipram als sildenafil verbeterden de prestatie in de OR test. Deze bevindingen ver-
sterken en vergroten het bewijs voor de cognitieverbeterende effecten van cAMP en cGMP 
via remming van PDEs. Hoewel de taakverbetering evident was kunnen we geen eenduidig 
onderliggende werkingsmechanismen en cellulaire paden aanduiden.
Hoofdstuk 8: In dit hoofdstuk worden de bevindingen van dit proefschrift bediscussieerd. 
Al met al geven de resultaten van de experimenten uit dit proefschrift overtuigend bewijs 
van de cognitie verbeterende eigenschappen van PDE remmers. De geheugenverbeterende 
effecten van PDE remmers werden aangetoond in ratten muizen en primaten. Er is bewijs dat 
er verschillende tijdsafhankelijke effecten van cAMP of cGMP selectieve PDEs zijn. Het lijkt 
zo te zijn dat cGMP met name betrokken is in vroege consolidatieprocessen en dat cAMP met 
name in late consolidatieprocessen betrokken is. De onderliggende mechanismen moeten 
nog volledig verklaard worden, maar cellulaire processen die in verband staan met LTP zijn 
een voor de hand liggende en plausibele mogelijkheid. Het cGMP/PKG/CREB proces voor 
vroege consolidatie processen en het cAMP/PKA/CREB proces voor late consolidatie proces-
sen zijn wellicht de meest waarschijnlijke mechanismen die ten grondslag kunnen liggen aan 
de gevonden geheugen verbeteringen. Verder zou het presynaptische NO/sGC/cGMP proces 
ook effecten kunnen hebben op het korte termijn geheugen, maar dat is tot heden nog niet 
onderzocht. Daarnaast kan cAMP ook betrokken zijn in korte termijn geheugen processen, 
waarschijnlijk via verhoging van neurotransmitter afgifte. Ten slotte wordt het ontrafelen 
van de onderliggende mechanismen van PDE remming nog moeilijker omdat is aangetoond 
dat E-LTP kan worden omgezet in L-LTP. In de toekomst zullen experimenten met specifieke 
antilichamen tegen PDEs uitsluitsel moeten geven over de pre- of postsynaptische localisatie 
van de PDEs en dit zou meer inzicht in de onderliggende werkingsmechanismen kunnen 
bieden. Recentelijk is in ons lab een specifiek PDE5 antilichaam ontwikkeld en de eerste im-
munohistochemische resultaten worden in de nabije toekomst verwacht.
PDE remmers, PDE5 remmers in het bijzonder, staan bekend om hun perifere effecten 
op vaatverwijding. Het is nog niet onomstotelijk aangetoond dat PDE remmers ook effecten 
hebben op de centrale doorbloeding en het centrale glucose metabolisme. In dit hoofdstuk 
wordt bediscussieerd waarom het op basis van de literatuur niet waarschijnlijk is dat onze 
geheugenverbeterende effecten van PDE remmers verklaard zouden kunnen worden door 
effecten op de doorbloeding.  
Isovorm specifieke studies zijn veelbelovende nieuwe manieren om de onderliggende mecha-
nismen van geheugenverbetering in diermodellen te onderzoeken. Genetische KO modellen 
voor PDE4 laten veranderingen in cognitie en depressie zien maar ontwikkelingsafwijkingen 
zouden de resultaten van deze experimenten kunnen vertroebelen. Nieuwe technieken zoals 
‘gen-silencing’, zouden ons begrip van de onderliggende mechanismen van PDE remming en 
cognitie aanzienlijk kunnen verbeteren en kunnen leiden tot meer specifieke targets voor 
cognitieve verbetering.
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